-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IXg0pBjZ1VmfWytlcPpTBH4emtUUh5sY59euwAbIpy6Bcpyf+kCTr+6P1FRvK+Bx NGn8CU2O8Yh+/yJdsmTluQ== 0000950144-97-003593.txt : 19970401 0000950144-97-003593.hdr.sgml : 19970401 ACCESSION NUMBER: 0000950144-97-003593 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 19961231 FILED AS OF DATE: 19970331 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: RESPONSE ONCOLOGY INC CENTRAL INDEX KEY: 0000763098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 621212264 STATE OF INCORPORATION: TN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09922 FILM NUMBER: 97571486 BUSINESS ADDRESS: STREET 1: 1775 MORIAH WOODS BLVD CITY: MEMPHIS STATE: TN ZIP: 38117 BUSINESS PHONE: 9017617000 MAIL ADDRESS: STREET 1: 1775 MORIAH WOODS BLVD CITY: MEMPHIS STATE: TN ZIP: 38117 FORMER COMPANY: FORMER CONFORMED NAME: RESPONSE TECHNOLOGIES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: BIOTHERAPEUTICS INC DATE OF NAME CHANGE: 19891221 10-K 1 RESPONSE ONCOLOGY, INC. FORM 10-K 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 - K (Mark One) X Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange - --- Act of 1934 [NO FEE REQUIRED, EFFECTIVE OCTOBER 7, 1996] For the fiscal year ended December 31, 1996 Transaction Report Pursuant to Section 13 or 15(d) of the Securities - --- Exchange Act of 1934 [NO FEE REQUIRED, EFFECTIVE OCTOBER 7, 1996] For the Transaction Period --------------------- Commission File Number --------------------- Response Oncology, Inc. - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Tennessee 62-1212264 ------------------------ ------------------------ (State of incorporation) (I.R.S. Employer ID No.) 1775 Moriah Woods Blvd., Memphis, TN 38117 ---------------------------------------- --------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (901) 761-7000 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange Title of each class on which registered ------------------- ------------------- Common Stock, par value $.01 per share.............NASDAQ National Market Securities registered pursuant to Section 12(g) of the Act: NONE Indicate by check mark whether the registrant (1) has filed all reports required by section 13 of 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes X No --- --- Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated in Part III of this Form 10-K or any Amendment to this form 10-K ___ As of March 3, 1997, 11,967,543 shares of Common Stock of Response Oncology, Inc. were outstanding and the aggregate market value of such Common Stock held by non affiliates was $21,357,765 based on the closing sale price of $7.50 as of that date. Portions of Registrant's Proxy Statement for use in connection with the Annual Meeting of Shareholders to be held on June 5, 1997 are incorporated by reference into Part III of this report, to the extent set forth therein, if such Proxy Statement is filed with the Securities and Exchange Commission on or before April 30, 1997. If such Proxy Statement is not filed by such date, the information required to be presented in Part III will be filed as an amendment to this report under cover of a Form 8. The exhibits for this Form 10-K are listed on Page ____. 2 PART I ITEM 1. BUSINESS THE COMPANY Response Oncology, Inc. (the "Company") is a comprehensive cancer management company. The Company provides advanced cancer treatment services through outpatient facilities known as IMPACT(R) Centers under the direction of approximately 350 independent oncologists, manages the practices of oncologists with whom the Company has affiliated and conducts clinical cancer research on behalf of pharmaceutical manufacturers. IMPACT(R) Services The Company presently operates 47 IMPACT(R) Centers in 23 states which provide high-dose chemotherapy with stem cell support to cancer patients on an outpatient basis. Through its IMPACT(R) Centers, the Company has developed extensive medical information systems and databases containing clinical and patient information, analysis of treatment results and side effects and clinical care pathways. These systems and databases support the Company's clinical trials program, which involves carefully planned, uniform treatment regimens administered to a significant group of patients together with the monitoring of outcomes and side effects of these treatments. The clinical trials program allows the Company to develop a rational means of improving future treatment regimens by predicting which patients are most likely to benefit from different treatments. Each IMPACT(R) Center is staffed by, and makes extensive use of, experienced oncology nurses, pharmacists, laboratory technologists, and other support personnel to deliver outpatient services under the direction of independent medical oncologists. IMPACT(R) Center services include preparation and collection of stem cells, administration of high-dose chemotherapy, reinfusion of stem cells and delivery of broad-based supportive care. IMPACT(R) Center personnel extend the support mechanism into the patient's home, further reducing the dependence on hospitalization. The advantages of this system to the physician and patient include (i) convenience of the local treatment facility; (ii) specialized on-site laboratory and pharmacy services, including home pharmacy support; (iii) access to the Company's clinical trials program to provide ongoing evaluation of current cancer treatment; (iv) specially trained medical and technical staff; (v) patient education and support materials through computer, video and staff consultation; and (vi) reimbursement assistance. High-dose chemotherapy is most appropriate for patients with lymphoma, acute leukemia, multiple myeloma and breast and ovarian cancer. Patients referred to the Company by the treating oncologist are placed on a treatment protocol developed from the cumulative analysis of the Company's approximately 3,000 high-dose cases. Protocols conducted at the IMPACT(R) Center begin with a drug regimen which allows for the collection and cryopreservation of stem cells. A stem cell is a cell which originates in the bone marrow and is a precursor to white blood cells. At the appropriate time, stem cells capable of restoring immune system and bone marrow function are harvested over a two to three day period. The harvested stem cells are then frozen and stored at the IMPACT(R) Center, and following confirmation of response to treatment and a satisfactory stem cell harvest, patients receive high-dose chemotherapy followed by reinfusion of stem cells. Most patients are then admitted to an affiliated hospital for 10-14 days. After discharge, the patient is monitored in the oncologist's office. The Company believes that the proprietary databases and the information gathering techniques developed from the foregoing programs enable practicing oncologists to manage cancer cases cost effectively. Clinical research conducted by the Company focuses on (i) improving cancer survival rates; (ii) enhancing the cancer patient's quality of life; (iii) reducing the costs of cancer care; and (iv) developing new approaches to cancer diagnosis, treatment and post-treatment monitoring. Since 1989, the Company has conducted a clinical trials program pursuant to which carefully planned, uniform treatments administered to a substantial number of patients have been monitored and studied, with the results being collected in a database and utilized to predict outcomes and determine utilization of high-dose -2- 3 chemotherapy as a treatment. In addition, the Company has recorded outcomes from over 3,000 cases in which high-dose chemotherapy was utilized as a treatment and has developed and continues to refine treatment pathways, which forecast the best outcome with the lowest possible cost. Pursuant to agreements between the Company and the oncologists who supervise their patients' treatment in IMPACT(R) Centers, such oncologists are obligated to record and monitor outcomes, collect information and report such information to the Company, for which the oncologists are paid a fixed fee. Oncology Practice Management Services During 1996 the Company commenced execution of a diversification strategy into physician practice management, consummating the acquisitions of 10 medical oncology practices including 38 medical oncologists in Florida and Tennessee. Through these acquisitions, the Company has sought to achieve deep geographic penetration in those markets, believing that significant market share is crucial to achieving efficiencies, revenue enhancements, and marketing of complete cancer services to diverse payors including managed care. Pursuant to management service agreements ("Service Agreements"), the Company provides management services that extend to all nonmedical aspects of the operations of the affiliated practices. Pursuant to the Service Agreements, the Company is the sole and exclusive manager and administrator of all day-to-day business functions connected with the medical practice of an affiliated physician group. The Company is responsible for providing facilities, equipment, supplies, support personnel, and management and financial advisory services. Under the terms of the Service Agreements in general, the Company (i) prepares annual capital and operating budgets; (ii) prepares financial statements; (iii) orders and purchases medical and office inventory and supplies; (iv) bills patients and third party payors; (v) maintains accounting, billing, medical, and collection records; (vi) negotiates and administers managed care contracts; (vii) arranges for legal and accounting services related to practice operations; (viii) recruits, hires and appoints an executive director to manage and administer all of the day-to-day business functions of each practice; and (ix) manages all non-physician professional support and administrative personnel, clerical, secretarial, bookkeeping and collection personnel. The Company seeks to combine the purchasing power of numerous physicians to obtain favorable pricing and terms for equipment, pharmaceuticals and supplies and to obtain favorable contracts with suppliers. In addition, the Company provides its outcomes database, treatment protocols and pathways to affiliated oncologists, permitting these physicians to more effectively manage cancer cases. The Company utilizes its management expertise to conduct utilization review and quality assurance programs and establish well-defined medical policies for its affiliated physicians. In return for its management services and expertise, the Company receives a service fee based on net revenue or net operating income of the practice. Pursuant to each Service Agreement, the physicians and the practice agree not to compete with the Company and the practice. Each Service Agreement has an initial term of 40 years and, after the initial term, will be automatically extended for additional five year terms unless either party delivers written notice to the other party, 180 days prior to the expiration of the preceding term. The Service Agreement may only be terminated for cause. If the Company terminates the Service Agreement for cause, the practice is typically obligated to purchase assets (which typically include intangible assets) and pay liquidated damages, which are guaranteed by individual physicians for a period of time. Each Service Agreement provides for the creation of an oversight committee, a majority of whom are designated by the practice. The oversight committee is responsible for developing management and administrative policies for the overall operation of each clinic. Cancer Research Services The Company also utilizes its database to provide various types of data to pharmaceutical companies regarding the use of their products. The IMPACT(R) Center network and the Company's medical information systems make the Company ideally suited to this process. The Company is currently participating in several projects with leading pharmaceutical manufacturers to furnish data in connection with FDA applications and post-FDA approval marketing studies. Revenue from these contracts helps to underwrite the Company's clinical trials expenses. Such relationships with pharmaceutical companies allow patients and physicians earlier access to drugs and therapies and ensure access to clinical trials under managed care, which guarantee the Company's role as a leader in oncological developments. -3- 4 COMPETITION As a result of growing interest among oncologists and the more widely recognized efficacy of high-dose chemotherapy treatments, the competitive environment in the field is starting to heighten. Most community hospitals with a commitment to cancer treatment are evaluating their need to provide high-dose treatments, and other entities are competing with the Company in providing high-dose services similar to those offered by the Company. Such competition has long been contemplated by the Company, and is indicative of the evolution of this field. While the Company believes that the demand for high-dose chemotherapy services is sufficiently large to support several significant providers of these services, it is subject to increasing competitive risks from these entities. In addition, the Company is aware of at least two competitors specializing in the management of oncology practices and two other physician management companies that manage at least one oncology practice. Several health care companies with established operating histories and significantly greater resources than the Company are also providing at least some management services to oncologists. There are certain other companies, including hospitals, large group practices, and outpatient care centers, that are expanding their presence in the oncology market and may have access to greater resources than the Company. Furthermore, organizations specializing in home and ambulatory infusion care, radiation therapy, and group practice management compete in the oncology market. The Company's revenue depends on the continued success of its affiliated physician groups. These physician groups face competition from several sources, including sole practitioners, single and multi-specialty groups, hospitals and managed care organizations. GOVERNMENT REGULATION The delivery of healthcare items and services has become one of the most highly regulated of professional and business endeavors in the United States. Both the federal government and the individual state governments are responsible for overseeing the activities of individuals and businesses engaged in the delivery of healthcare services. Federal law and regulations are based primarily upon the Medicare program and the Medicaid program, each of which is financed, at least in part, with federal money. State jurisdiction is based upon the state's authority to license certain categories of healthcare professionals and providers, and the state's interest in regulating the quality of healthcare in the state, regardless of the source of payment. The Company believes it is in material compliance with applicable laws. However, the laws applicable to the Company are subject to evolving interpretations and therefore, there can be no assurance that a review of the Company's or the affiliated physicians' practices by a court or law enforcement or regulatory authority will not result in a determination that could adversely affect the operations of the Company or the affiliated physicians. Furthermore, there can be no assurance that the laws applicable to the Company will not be amended in a manner that could adversely affect the Company. FEDERAL LAW The federal healthcare laws apply in any case in which the Company is providing an item or service that is reimbursable under Medicare or Medicaid or is claiming reimbursement from Medicare or Medicaid on behalf of physicians with whom the Company has a Service Agreement. The principal federal laws include those that prohibit the filing of false or improper claims with the Medicare or Medicaid program, those -4- 5 that prohibit unlawful inducements for the referral of business reimbursable under Medicare or Medicaid and those that prohibit the provision of certain services by a provider to a patient if the patient was referred by a physician with which the provider has certain types of financial relationships. False and Other Improper Claims The federal government is authorized to impose criminal, civil and administrative penalties on any healthcare provider that files a false claim for reimbursement from Medicare or Medicaid. Criminal penalties are also available in the case of claims filed with private insurers if the government can show that the claims constitute mail fraud or wire fraud. While the criminal statutes are generally reserved for instances evidencing an obviously fraudulent intent, the civil and administrative penalty statutes are being applied by the government in an increasingly broader range of circumstances. For example, the government takes the position that a pattern of claiming reimbursement for unnecessary services violates these statutes if the claimant should have known that the services were unnecessary. The government also takes the position that claiming reimbursement for services that are substandard is a violation of these statutes if the claimant should have known that the care was substandard. Anti-Kickback Law Federal law commonly known as the "Anti-kickback Amendments" prohibits the offer, solicitation, payment or receipt of anything of value (direct or indirect, overt or covert, in cash or in kind) which is intended to induce the referral of Medicare or Medicaid patients, or the ordering of items or services reimbursable under those programs. The law also prohibits remuneration that is intended to induce the recommendation of, or the arranging for, the provision of items or services reimbursable under Medicare and Medicaid. The law has been broadly interpreted by a number of courts to prohibit remuneration which is offered or paid for otherwise legitimate purposes if the circumstances show that one purpose of the arrangement is to induce referrals. Even bona fide investment interests in a healthcare provider may be questioned under the Anti-kickback Amendment if the government concludes that the opportunity to invest was offered as an inducement for referrals. The penalties for violations of this law include criminal sanctions and exclusion from the federal healthcare program. In part to address concerns regarding the implementation of the Anti-kickback Amendments, the federal government in 1991 published regulations that provide exceptions, or "safe harbors," for certain transactions that will not be deemed to violate the Anti-kickback Amendments. Among the safe harbors included in the regulations were provisions relating to the sale of physician practices, management and personal services agreements and employee relationships. Subsequently, regulations were published offering safe harbor protection to additional activities, including referrals within group practices consisting of active investors. Proposed amendments to the Anti-kickback Regulations were published in 1994 which, if ultimately adopted, would result in substantive changes to existing regulations. The failure to qualify under a safe harbor provision, while potentially subjecting the activity to greater regulatory scrutiny, does not render the activity illegal per se. There are several aspects of the Company's relationships with physicians to which the Anti-kickback Law may be relevant. In some instances, the Company itself may become a provider of services for which it will claim reimbursement from Medicare or Medicaid, and physicians who are investors in the Company may refer patients to the Company for those services. Furthermore, the government may construe some of the marketing and managed care contracting activities of the Company as arranging for the referral of patients to the physicians with whom the Company has a management contract. Finally, at the request of a physician or medical practice with which the Company has a contract, the Company will manage in the physician's office the provision of ancillary services which the physician desires to make available to his patients. At the present time, the services provided by the Company in its IMPACT(R) Centers are generally not reimbursable by Medicare or Medicaid. Although neither the investments in the Company by physicians nor the management contracts between the Company and physicians qualify for protection under the safe harbor regulations, the Company does not believe that these activities fall within the type of activities the Anti-kickback Amendments were intended to prohibit. A determination that the Company had violated the Anti-kickback Amendments would have a material adverse effect on the Company's business. The Stark Self-Referral Law The Stark Self-Referral Law ("Stark Law") prohibits a physician from referring a patient to a healthcare provider for certain designated health services reimbursable by Medicare or -5- 6 Medicaid if the physician has a financial relationship with that provider, including an investment interest, a loan or debt relationship or a compensation relationship. The designated services covered by the law include radiology services, infusion therapy, radiation therapy, outpatient prescription drugs and hospital services, among others. In addition to the conduct directly prohibited by the law, the statute also prohibits "circumvention schemes," that are designed to obtain referrals indirectly that cannot be made directly. The penalties for violating the law include (i) a refund of any Medicare or Medicaid payments for services that resulted from an unlawful referral; (ii) civil fines; and (iii) exclusion from the Medicare and Medicaid programs. The Stark Law contains a number of exceptions potentially applicable to the Company's operations. These include exceptions for a physician's ownership of publicly traded securities in a corporation with stockholders' equity exceeding $75 million as of the end of its most recent fiscal year, for certain in-office ancillary services and for certain personal services arrangements. The Company is not currently a provider of any designated health service under the Stark Law for which the Company claims reimbursement from Medicare or Medicaid. The Company intends to assure that any designated health services provided by physicians with whom the Company has a management contract will qualify under the applicable exception in the Stark Law for in-office services. However, because the Company will provide management services related to those designated health services, there can be no certainty that the Company will not be considered as the provider for those services. In that event, the referrals from the physicians will be permissible only if (i) the Company qualifies for the exception for publicly-traded corporations and (ii) the management contract meets the exception in the Stark Law for payments by physicians to a health care entity. To qualify for such exception, such payments must be set at a fair market value. The Company intends to structure its arrangements so as to qualify for applicable exceptions under the Stark Law, however, there can be no assurance that a review by courts or regulatory authorities would not result in a contrary determination. STATE LAW State Anti-Kickback Laws Many states have laws that prohibit the payment of kickbacks in return for the referral of patients. Some of these laws apply only to services reimbursable under the state Medicaid program. However, a number of these laws apply to all healthcare services in the state, regardless of the source of payment for the service. The Company believes, based on the advice of counsel, that these laws prohibit payments to referral sources only where a principal purpose for the payment is for the referral. The Company pays oncologists, who supervise their patients' treatment at the IMPACT(R) Centers, fees for collecting and monitoring treatment and outcomes data and reporting such data to the Company. The Company believes such fees reflect the fair market value of the services rendered by such physicians to the Company. However, the laws in most states regarding kickbacks have been subjected to limited judicial and regulatory interpretation and therefore, no assurances can be given that the Company's activities will be found to be in compliance. Noncompliance with such laws could have an adverse effect upon the Company and subject it and such physicians to penalties and sanctions. State Self-Referral Laws A number of states have enacted self-referral laws that are similar in purpose to the Stark Self-Referral Law. However, each state law is unique. For example, some states only prohibit referrals where the physician's financial relationship with a healthcare provider is based upon an investment interest. Other state laws apply only to a limited number of designated health services. Finally, some states do not prohibit referrals, but merely require that a patient be informed of the financial relationship before the referral is made. The Company believes that it is in compliance with the self-referral law of any state in which the Company has a financial relationship with a physician. Fee-Splitting Laws Many states prohibit a physician from splitting with a referral source the fees generated from physician services. Other states have a broader prohibition against any splitting of a physician's fees, regardless of whether the other party is a referral source. In most cases, it is not considered to be fee-splitting when the payment made by the physician is reasonable reimbursement for services rendered on the physician's behalf. -6- 7 The Company will be reimbursed by physicians on whose behalf the Company provides management services. The Company intends to structure the reimbursement provisions of its management contracts with physicians in order to comply with applicable state laws relating to fee-splitting. However, there can be no certainty that, if challenged, the Company and its affiliated physicians will be found to be in compliance with each state's fee-splitting laws. Corporate Practice of Medicine Most states prohibit corporations from engaging in the practice of medicine. Many of these state doctrines prohibit a business corporation from employing a physician. However, states differ with respect to the extent to which a licensed physician can affiliate with corporate entities for the delivery of medical services. Some states interpret the "practice of medicine" broadly to include decisions that have an impact on the practice of medicine, even where the physician is not an employee of the corporation and the corporation exercises no discretion with respect to the diagnosis or treatment of a particular patient. The Company's standard practice under its management contracts is to avoid the exercise of any responsibility on behalf of its physicians that could be construed as affecting the practice of medicine. Accordingly, the Company believes that it is not in violation of applicable state laws relating to the corporate practice of medicine. However, because such laws and legal doctrines have been subjected to only limited judicial and regulatory interpretation, there can be no assurance that, if challenged, the Company will be adjudicated to be in compliance with all such laws and doctrines. Insurance Laws Laws in all states regulate the business of insurance and the operation of HMOs. Many states also regulate the establishment and operation of networks of health care providers. While these laws do not generally apply to companies that provide management services to networks of physicians, there can be no assurance that regulatory authorities of the states in which the Company operates would not apply these laws to require licensure of the Company's operations as an insurer, as an HMO or as a provider network. The Company believes that it is in compliance with these laws in the states in which it does business, but there can be no assurance that future interpretations of insurance and health care network laws by regulatory authorities in these states or in the states into which the Company may expand will not require licensure or a restructuring of some or all of the Company's operations. State Licensing The Company's laboratories operated in conjunction with certain IMPACT(R) Centers are registered with the U.S. Food & Drug Administration and are certified pursuant to the Clinical Laboratory Improvement Amendments of 1988. In addition, the Company maintains pharmacy licenses for all IMPACT(R) Centers having self-contained pharmacies, and state health care facility licenses, where required. REIMBURSEMENT AND COST CONTAINMENT Approximately 50% of the net revenue of the Company's practice management division and less than five percent of the revenue of the Company's IMPACT(R) division is derived from payments made by government sponsored health care programs (principally, Medicare and Medicaid). As a result, any change in reimbursement regulations, policies, practices, interpretations or statutes could adversely affect the operations of the Company. In recent years, the federal government has sought to constrain the growth of spending in the Medicare and Medicaid programs. Through the Medicare program, the federal government has implemented a resource-based relative value scale ("RBRVS") payment methodology for physician services. RBRVS is a fee schedule that, except for certain geographical and other adjustments, pays similarly situated physicians the same amount for the same services. The RBRVS is adjusted each year and is subject to increases or decreases at the discretion of Congress. The implementation of RBRVS may result in reductions in payment rates for procedures provided by physicians under current contract with the Company. RBRVS-type payment systems have also been adopted by certain private third party payors and may become a predominant payment methodology. A broader implementation of such programs would reduce payments by private third party payors and could indirectly reduce the Company's operating margins to the extent that the cost of providing management services related to such procedures could not be proportionately reduced. To the extent the Company's costs increase, the Company may not be able to recover such cost increases from government reimbursement programs. In addition, because of cost containment measures and market changes in non-governmental insurance plans, the Company may not be able to shift cost increases to non-governmental payors. The Company expects a reduction -7- 8 from historical levels in per patient Medicare revenue received by certain of the physician groups with which the Company contracts; however, the Company does not believe such reductions would, if implemented, result in a material adverse effect on the Company. In addition to current governmental regulation, the Clinton Administration and several members of Congress have proposed legislation for comprehensive reforms affecting the payment for and availability of health care services. Aspects of certain of such health care proposals, such as reductions in Medicare and Medicaid payments, if adopted, could adversely affect the Company. Other aspects of such proposals, such as universal health insurance coverage and coverage of certain previously uncovered services, could have a positive impact on the Company's business. It is not possible at this time to predict what, if any, reforms will be adopted by Congress or state legislatures, or when such reforms would be adopted and implemented. As health care reform progresses and the regulatory environment accommodates reform, it is likely that changes in state and federal regulations will necessitate modifications to the Company's agreements and operations. While the Company believes it will be able to restructure in accordance with applicable laws and regulations, the Company cannot assure that such restructuring in all cases will be possible or profitable. Rates paid by private third party payors, including those that provide Medicare supplemental insurance, are based on established physician, clinic and hospital charges and are generally higher than Medicare payment rates. Changes in the mix of the Company's patients among the non-governmental payors and government sponsored health care programs, and among different types of non-government payor sources, could have a material adverse effect on the Company. EMPLOYEES As of March 1, 1997, the Company employed approximately 500 persons, approximately 400 of whom were full-time employees. Under the terms of the Service Agreements with the affiliated physician groups, the Company is responsible for the practice compensation and benefits of the groups' non-physician medical personnel. No employee of the Company or of any affiliated physician group is a member of a labor union or subject to a collective bargaining agreement. The Company believes that its labor relations are good. ITEM 2. PROPERTIES As of March 1, 1997 the Company leased 36,500 square feet of space at 1775 Moriah Woods Boulevard, in Memphis, Tennessee, where the Company's headquarters are located. The lease expires in 2002. The Company also leases all facilities housing the Company's operating facilities. The Company is also liable under leases for facilities where affiliated practices to which the Company provides management services are located. Management believes that the Company's properties are well maintained and suitable for its business operations. The Company may lease additional space in connection with the development of future treatment facilities or practice affiliations. ITEM 3. LEGAL PROCEEDINGS No material litigation is currently pending against the Company, and the Company is not aware of any outstanding claims against any affiliated physician group that would have a material adverse effect on the Company's financial condition or results of operations. The Company expects its affiliated physician groups to be involved in legal proceedings incident to their business, most of which are expected to involve claims related to the alleged medical malpractice of its affiliated oncologists. ITEM 4. MATTERS SUBMITTED TO STOCKHOLDERS' VOTE Not applicable. -8- 9 PART II ITEM 5. MARKET INFORMATION AND RELATED STOCKHOLDER MATTERS The Company's common stock is quoted on The Nasdaq Stock Market's National Market under the symbol "ROIX". Prior to October 26, 1995, the common stock was listed on the American Stock Exchange under the symbol "RTK". As of March 1, 1997 the Company's common stock was held by approximately 600 shareholders of record. The Company has not paid any cash dividends on the common stock since its inception. The Board of Directors does not intend to pay cash dividends on the common stock in the foreseeable future, but intends to retain all earnings, if any, for use in the Company's business. The following tables set forth, for the periods indicated, the high and low sale prices for the Company's common stock. All prices are adjusted to give effect to a reverse stock split effected by the Company on November 2, 1995.
Year Ended December 31, 1996 Year Ended December 31, 1995 - ---------------------------- ---------------------------- High Low High Low ---- --- ---- --- First Quarter 16 1/2 12 First Quarter 12 1/2 8 1/2 Second Quarter 21 12 1/2 Second Quarter 13 3/4 9 1/16 Third Quarter 17 12 1/2 Third Quarter 21 1/4 7 1/2 Fourth Quarter 14 7/8 9 1/4 Fourth Quarter 20 9 1/4
Recent Sales of Unregistered Securities Securities Issued in connection with Physician Practice Affiliations: During the Registrant's 1996 fiscal year, the Registrant issued shares of its Common Stock, warrants to purchase the Registrant's Common Stock and unsecured, and subordinated promissory notes ("PIK Notes") payable at the option of holders in shares of Common Stock (collectively, the "Unregistered Securities") in ten separate acquisition transactions pursuant to which the Registrant acquired the operating assets or stock of ten medical oncology practices from the physician owners ("Physician Owners") thereof or the professional association owned by such Physician Owners ("PA"). In each case, the Unregistered Securities were issued in exchange for either 100% of the outstanding stock owned by the Physician Owners of the practices or, in one case, certain of the assets of the PA. The Unregistered Securities were offered and issued to the Physician Owners or, in one instance, the PA, in reliance upon the exemption from registration under Section 4(2) of the Securities Act of 1933. Each of the Physician Owners was an accredited investor, as that term is defined in Rule 501 under Regulation D, and each Physician Owner was represented by competent transactional counsel. The affiliation transactions and Unregistered Securities issued in connection with the affiliations are as follows: In January 1996, the Registrant issued to Physician Owners a single 9% PIK Note in the principal amount of $5,959,972 that matures in 2011, with principal and interest payable on an amortized basis. Any payment of principal and interest may be paid, at the option of the holder of the PIK Note, in shares of Common Stock at a conversion price of $14.00 per share. In April 1996, the Registrant issued to Physician Owners 80,000 warrants to purchase Common Stock at a price of $11.75. In addition, the Registrant issued a 5% PIK Note to a Physician Owner in the principal amount of $150,000 maturing in 1997, payment of which may be made, at the option of the holder, in shares of Common Stock at a conversion price of $11.75 per share. In June 1996, the Registrant issued to a Physician Owner 196,154 shares of Common Stock. In addition, the Registrant issued to the Physician Owner a $5.1 million 4% PIK Note maturing in 1998, payment of which may be made, at the option of the holder, in shares of Common Stock at a conversion price of $15.60 per share. In July 1996, the Registrant issued to Physician Owners an aggregate of 117,600 shares of Common Stock. In August 1996, the Registrant issued to Physician Owners 5% PIK Notes in the aggregate of $1,900,000 maturing August 1, 2001, payment of which may be made, at the option of the holders, in shares of Common Stock at a conversion price of $13.75. In October 1996, the Registrant issued to the P.A. or Physician Owners an aggregate of 326,170 shares of Common Stock. In addition, the Registrant issued 4% and 5% PIK Notes in the aggregate of $5,636,625 maturing through 2001, payment of which may be made, at the option of the holders, in shares of Common Stock at conversion prices ranging from $12.73 to $18.00 (approximately $4 million of which has a conversion price of $12.73). In November 1996, the Registrant issued 47,836 shares of Common Stock. In addition, the Registrant issued to Physician Owners 5.6% PIK Notes in the aggregate of $772,500, payment of which may be made, at the option of the holders, in shares of Common Stock at a conversion price of $14.20. Securities Issued to Controlling Shareholder In April 1996, the Registrant issued an unsecured, $10 million convertible note to Seafield Capital Corporation ("Seafield"), the Registrant's controlling shareholder, bearing interest at the rate of prime plus 1%, which after August 1, 1996, became convertible at the election of Seafield into shares of the Company's Common Stock. Proceeds of the loan were used to finance a practice management affiliation. The note was exchanged for 909,090 shares of Common Stock during August 1996. In October 1996, the Registrant obtained a $23.5 million credit facility from Seafield to be used to finance practice affiliations and for working capital. The facility was evidenced by a convertible note payable upon the earlier of the closing of an equity offering or August 1, 1998. The note provided for interest at a rate of 8% escalating at certain points during the term of the note, was unsecured and was convertible at the election of Seafield Capital Corporation into shares of the Company's common stock at a conversion price equal to the market price of the common stock at the date of conversion; provided, however, that after December 31, 1996, the conversion price would be the lower of market or $11.00 per share. ITEM 6. SELECTED FINANCIAL DATA (in thousands except per share data)
Year Ended December 31 --------------------------------------------- 1996 1995 1994 1993 1992 -------- ------- -------- ------- ------- Net revenue and other income $ 67,553 $44,580 $38,471 $37,885 $28,043 Net earnings (loss) 910 2,314 (2,346) 700 591 Net earning (loss) to common shareholders 907 2,310 (2,349) 697 584 Total assets 142,950 24,765 21,037 25,877 17,100 Long-term debt and lease obligations 62,230 15 29 185 320 Earnings (loss) per common share (1) $ 0.11 $ 0.32 $ (0.34) $ 0.10 $ 0.09
(1) On November 2, 1995, the Company effected a one-for-five reverse split of its common stock. Earnings (loss) per common share computations have been restated to retroactively reflect the reverse split. -9- 10 ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OVERVIEW The Company is a comprehensive cancer management company. The Company provides advanced cancer treatment services through outpatient facilities known as IMPACT(R) Centers under the direction of practicing oncologists; owns the assets of and manages the nonmedical aspects of oncology practices; and conducts clinical cancer research on behalf of pharmaceutical manufacturers. Approximately 350 medical oncologists are associated with the Company through these programs. In 1990 the Company began development of a network of specialized IMPACT(R) Centers to provide complex outpatient chemotherapy services under the direction of practicing oncologists. The majority of the therapies provided at the IMPACT(R) Centers entail the administration of high-dose chemotherapy coupled with peripheral blood stem cell support of the patient's immune system. At December 31, 1996, the Company's network consisted of 47 IMPACT(R) Centers, including 24 wholly-owned, 12 managed programs, and 11 owned and operated in joint venture with a host hospital. Prior to January 1996, the Company derived substantially all of its revenues from outpatient cancer treatment services through reimbursements from third party payors on a fee-for-service or discounted fee-for-service basis. During 1996 the Company commenced execution of a diversification strategy into practice management. Such diversification included the affiliation during 1996 with 38 physicians in 10 medical oncology practices in Florida and Tennessee. The Company has sought deep geographic penetration in those markets believing that significant market share is crucial to achieving efficiencies, revenue enhancements, and marketing of complete cancer services to diverse payors including managed care. Pursuant to Service Agreements, the Company provides management services that extend to all nonmedical aspects of the operations of the affiliated practices. The Company is responsible for providing facilities, equipment, supplies, support personnel, and management and financial advisory services. In its practice management relationships, the Company has predominantly used two models of Service Agreements: (i) an "adjusted net revenue" model; and (ii) a "net operating income" model. Service Agreements utilizing the adjusted net revenue concept provide for the payment by the physician group out of practice net revenue, in the following order of payment (A) physician retainage (i.e. physician compensation, benefits, and perquisites, including malpractice insurance) of between 24% and 50% of net revenue ("Physician Expense"); (B) a clinic expense portion of the management fee (the "Clinic Expense Portion") equal to the aggregate actual practice operating expenses exclusive of Physician Expense; and (C) a base service fee portion (the "Base Fee") of between 8.7% and 29.5% of net revenue. In the event that net revenue is insufficient to pay all of the foregoing in full, then the Base Fee is first reduced, followed by the Clinic Expense Portion of the management fee, and finally, physician retainage, therefore effectively shifting all operating risk to the Company. In each Service Agreement utilizing the adjusted net revenue model, the Company is entitled to a Performance Fee generally equal to 50% of Annual Surplus, defined as the excess of practice revenue over the sum of Physician Retainage, the Clinic Expense Portion, and the Base Fee. Service Agreements utilizing the net operating income model provide for a management fee equal to the sum of a Clinic Expense Portion (see preceding paragraph) plus a percentage (the "Percentage Portion"), ranging from 20% to 40%, of the net operating income of the practice (defined as net revenue minus practice operating expenses). In those practice management relationships utilizing the net operating income model Service Agreement, the Company and the physician group share the risk of expense increases and revenue declines, but likewise share the benefits of expense savings, economies of scale and practice enhancements. -10- 11 Each Service Agreement contains a liquidated damages provision binding the physician practice and the principals thereof in the event the Service Agreement is terminated "for cause" by the Company. The liquidated damages are a declining amount, equal in the first year to the purchase price paid by the Company for practice assets and declining over a period of between 5 and 17.5 years. Principals are relieved of their individual obligations for liquidated damages only in the event of death, disability, or retirement at a predetermined age. RESULTS OF OPERATIONS 1996 Compared to 1995 Net revenue increased 52% to $67.4 million compared to $44.3 million for the year ended December 31, 1995. Net revenue from patient services decreased $.4 million from $33.8 million in 1995 to $33.4 million in 1996. Several jointly-owned IMPACT(R) Centers became operational during 1996 that minimized the effect of the closure of three wholly-owned IMPACT(R) Centers. These sites were closed due to affiliations by referring physicians with another physician practice management company prior to the Company establishing its own practice management alternative for oncologists. Practice management service fees from affiliations consummated beginning in January 1996, were $19.3 million or 84% of the overall increase in net revenue. Additionally, pharmaceutical sales to physicians increased $3.7 million from $9.8 million in 1995 to $13.5 million in 1996. Practice management service fees and pharmaceutical sales to physicians both carry a lower operating margin than the Company's traditional patient service revenue. EBITDA (earnings before interest, taxes, depreciation and amortization) increased $3.3 million or 80% to $7.4 million for the year ended December 31, 1996, in comparison to $4.1 million for the year ended December 31, 1995. EBITDA is not intended to represent net income, cash flow, or any other measure of performance in accordance with generally accepted accounting principles, but is included because the Company believes it is useful for measuring and identifying trends with respect to the Company's operating performance and creditworthiness. The increase in EBITDA is primarily due to the increase in revenues related to Service Agreements with affiliated physicians. Operating expenses increased $18.9 million, or 57%, from $32.9 million in 1995 to $51.8 million in 1996. Operating expenses consist primarily of payroll costs, pharmaceutical and laboratory expenses, medical director fees, rent expense, and other operational costs. Operating expenses as a percentage of net revenue were 77% and 74% for the years ended 1996 and 1995, respectively. The increase is primarily due to clinic expenses incurred at the affiliated physician practices under the Service Agreements. The increase as a percentage of net revenue is due to the lower margins realized on increased practice management service fees and pharmaceutical sales to physicians. Lab and pharmacy expense, which represents the largest component of operating expenses, increased $11.6 million, or 62%, from 1995 to 1996. Payroll costs increased $2.8 million, or 42%, from 1995 to 1996. The increases are primarily related to lab and pharmacy expenses and payroll costs at the affiliated physician practices that were not included in the Company's operating results in 1995. General and administrative costs increased $.7 million, or 12%, from $5.5 million in 1995 to $6.2 million in 1996. Salaries and benefits, which represent the largest component of general and administrative expenses, were $4.2 million in 1996 and $3.3 million in 1995. The increase is primarily due to the addition of operational management personnel for the practice management division and general increases in salaries and benefits. General and administrative costs as a percentage of net revenue were 9% and 12% in 1996 and 1995, respectively. The decrease as a percentage of net revenue is due to the significant increase in the revenue base from practice management service fees without a significant increase in general and administrative costs. -11- 12 Depreciation and amortization increased $1.8 million from $1.7 million in 1995 to $3.5 million in 1996. The increase is primarily attributable to the amortization of the Service Agreements purchased in practice management affiliations consummated during 1996. Interest expense was $2.6 million in 1996 related to borrowings under the Company's Credit Facility and debt assumed and/or issued in connection with practice management affiliations. The provision for doubtful accounts decreased $.5 million from $2.1 million in 1995 to $1.6 million in 1996. The provision as a percentage of net revenue from patient services was 5% and 6% for 1996 and 1995, respectively. The decrease is attributable to a higher proportion of contracted patient accounts. The Company's collection experience in 1996 and 1995 may not be indicative of future periods. Other costs of $.6 million were primarily non-recurring costs associated with the Company's financing efforts in 1996. Tax net operating loss carryforwards were utilized to reduce income tax expense to zero. As of December 31, 1996, the Company had available net operating loss carryforwards totaling approximately $4.5 million, all of which is subject to certain annual limitations due to a change in ownership for tax purposes in 1990. The use of net operating loss carryforwards is also dependent upon future taxable income. See Note G to the consolidated financial statements. 1995 Compared to 1994 The Company recorded net earnings of $2.3 million compared to a loss of $2.3 million for the year ended December 31, 1994. The significant improvement in operations in 1995 compared to 1994 is attributable to increased revenues from the increased referrals of high-dose chemotherapy patients, including the establishment of additional IMPACT(R) Centers, principally in joint venture with hospitals, and the further development of physician investigator studies for the pharmaceutical industry. Net revenue increased $6.0 million, or 16%, from 1994 to 1995. In addition to an approximate $2.1 million increase in net revenues from services to patients to $33.8 million in 1995, sales of pharmaceuticals to physicians increased by $3.3 million to $9.8 million and revenues from physician investigator studies in 1995, the first year of significant revenues generated from this source, amounted to $.7 million. Operating expenses increased $1.1 million, or 4%, from 1994 to 1995. Operating expenses consist primarily of payroll costs, pharmaceutical and laboratory expenses, medical director fees, rent expense and other operational costs. These expenses are expected to display a high degree of variability in proportion to Center revenues. Operating expenses as a percentage of net revenue were 74% and 83% for the years ended 1995 and 1994, respectively. This decrease is primarily attributable to operating efficiencies at higher levels of Center activity and certain fixed operating expenses being spread over a larger revenue base. Lab and pharmacy expense, which represents the largest component of operating expenses, increased $1.7 million, or 10%, from 1994 to 1995. The increase is primarily due to an increase in patient referrals and pharmaceutical supply expense related to sales to physicians. A reduction in medical director fees and other operating expenses of $.5 million was realized during 1995. General and administrative costs increased $1.2 million, or 29%, from 1994 to 1995. Salaries and benefits, which represent the largest component of general and administrative expenses, were $3.3 million in 1995 and $2.2 million in 1994. The increase is primarily due to management incentive compensation relative to -12- 13 significant improvement in operations and general increases in salaries and benefits. General and administrative costs as a percentage of net revenue were 12% and 11% in 1995 and 1994, respectively. Depreciation expense decreased $.1 million from 1994 to 1995. The decrease is primarily attributable to many prior capital expenditures becoming fully depreciated. Amortization expense decreased $.2 million from 1994 to 1995 due to the startup costs of many Centers being fully amortized after a two-year operational period. The provision for doubtful accounts decreased $.4 million from 1994 to 1995. The provision as a percentage of net revenue was 5% and 7% for 1995 and 1994, respectively. The decrease is attributable to a higher proportion of contracted patient accounts, improved collections performance and an increase in revenues from physician sales, hospital management fees, and contract research for which collection is more certain. The Company's collection experience in 1995 and 1994 may not be indicative of future periods. Tax net operating loss carryforwards were utilized to fully offset 1995 taxable income. LIQUIDITY AND CAPITAL RESOURCES At December 31, 1996, the Company's working capital was $14.6 million with current assets of $31.7 million and current liabilities of $17.1 million. Cash, cash equivalents, and short-term investments represented $.4 million of the Company's current assets. The increases in other current assets are related to receivables acquired through practice management affiliations and amounts due from affiliated physicians for practice management service fees. Current liabilities increased for amounts payable for operating expenses of practices under management and liabilities assumed as consideration in the practice management affiliations. Cash used by operating activities was $3.7 million in 1996 as compared to cash provided by operating activities of $2.1 million in 1995. The decrease in operating cash flow is primarily due to advances made to fund operations of recent practice management affiliations and increased general and administrative expenses in 1996 related to the Company's diversification into physician practice management. Cash used by investing activities was $53.3 million and $1.6 million in 1996 and 1995, respectively. The increase primarily represents funds used to acquire the nonmedical assets of the physician practices. Cash provided by financing activities was $53.3 million in 1996 and $.8 million in 1995. The increase in 1996 primarily represents proceeds from borrowings under the Company's Acquisition Facility and from Seafield Capital Corporation ("Seafield") to finance practice management affiliations. In April 1996, the Company obtained an unsecured $10.0 million loan (the "Seafield Note") from Seafield bearing interest at the rate of prime plus 1%, which after August 1, 1996, became convertible at the election of Seafield into shares of the Company's common stock. Proceeds of the loan were used to finance a practice management affiliation. The loan was exchanged for 909,090 shares of common stock during August, 1996. In May 1996, the Company entered into a $27.5 million Credit Facility with NationsBank and Union Planters to fund the Company's acquisition and working capital needs and to repay its existing facility with Union Planters. The Credit Facility, comprised of a $22.0 million Acquisition Facility and a $5.5 million Working Capital Facility, is collateralized by the common stock of the Company's subsidiaries. The Acquisition Facility matures May 31, 1998, and bears interest at a variable rate equal to LIBOR plus a spread between 1.5% and 2.625%, depending upon borrowing levels. The Working Capital Facility matures May 30, 1997, subject to a one-year extension, and bears interest at a variable rate equal to LIBOR plus a spread between 1.875% and 2.375%. At December 31, 1996, $20.9 million aggregate principal was outstanding under the Credit Facility with a current interest rate of approximately 7.7%. The Company's available credit under the -13- 14 Credit Facility at December 31, 1996 was $.2 million. The Credit Facility contains affirmative and negative covenants which, among other things, require the Company to maintain certain financial ratios, including minimum fixed charges coverage, funded debt to EBITDA, net worth and current ratio. As of December 31, 1996, the Company was in compliance with the covenants included in the Credit Facility. The Company has received a commitment to increase the Credit Facility to $45 million. The Company anticipates that working capital generated from operations and anticipated availability under the Credit Facility will be adequate to expand the IMPACT(R) Center network, manage the practices with which the Company has affiliated, and to make certain strategic acquisitions for the next 12 months. The Company's acquisition strategy is dependent upon capital resources in excess of working capital generated from operations and currently available credit facilities. Additionally, long-term unsecured, amortizing, promissory notes bearing interest at rates from 4% to 9% were issued as partial consideration for the practice management affiliations. Principal and interest under the long-term notes may, at the election of the holders, be paid in shares of common stock of the Company based upon conversion rates ranging from $11.75 to $18.00. The unpaid principal amount of the long-term notes was $26.5 million at December 31, 1996. In October 1996, the Company procured a $23.5 million credit facility from Seafield (the "Seafield Facility") to finance acquisitions and for working capital. At December 31, 1996, $22.5 million was outstanding under the Seafield Facility at an interest rate of 8%. On February 26, 1997, the $23.5 million loan and accrued interest of $.7 million was exchanged for 3,020,536 shares of the Company's common stock at a rate of $8 per share (which exchange rate was above the quoted market price of the common stock at the date of conversion). Simultaneous with the conversion, Seafield announced its intention to consider a distribution to its shareholders in 1997 of Seafield's shares of the Company's common stock. On July 17, 1996, the Company filed a registration statement with the Securities and Exchange Commission with respect to the public offering of 5.3 million shares of its common stock, $.01 par value per share. Because of market conditions subsequent to filing, the Company chose not to pursue the public offering and sought acquisition financing from the aforementioned sources. The registration statement has not been withdrawn and could be utilized in connection with any distribution by Seafield, if made. Capital expenditures of $1.0 million for the year ended December 31, 1996, were primarily associated with the expansion of the Company's network of IMPACT(R) Centers. No material commitments for capital expenditures currently exist. The Company is committed to future minimum lease payments under operating leases of $18.7 million for administrative and operational facilities. NEW ACCOUNTING STANDARDS The Financial Accounting Standards Board has issued Statement of Financial Accounting Standards No. 128 (SFAS 128), Earnings per Share, and Statement of Financial Accounting Standards No. 129 (SFAS 129), Disclosure of Information about Capital Structure. SFAS 128 establishes standards for computing and presenting earnings per share and applies to entities with publicly held common stock. SFAS 129 establishes standards for disclosing information about an entity's capital structure and applies to all entities. Management believes that the Company's adoption of these standards, when effective, will not have a significant impact on the Company's financial statements. -14- 15 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA This item is submitted in a separate section of this report (see pages ___ through ___). ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE Not applicable. PART III ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS The information required by this item with respect to the executive officers and directors of the Company is incorporated herein by reference to the sections entitled "Executive Officers" and "Nominees for Election as Directors" in the Company's definitive proxy statement for its Annual Meeting of Shareholders to be held June 5, 1997. ITEM 11. EXECUTIVE COMPENSATION The information required by this item with respect to executive compensation is incorporated herein by reference to the section entitled "Executive Compensation" in the Company's definitive proxy statement for its Annual Meeting of Shareholders to be held June 5, 1997. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The information required by this item with respect to executive compensation is incorporated herein by reference to the section entitled "Security Ownership of Certain Beneficial Owners, Directors and Management" in the Company's definitive proxy statement for its Annual Meeting of Shareholders to be held June 5, 1997. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS The information required by this item is incorporated herein by reference to the section entitled "Certain Transactions" in the Company's definitive proxy statement for its Annual Meeting of Shareholders to be held June 5, 1997. PART IV ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K (A)(1) and (2) -- The response to this portion of Item 14 is submitted as a separate section of this report (A)(3) LISTING OF EXHIBITS -15- 16 3(a) Charter(1) 3(b) Bylaws(1) 4 Trust Indenture, Deed of Trust and Security Agreement dated April 3, 1990(2) 10(a) Securities Purchase Agreement dated September 26, 1990 between the Registrant and Investor(3) 10(b) Amendment to Securities Purchase Agreement dated July 25, 1991 (reference 10(a) above)(3) 10(c)* Registrant's 1990 Non-Qualified Stock Option Plan, as amended**(4)(6) 10(d) Employment agreement between the Registrant and William H. West, M.D. dated July 1, 1995* 10(e) Employment agreement between the Registrant and Joseph T. Clark dated July 1, 1995**(5) 10(f) Stock Purchase Agreement between the Registrant and stockholders of Oncology Hematology Group of South Florida (incorporated herein by reference)(8) 10(g) Service Agreement between the Registrant and stockholders of Oncology Hematology Group of South Florida (incorporated herein by reference)(8) 10(h)** Amendment to 1990 Registrant's Non-Qualified Stock Option Plan adopted April 20, 1995(5) 10(i) Employment agreement between the Registrant and Charles H. Weaver, M.D. dated July 1, 1995**(5) 10(j) Purchase and Sale Agreement by and among Response Oncology, Inc., Knoxville Hematology Oncology Associates and Partners of Knoxville Hematology Oncology Associates dated April 12, 1996 (incorporated herein by reference)(9) 10(k) Service Agreement between Response Oncology, Inc., Knoxville Hematology Oncology Associates, P.L.L.C. and Members of Knoxville Hematology Oncology Associates, P.L.L.C. dated April 12, 1996 (incorporated herein by reference)(9) 10(l) Stock Purchase Agreement among Registrant, Jeffrey L. Paonessa, M.D. and J. Paonessa, M.D., P.A. (incorporated herein by reference)(10) 10(m) Service Agreement between the Registrant and stockholders of Jeffrey L. Paonessa, M.D., P.A. (incorporated herein by reference)(10) 10(n) Service Agreement between the Registrant and stockholders of Southeast Florida Hematology Oncology Group, P.A. (incorporated herein by reference)(11) 10(o) Stock Purchase Agreement between the Registrant and stockholders of Southeast Florida Hematology Oncology Group, P.A. (incorporated herein by reference)(7) 10(p) Stock Purchase Agreement by and among the Registrant and Stockholders of Rosenberg and Kalman, M.D., P.A. (incorporated herein by reference)(11) 10(q)** Amendment No. 3 to 1990 Registrant's Non-Qualified Stock Option Plan adopted December 16, 1995(6) 10(r) Service Agreement between the Registrant, Rosenberg & Kalman, M.D., P.A., and Stockholders of R&K, M.D., P.A. (incorporated herein by reference)(11) 16 17 10(s) Asset Purchase Agreement by and among the Registrant, Stockholders of The Center for Hematology-Oncology, P.A. and The Center for Hematology-Oncology, P.A. (incorporated herein by reference)(12) 10(t) Stock Purchase Agreement by and among the Registrant, Stockholders of Hematology Oncology Associates of the Treasure Coast, P.A. and Hematology Oncology Associates of the Treasure Coast, P.A. (incorporated herein by reference)(13) 10(u) Loan Agreement dated May 31, 1996 between Registrant, NationsBank of Tennessee, N.A. and Union Planters National Bank 10(v) Agreement of Payment and Satisfaction dated as of February 26, 1997, between the Registrant and Seafield Capital Corporation(14) 10(w) Registrant's 1985 Stock Option Plan, as amended(15) 11 Statement re Computation of Per Share Earnings. 13 Annual Report to Stockholders for the year ended December 31, 1996 - to be filed 21 List of Subsidiaries 23 Consent of Independent Auditors 27 Financial Data Schedule (for SEC use only) - ----------- * These documents may be obtained by stockholders of Registrant upon written request to: Response Oncology, Inc., 1775 Moriah Woods Blvd., Memphis, Tennessee 38117 ** Management Compensatory Plan + Response Tech Healthcare Corporation, formerly a wholly-owned subsidiary of the Registrant, was merged into the Registrant effective on February 25, 1997 (1) Incorporated by reference to the Registrant's 1989 10-K, dated July 31, 1989 (2) Incorporated by reference in the initial filing of the Registrant's 1990 10-K, dated July 18, 1990, filed July 20, 1990 and amended on September 19, 1990 (3) Incorporated by reference to the Registrant's 1991 10-K, dated July 26, 1991 (4) Incorporated by reference to the Registrant's Registration Statement on Form S-8 under the Securities Act of 1933 (File No. 33-45616) effective February 11, 1992 (5) Incorporated by reference to the Registrant's 1995 10-K, dated March 29, 1996 (6) Incorporated by reference to the Registrant's Registration Statement on Form S-8 under the Securities Act of 1933 (File No. 333-14371) effective October 11, 1996 (7) Form 8-K filed July 15, 1996 (File No. 0-15416) (8) Form 8-K filed January 17, 1996 (File No. 0-15416) (9) Form 8-K filed April 30, 1996 (File No. 0-15416) (10) Form 8-K filed July 5, 1996 (File No. 0-15416) (11) Form 8-K filed September 18, 1996 (File No. 1-09922) (12) Form 8-K filed October 21, 1996 (File No. 1-09922) (13) Form 8-K filed November 5, 1996 (File No. 1-09922) (14) Form 13D/A filed March 10, 1997 (File No. 005-37885) (15) Incorporated by reference to the Registrant's Registration Statement on Form S-8 under the Securities Act of 1933 (File No. 33-21333) effective April 26, 1988 - 17 - 18 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Response Oncology, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RESPONSE ONCOLOGY, INC. By:/s/Joseph T. Clark -------------------------- Joseph T. Clark President, Chief Executive Officer, and Director Date: March --, 1997 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated. By: /s/Frank M. Bumstead By: /s/P. Anthony Jacobs -------------------------- -------------------- Frank M. Bumstead P. Anthony Jacobs Vice-Chairman of the Board Director Date: March --, 1997 Date: March --, 1997 By: /s/Joseph T. Clark By: /s/Dena L. Mullen -------------------------- ------------------------ Joseph T. Clark Dena L. Mullen President, Chief Executive Controller and Principal Officer, and Director Accounting Officer Date: March --, 1997 Date: March --, 1997 By: /s/Mary E. Clements By: /s/James R. Seward -------------------- ------------------------ Mary E. Clements James R. Seward Executive Vice Director President of Finance and Principal Financial Officer Date: March --, 1997 Date: March --, 1997 By: /s/William H. West, M.D. ------------------------ William H. West, M.D. Chairman of the Board Date: March --, 1997 -18- 19 Independent Auditors' Report The Board of Directors Response Oncology, Inc. We have audited the consolidated balance sheets of Response Oncology, Inc. and subsidiaries as of December 31, 1996 and 1995, and the related consolidated statements of operations, stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 1996. Our audits also included the financial statement schedule listed in the Index at Item 14(a). These financial statements and financial statement schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and financial statement schedule based on our audits. We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Response Oncology, Inc. and subsidiaries as of December 31, 1996 and 1995, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 1996, in conformity with generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein. KPMG PEAT MARWICK LLP Memphis, Tennessee February 12, 1997 -19- 20 PART I - FINANCIAL INFORMATION
ITEM 1: FINANCIAL STATEMENTS RESPONSE ONCOLOGY, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Dollar amounts in thousands) December 31 -------------------- ASSETS 1996 1995 ---------- -------- CURRENT ASSETS Cash and cash equivalents $ 415 $ 4,205 Short-term investments - 362 Accounts receivable, less allowance for doubtful accounts of $1,774 and $2,080 14,297 13,935 Supplies 2,415 1,119 Prepaid expenses and other current assets 2,168 1,016 Due from affiliated physicians 12,423 - -------- -------- TOTAL CURRENT ASSETS 31,718 20,637 Property and equipment - at cost, less accumulated depreciation and amortization of $8,160 and $6,236 5,406 3,822 Deferred charges, less accumulated amortization of $232 and $66 490 187 Management service agreements, less accumulated amortization of $1,345 101,963 - Deferred tax asset 3,267 - Other assets 106 119 -------- -------- TOTAL ASSETS $142,950 $ 24,765 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 4,863 $ 3,691 Accrued expenses and other liabilities 4,268 1,135 Notes payable 7,847 - Capital lease obligations 74 58 -------- -------- TOTAL CURRENT LIABILITIES 17,052 4,884 Capital lease obligations, less current portion 124 15 Notes payable, less current portion (including $22,494 due to Parent) 62,106 - Deferred tax liability 25,127 - Minority interest 374 23 STOCKHOLDERS' EQUITY Series A convertible preferred stock, $1.00 par value, authorized 3,000,000 shares; issued and outstanding 27,233 and 27,833 shares, respectively, liquidating preference $11.00 per share 27 28 Common Stock, $.01 par value, authorized 30,000,000 shares; issued and outstanding 8,947,018 and 7,371,589 shares, respectively 89 74 Paid-in capital 77,454 60,054 Accumulated deficit (39,403) (40,313) -------- -------- 38,167 19,843 -------- -------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $142,950 $ 24,765 ======== ========
See accompanying notes to consolidated financial statements. -20- 21 RESPONSE ONCOLOGY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Dollar amounts in thousands except for share data)
Years Ended December 31 ---------------------------------- 1996 1995 1994 --------- --------- --------- NET REVENUE $ 67,353 $ 44,298 $ 38,251 Other income 200 282 220 ---------- ---------- ---------- 67,553 44,580 38,471 COSTS AND EXPENSES Operating 51,842 32,893 31,758 General and administrative 6,152 5,512 4,286 Depreciation and amortization 3,485 1,736 2,125 Interest 2,589 17 120 Provision for doubtful accounts 1,594 2,106 2,528 Other 608 - - ---------- ---------- ---------- 66,270 42,264 40,817 ---------- ---------- ---------- EARNINGS (LOSS) BEFORE MINORITY INTEREST 1,283 2,316 (2,346) Minority owners' share of net earnings (373) (2) - ---------- ---------- ---------- NET EARNINGS (LOSS) 910 2,314 (2,346) Common Stock Dividend to Preferred Stockholders (3) (4) (3) ---------- ---------- ---------- NET EARNINGS (LOSS) TO COMMON STOCKHOLDERS $ 907 $ 2,310 $ (2,349) ========== ========== ========== EARNINGS (LOSS) PER COMMON SHARE $ 0.11 $ 0.32 $ (0.34) ========== ========== ========== Weighted average number of shares 8,245,782 7,171,274 6,953,157 ========== ========== ==========
See accompanying notes to consolidated financial statements. -21- 22 RESPONSE ONCOLOGY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Dollar amounts in thousands)
Series A Convertible Preferred Stock Common Stock ------------------------ ---------------------------- Par Value Par Value Paid-In Shares ($1.00 Per Shares ($.01 Per Share) Capital ---------- Share) ------------ ------------------------ ---------- Balances at December 31, 1993 29,568 $29 34,664,982 $69 $58,962 Net loss Exercise of common stock warrants and options 154,500 - 74 Conversion of preferred stock (1,235) (1) 1,130 - 1 Dividend on preferred stock 1,545 - - ------- --- ----------- --- ------- Balances at December 31, 1994 28,333 28 34,822,157 69 59,037 Net earnings Exercise of common stock warrants and options 497,000 5 1,017 Conversion of preferred stock (500) - 458 - - One-for-five reverse split (27,948,332) - - Dividend on preferred stock 306 - - ------- --- ----------- --- ------- Balances at December 31, 1995 27,833 28 7,371,589 74 60,054 Net earnings Exercise of common stock options 26,000 - 275 Conversion of preferred stock (600) (1) 109 - 1 Common stock issued in connection with practice affiliations 639,924 6 6,583 Conversion of Seafield Note 909,090 9 9,991 Dividend on preferred stock 306 - - Warrants issued in connection with practice affiliations 550 ------- --- ----------- --- ------- Balances at December 31, 1996 27,233 $27 8,947,018 $89 $77,454 ======= === =========== === =======
Total Accummulated Stockholders' Deficit Equity --------------- ----------- Balances at December 31, 1993 $(40,281) $ 18,779 Net loss (2,346) (2,346) Exercise of common stock warrants and options - 74 Conversion of preferred stock - - Dividend on preferred stock - - -------- -------- Balances at December 31, 1994 (42,627) 16,507 Net earnings 2,314 2,314 Exercise of common stock warrants and options - 1,022 Conversion of preferred stock - - One-for-five reverse split - - Dividend on preferred stock - - -------- -------- Balances at December 31, 1995 (40,313) 19,843 Net earnings 910 910 Exercise of common stock options - 275 Conversion of preferred stock - - Common stock issued in connection with practice affiliations - 6,589 Conversion of Seafield Note - 10,000 Dividend on preferred stock - - Warrants issued in connection with practice affiliations - 550 -------- -------- Balances at December 31, 1996 $(39,403) $ 38,167 ======== ========
See accompanying notes to consolidated financial statements - 22 - 23 RESPONSE ONCOLOGY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollar amounts in thousands)
Years Ended December 31, ---------------------------- 1996 1995 1994 -------- --------- ------- OPERATING ACTIVITIES Net earnings (loss) $ 910 $ 2,314 $ (2,346) Adjustments to reconcile net earnings (loss) from operations: Depreciation and amortization 3,485 1,736 2,125 Loss on disposal of equipment - - 51 Provisions for losses on accounts receivable 1,594 2,106 2,528 Minority owners' share of net income 373 2 - Changes in assets and liabilities, net of effect of acquisitions: Accounts receivable (1,956) (3,641) 161 Supplies, prepaid expenses, and other current assets (1,332) (772) 623 Deferred charges and other assets (176) (207) (79) Net advances to affiliated physician groups (6,846) - - Accounts payable and accrued expenses 225 553 21 ------- ------ ----- NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES (3,723) 2,091 3,084 INVESTING ACTIVITIES Purchase of equipment (1,034) (1,330) (586) Proceeds from sale of equipment - - 24 Hollywood Center net assets assumed in excess of investment basis - - (53) Sale (purchase) of short-term investments 362 (262) - Acquisition of nonmedical assets of affiliated physician practices (53,683) - - ------- ------ ----- NET CASH USED IN INVESTING ACTIVITIES (53,355) (1,592) (615) FINANCING ACTIVITIES Bank overdraft 491 - - Financing costs incurred (324) - - Proceeds from exercise of stock options and warrants 275 1,022 74 Proceeds from notes payable 26,631 - 59 Principal payments on notes payable (6,895) (71) - Net proceeds (payments) on line of credit 681 - (2,420) Proceeds from note payable to parent 32,494 - - Principal payments on capital lease obligations (65) (168) (360) ------- ------ ------ NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 53,288 783 (2,647) INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (3,790) 1,282 (178) Cash and cash equivalents at beginning of period 4,205 2,923 3,101 ------- ------- ------- CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 415 $ 4,205 $ 2,923 ======= ======= =======
Continued - 23 - 24 RESPONSE ONCOLOGY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollar amounts in thousands)
1996 1995 1994 --------- ---- ---- Supplemental schedule of noncash investing and financing activities: Effect of practice acquisitions (Note C): Intangible assets $103,308 Property and equipment, net 2,474 Acquired accounts receivable, net 6,430 Other assets 4,643 -------- Total assets acquired, net of cash 116,855 Liabilities assumed (29,926) Issuance of notes payable (27,107) Issuance of common stock (7,139) -------- Payments for clinic operating assets $ 52,683 ======== Cash paid for- Interest $ 1,642 $17 $130 ======== ==== ====
See accompanying notes to consolidated financial statements. - 24 - 25 RESPONSE ONCOLOGY, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 1996 NOTE A -- ORGANIZATION AND DESCRIPTION OF BUSINESS Response Oncology is a comprehensive cancer management company which owns and/or operates a network of outpatient treatment centers or IMPACT Centers, which provide stem cell supported high-dose chemotherapy and other advanced cancer treatment services under the direction of practicing oncologists, owns the assets of and manages oncology practices, and conducts clinical cancer research on behalf of pharmaceutical manufacturers. The Company, formerly known as Response Technologies, Inc., changed its name to Response Oncology, Inc. effective November 2, 1995. The Company is a subsidiary of Seafield Capital Corporation ("Seafield"). On February 10, 1995, Seafield announced its retention of a financial advisor to evaluate and recommend steps to enhance the value of Seafield to its shareholders. Any transaction pursued by Seafield will be likely to result in a significant change in the Company's ownership. NOTE B -- SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and majority-owned or controlled joint ventures. All significant intercompany accounts and transactions have been eliminated in consolidation. Cash Equivalents: All highly liquid investments with an original maturity of three months or less when purchased are considered to be cash equivalents. Short-Term Investments: Short-term investments consist of certificates of deposit maturing in less than one year. These investments are carried at cost which approximates market. Accounts Receivable: Accounts receivable represents amounts due from patients for medical services provided. Such amounts are recorded net of uncollectible amounts. Due From Affiliated Physicians: Due from affiliated physicians consists of management fees earned pursuant to the management service agreements ("Service Agreements") during the year ended December 31, 1996. In addition, the Company may also fund certain working capital needs of the affiliated physicians from time to time. Due to the demographics of oncology patients, a significant portion of the affiliated physicians' medical service revenues are related to third-party reimbursement agreements, primarily Medicare and other governmental programs. Medicare and other governmental programs reimburse physicians based on fee schedules which are determined by the related governmental agency. In the ordinary course of business, affiliated physicians receiving reimbursement from Medicare and other governmental programs are potentially subject to a review by regulatory agencies concerning the accuracy of billings and sufficiency of supporting documentation of procedures performed. Provisions for estimated third-party payor settlements and adjustments are estimated in the period the related services are rendered and adjusted in future periods as final settlements are determined. Supplies: Supplies are recorded at lower of cost (first-in, first-out) or market. -25- 26 Property and Equipment: Property and equipment are stated at cost. Depreciation and amortization are provided by the straight-line method over the estimated useful lives which range from three to ten years. Management Service Agreements: Costs of obtaining Service Agreements arose from the acquisitions described in Note C and were created by the excess of the purchase price over the fair value of net assets of the acquired practices. The Service Agreements are noncancelable except for performance defaults, as defined. In the event a practice breaches the agreement, or if the Company terminates with cause, the practice is required to purchase all tangible assets at fair market value and pay substantial liquidating damages. Cost of obtaining Service Agreements are amortized using the straight-line method over the 40-year terms of the agreements. At each reporting period, the Company reviews the carrying value of Service Agreements on a practice by practice basis to determine if facts and circumstances exist which would suggest that the value of the Service Agreements may be impaired or that the amortization period needs to be modified. Among the factors considered by the Company in making the evaluation are changes in the practices' market position, reputation, profitability and geographical penetration. Using these factors, if circumstances are present which may indicate impairment is probable, the Company will prepare a projection of the undiscounted cash flows before interest charges of the specific practice and determine if the Service Agreements are recoverable based on these undiscounted cash flows. If impairment is indicated, then an adjustment will be made to reduce the carrying value of intangible assets to fair value. Based on the factors considered above, the Company does not believe that there are any current factors indicating any impairment of Service Agreements as of December 31, 1996. Deferred Charges: Deferred charges consist primarily of startup costs representing direct and incremental expenses incurred prior to the operational date of a new IMPACT Center which are capitalized and amortized from the operational date over a period of two years. Deferred charges also include costs capitalized in connection with obtaining long-term financing and are being amortized using the interest method over the terms of the related debt. Net Revenue: The following table is a summary of net revenue by source for the respective periods ended December 31. Patient services revenue is recorded net of contractual allowances and discounts of $4,898,000, $4,224,000, and $3,894,000 for the years ended December 31, 1996, 1995, and 1994, respectively. The Company's revenue from practice management affiliations includes practice operating expenses (other than amounts retained by physicians) and a management fee either fixed in amount or equal to a percentage of each affiliated oncology group's adjusted net revenue or net operating income. In certain affiliations, the Company may also be entitled to a performance fee if certain financial criteria are satisfied.
(In thousands) December 31 1996 1995 1994 -------- ------- ------- Net patient services revenue $33,423 $33,827 $31,772 Practice management service fees 19,292 - - Pharmaceutical sales to physicians 13,531 9,806 6,479 Physician investigator studies 1,107 665 - -------- ------- ------- $67,353 $44,298 $38,251 ======== ======= =======
Income Taxes: The Company follows the liability method of accounting for income taxes, whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Net Earnings (Loss) Per Common Share: Net earnings (loss) per common share has been computed based upon the weighted average number of shares of common stock outstanding during the period, plus (in periods in which they have a dilutive effect) common stock equivalents, primarily stock options and warrants. Fully diluted earnings per share are not disclosed as the effect of assuming the conversion of the preferred stock is clearly immaterial. All share and per share amounts have been restated to reflect a one-for-five reverse split effected November 2, 1995. Fair Value of Financial Instruments: The carrying amounts of all asset and liability financial instruments approximate their estimated fair values at December 31, 1996. Fair value of a financial instrument is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. -26- 27 Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. New Accounting Standards: The Financial Accounting Standards Board has issued Statement of Financial Accounting Standards No. 128 (SFAS 128), Earnings Per Share, and Statement of Financial Accounting Standards No. 129 (SFAS 129), Disclosure of Information about Capital Structure. SFAS 128 establishes standards for computing and presenting earnings per share and applies to entities with publicly held common stock. SFAS 129 establishes standards for disclosing information about an entity's capital structure and applies to all entities. Management believes that the Company's adoption of these standards, when effective, will not have a significant impact on the Company's financial statements. NOTE C -- ACQUISITIONS During 1996, the Company acquired stock in or certain operating assets and assumed certain liabilities of ten oncology practices in Tennessee and Florida. The Company's consideration in exchange for the practice affiliations consisted of $53 million in cash, $27 million in notes payable, and 640,000 shares of its common stock. The practice affiliations have been accounted for as purchases and the accompanying financial statements include the results of their operations from their respective dates of acquisition. The following unaudited pro forma information for the years ended December 31, 1996 and 1995 is presented as if the acquisitions described above had occurred at the beginning of 1995 after giving effect to certain adjustments including additional depreciation and amortization and increased expense on debt related to the acquisitions. The following information is not necessarily indicative of what actual results of operations would have been had such acquisitions been completed on January 1, 1995, nor does it purport to represent the results of operations for future periods. In management's opinion, all adjustments necessary to reflect the acquisitions have been made. Summarized pro forma information is as follows: Statement of Operations (Unaudited, dollar amounts in thousands except for share data)
1996 1995 ----------- ------------ Revenues $ 87,687 $ 77,866 Net income $ 4,357 $ 1,737 =========== =========== Net income per common share $ 0.35 $ 0.15 ============ =========== Weighted average number of common shares outstanding 12,277,869 11,735,721 ============ ===========
-27- 28 NOTE D -- PROPERTY AND EQUIPMENT Balances of major classes of property and equipment are as follows: (In thousands)
December 31, ----------------- 1996 1995 ------- ------- Lab and pharmacy equipment $ 4,730 $ 4,213 Furniture and office equipment 3,803 2,904 Equipment under capital leases 1,515 1,558 Leasehold improvements 3,518 1,383 ------- ------- 13,566 10,058 Less accumulated depreciation and amortization (8,160) (6,236) ------- ------- $ 5,406 $ 3,822 ======= =======
Purchases of equipment reflected in the "Consolidated Statements of Cash Flows" of $1,330,000 for the year ended December 31, 1995, does not include purchases included in accounts payable of $24,000 or property acquired under capital lease transactions of $55,000. NOTE E -- NOTES PAYABLE Notes payable at December 31, 1996, consists of the following: (In thousands) Subordinated line of credit with Seafield $22,494 Bank credit facility 20,861 Various subordinated notes payable to affiliated physicians and physician practices, bearing interest ranging from 4% to 9% per annum, with maturities through 2011 26,467 Other notes payable collateralized by furniture and equipment with interest rates between 8% and 10% per annum and payable in monthly installments of principal and interest through 2001 131 ------- Total notes payable 69,953 Less current installments (7,847) ------- $62,106 =======
In April 1996, the Company obtained an unsecured $10 million loan (the "Seafield Note") from Seafield bearing interest at an annual rate of prime plus 1%, which after August 1, 1996, became convertible at the election of Seafield into shares of the Company's common stock. Proceeds of the loan were used to finance a practice acquisition. The Seafield Note was exchanged for shares of the Company's common stock in August 1996 (See Note H). -28- 29 In October 1996, the Company procured a $23.5 million subordinated line of credit from Seafield (the "Seafield Facility"), to be used to finance acquisitions and working capital. The loan is payable upon the earlier of the closing of an equity offering by the Company or August 1998. The Seafield Facility bears interest at a rate of 8% per annum escalating at certain points during the term of the loan, is uncollateralized, and is convertible at the election of Seafield into shares of the Company's common stock at a conversion price equal to the market price of the common stock at the date of conversion provided, however, that after December 31, 1996, the conversion price will be the lower of market or $11.00 per share. The Seafield Facility was exchanged for shares of the Company's common stock in February 1997 (See Note L). In May 1996, the Company entered into a $27.5 million Credit Facility with NationsBank and Union Planters to fund the Company's acquisitions and working capital needs and to repay its existing facility with Union Planters. The Credit Facility, comprised of a $22 million Acquisition Facility and a $5.5 million Working Capital Facility, is collateralized by the common stock of the Company's subsidiaries. The Acquisition Facility matures May 31, 1998 and bears interest at a variable rate equal to LIBOR plus a spread between 1.5% and 2.625%, depending upon borrowing levels. The Working Capital Facility matures May 30, 1997, subject to a one year extension, and bears interest at a variable rate equal to LIBOR plus a spread between 1.875% and 2.375%. At December 31, 1996, $20.9 million aggregate principal was outstanding under the Credit Facility with a current interest rate of approximately 7.7%. The Company's available credit under the Credit Facility at December 31, 1996 was $.2 million. The Credit Facility contains affirmative and negative covenants which, among other things, require the Company to maintain certain financial ratios, including minimum fixed charges coverage, funded debt to EBITDA, net worth and current ratio. As of December 31, 1996, the Company was in compliance with the covenants included in the Credit Facility. The installment notes payable to affiliated physicians and physician practices were issued as partial consideration for the practice management affiliations described in Note C. Principal and interest under the long-term notes may, at the election of the holders, be paid in shares of common stock of the Company based on conversion prices ranging from $11.75 to $18.00. The aggregate maturities of notes payable at December 31, 1996 are as follows: (In thousands) 1997 $ 7,847 1998 53,762 1999 1,296 2000 762 2001 1,453 Thereafter 4,833 ------- $69,953 =======
NOTE F -- LEASES The Company leases certain office facilities and equipment under lease agreements with original terms ranging from one to forty years that generally provide for one or more renewal options. Interest has been imputed on capital leases at rates of 6% to 12%. Accumulated amortization of assets recorded under capital leases totaled $1,308,000, $1,001,000, and $742,000 at December 31, 1996, 1995, and 1994, respectively. Amortization of leased assets is included in depreciation and amortization expense. -29- 30 Total rent expense under operating leases amounted to $2,361,000, $1,800,000, and $1,791,000 for the years ended December 31, 1996, 1995, and 1994, respectively. The Company is generally obligated to the lessors for its proportionate share of operating expenses of the leased premises. At December 31, 1996, future minimum lease payments under capital and operating leases with initial terms of one year or more are as follows (in thousands):
Capital Operating Leases Leases ------- ---------- Fiscal year ended December 31: 1997 $ 88 $ 2,143 1998 67 1,677 1999 44 1,380 2000 12 1,196 2001 - 1,113 Thereafter - 11,214 ---- ------- Total minimum payments 211 $18,723 ======= Less imputed interest 13 ---- Present value of minimum rental payments 198 Less current installments 74 ---- Obligations under capital leases excluding current installments $124 ====
NOTE G -- INCOME TAXES The actual tax expense for the years ended December 31, 1996, 1995, and 1994, respectively, differs from the expected tax expense for those years (computed by applying the federal corporate tax rate of 34% to net earnings before minority interest) as follows (in thousands):
1996 1995 1994 ---- ---- ---- Computed expected tax expense (benefit) $ 436 $ 787 $(798) Non-deductible expenses 14 13 10 Utilization of net operating loss carryforwards (450) (800) - Loss for which no benefit was provided - - $ 788 ----- ----- ----- Actual income tax expense $ 0 $ 0 $ 0 ===== ===== =====
-30- 31 The approximate tax effects of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax assets and deferred tax liabilities are as follows (in thousands):
December 31, ------------------ 1996 1995 ------- ------- Deferred tax assets: Net operating loss carryforwards $ 1,678 $ 2,366 Reserve for bad debts 674 409 Excess book depreciation/amortization 665 547 Partnership basis differences 204 - Excess book expense accruals 46 152 Other - 41 ------- ------- Total deferred assets 3,267 3,515 Valuation allowance (3,515) ------- ------- Net deferred tax assets 3,267 0 ------- ------- Deferred tax liability - Management service agreements 25,127 0 ------- ------- Net deferred tax liability $21,860 $ 0 ======= =======
The deferred tax liability of $25,127,000 is calculated by applying the applicable expected tax rate of 38 percent to the future taxable amounts resulting from the taxable temporary differences between the assigned value of identifiable net assets (Service Agreements) and their tax basis. The valuation allowance for deferred tax assets as of January 1, 1995 was $4,191,000. The net change in the total valuation allowance for the years ended December 31, 1996 and 1995, was a decrease of $3,515,000 and $676,000, respectively. The 1996 decrease was reflected in the accounting for the purchase of management services agreements whose book basis exceeded their tax basis. The amount of income that the Company may offset in future years by the net operating loss carryforwards incurred prior to an ownership change in 1990 will be limited, by the application of the Internal Revenue Code Section 382, to $475,000 annually through the year 2005. The unused portion of the net operating losses may be carried forward and realized in future years subject to this limitation. The net operating loss carryforwards incurred subsequent to the October 31, 1990, ownership change are available to fully offset future earnings of the Company and expire in the years 2005 through 2009. As of December 31, 1996, the Company had available tax net operating loss carryforwards totaling $4,500,000, all of which is subject to certain annual limitations due to a change in ownership for tax purposes in 1990. The use of net operating loss carryforwards, for income tax purposes, is also dependent upon future taxable income. A benefit for the net operating loss carryforwards has been provided for the reversal of taxable temporary differences during the carryforward period. NOTE H -- COMMON STOCK, CONVERTIBLE PREFERRED STOCK, WARRANTS, AND OPTIONS Common Stock: On November 1, 1995, an amendment to the Company's charter was approved at a special meeting of the stockholders decreasing the number of authorized shares from 60,000,000 shares, $.002 par value, to 30,000,000 shares, $.01 par value, with a corresponding reclassification to which each issued and outstanding -31- 32 share was reclassified, converted, and changed into one-fifth (1/5) of an issued and outstanding share. The amendment became effective November 2, 1995. The one-for-five reverse split resulted in the reduction of 27,948,332 outstanding shares of common stock. Accordingly, all references in the financial statements to weighted average shares outstanding, per share amounts and stock option plan data have been restated to reflect the reverse split. The $10 million Seafield Note was exchanged for 909,090 shares of common stock during August 1996. At December 31, 1996, Seafield's ownership interest in the Company was approximately 56%. Subsequent to December 31, 1996, the $23.5 million Seafield Facility and accrued interest thereon was converted into 3,020,536 shares of the Company's common stock at a rate of $8 per share. The conversion increased Seafield's ownership as of February 26, 1997 to 67%. Simultaneous with the conversion, Seafield announced its intention to consider a distribution to its shareholders in 1997 of Seafield's shares of the Company's common stock. During 1996, 639,924 shares of common stock were issued as consideration in the acquisition of certain oncology practices. Additionally, 26,000, 497,000, and 154,500 shares of common stock were issued pursuant to the exercise of warrants and employee stock options during the years ended December 31, 1996, 1995, and 1994, respectively. Proceeds to the Company amounted to $275,000, $1,022,000, and $74,000, for the respective periods. The Company also has reserved 3,111,000 shares of its common stock for issuance upon the exercise of options (1,783,000 shares), the conversion of Convertible Preferred Stock (5,000 shares), and the exercise of warrants or conversion of debt issued in the practice affiliations consummated during 1996 (1,323,000 shares). Convertible Preferred Stock: The shares of Series A Convertible Preferred Stock have the following rights and restrictions: (a) a preference in the event of liquidation equal to $11.00 per share; (b) the right to convert into the number of shares of common stock equal to the stated value of shares surrendered ($11.00) divided by the conversion price of $60.00 -- subject to certain adjustments; (c) the right to receive dividends in the form of common stock at the rate of .011 share of common stock per annum per share payable annually each year commencing January 15, 1988; (d) the shares are redeemable at the Company's option at $11.00 per share; and (e) holders of the preferred stock will not be entitled to vote. In December 1996, 1995, and September 1994, the Board of Directors approved a common stock dividend of 306, 306, and 1,545 shares to the holders of the Series A Convertible Preferred Stock of record as of December 15, 1996, 1995, and 1994 that was paid in January 1997, 1996, and 1995, respectively. The market value of the common stock distributed was $3,000, $4,000 and $3,000 in the years 1996, 1995, and 1994, respectively. The dividends have been reflected in the "Consolidated Statements of Operations" and the weighted average number of common shares in the determination of net earnings (loss) to common stockholders and the earnings (loss) per common share calculations. The par value of the common stock distributed was charged to paid-in capital. Options: The 1985 Stock Option Plan (the "1985 Plan"), as amended in fiscal year 1988, allows for granting of incentive stock options, non-qualified stock options, and stock appreciation rights of up to 122,000 shares of common stock to eligible officers and key employees of the Company at an exercise price of not less than the fair market value of the common stock on the date of grant for an incentive stock option and not less than 85% of the fair market value of the common stock on the date of grant for a non-qualified stock option. The 1985 Plan expired in 1995; no additional shares are available for grant. -32- 33 The 1990 Non-Qualified Stock Option Plan (the "1990 Plan"), as amended in 1995, allows for the granting of non-qualified stock options, up to 1,125,000 options to eligible officers, directors, key employees, and consultants of the Company at an exercise price of not less than the market price of the common stock on the date of grant with an option period up to 10 years. During the year, the 1996 Incentive and Non-Qualified Stock Option Plan (the "1996 Plan"), was adopted and allows for the granting of up to 630,000 options to eligible officers, directors, advisors, medical directors, consultants, and key employees of the Company at an exercise price of not less that the market price of the common stock on the date of grant with an option period up to 10 years. A summary status of the 1985 Plan as of December 31, 1996, 1995, and 1994, and changes during the years then ended is presented below:
1996 1995 -------------------------------------- -------------------------------------- Weighted Weighted Average Average Number of exercise Number exercise Fixed Options shares price of shares price ------------- ---------------- -------------------- ---------------- ------------------- Outstanding at beginning of year 74,200 $ 5.79 75,360 $ 5.86 Granted Exercised (2,700) 5.76 (560) 9.02 Forfeited (400) 11.88 (600) 11.88 --------- ------ Outstanding at end of year 71,100 5.76 74,200 5.79 ========= ====== Options exercisable at year-end 66,060 65,820 ========= ======
1994 --------------------------- Weighted Average Number exercise Fixed Options of shares price - -------------------------------- --------- -------- Outstanding at beginning of year 65,160 $ 4.34 Granted 14,600 11.88 Exercised (3,900) 2.13 Forfeited (500) 11.88 ------ Outstanding at end of year 75,360 5.86 ====== Options exercisable at year-end 63,040 ======
A summary status of the 1990 Plan as of December 31, 1996, 1995, and 1994 and changes during the years then ended is presented below:
1996 1995 1994 ------------------------------- --------------------------- -------------------------------- Weighted Weighted Average Weighted Average Average Number exercise Number exercise Number exercise Fixed Options of shares price of shares price of shares price - -------------------------------- --------- -------------------- --------- ---------------- ---------------- -------------- Outstanding at beginning of year 933,440 $11.02 559,550 $10.21 431,550 $10.10 Granted 172,000 12.50 400,900 11.91 132,500 10.48 Exercised (22,300) 11.09 (12,800) 2.82 (4,000) 2.50 Forfeited (29,990) 11.69 (14,210) 11.88 (500) 23.75 --------- ------- ------ Outstanding at end of year 1,053,150 11.24 933,440 11.02 559,550 10.21 ========= ======= ======= Options exercisable at year-end 694,020 396,210 317,320 ========= ======= =======
-33- 34 A summary status of the 1996 Plan for the year ended December 31, 1996 is presented below:
1996 --------------------------- Weighted Average Number exercise Fixed Options of shares price - -------------------------------- --------- ---------------- Outstanding at beginning of year - - Granted 621,400 $11.87 Exercised (1,000) 12.50 Forfeited (50,000) 12.50 ------- Outstanding at end of year 570,400 11.81 ======= Options exercisable at year-end 130,080 =======
The following table summarizes information about fixed stock options outstanding at December 31, 1996:
Options Outstanding Options Exercisable -------------------------------------------------------------- ---------------------------------------- Weighted average Weighted remaining average Weighted Range of Number contractual life exercise Number average exercise exercise prices outstanding (years) price exercisable price - -------------------- ----------- ------------------ -------------------- ------------------ -------------------- $1.56 - $9.75 329,700 7.50 $ 7.20 177,700 $ 5.07 10.00 - 10.63 247,700 7.20 10.23 176,120 10.23 11.50 - 12.25 232,700 8.70 11.61 98,100 11.60 12.50 - 12.50 702,250 10.90 12.50 306,180 12.50 13.13 - 16.50 178,700 7.20 14.10 128,460 13.92 16.88 - 16.88 1,000 8.80 16.88 1,000 16.88 23.75 - 23.75 2,600 5.30 23.75 2,600 23.75
The Company accounts for stock options in accordance with the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations (APB 25). As such, compensation expense is recorded on the date of grant only if the current market price of the underlying stock exceeds the exercise price. During 1996, the Company adopted Statement of Financial Accounting Standards No. 123, "Accounting for Stock Based Compensation" (FAS 123), which permits entities to recognize as expense over the vesting period the fair value of all stock-based awards on the date of grant. Alternately, FAS 123 allows entities to continue to apply the provisions of APB 25 and provide pro forma net earnings and pro forma earnings per share disclosures for employee stock option grants made in 1995 and future years as if the fair-value-based method defined in FAS 123 had been applied. The Company has elected to continue to apply the provisions of APB 25 and provide the pro forma disclosure provisions of FAS 123. The per share weighted average fair value of stock options granted during 1996 and 1995 was $12.00 and $11.91 on the date of grant using the "Black Scholes" option-pricing model with the following average assumptions: 1996 - expected dividend yield of 0%, risk-free interest rate of 6%, expected volatility factor of 77% and an expected life of five years; 1995 - expected dividend yield of 0%, risk-free interest rate of 6.3%, expected volatility factor of 77% and an expected life of five years. -34- 35 Since the Company applies APB 25 in accounting for its plans, no compensation cost has been recognized for its stock options in the financial statements. Had the Company recorded compensation cost based on the fair value at the grant date for its stock options under FAS 123, the Company's net earnings and earnings per share would have been reduced by approximately $2,366,000 or $.16 per share in 1996 and approximately $1,319,000 or $.33 per share in 1995. Pro forma net earnings reflect only options granted in 1996 and 1995. Therefore, the full impact of calculating compensation cost for stock options under FAS 123 is not reflected in the pro forma net earnings amounts presented above because compensation costs are reflected over the option's vesting period of five years for the 1996 and 1995 options. Compensation cost for options granted prior to January 1, 1995, is not considered material. NOTE I -- BENEFIT PLAN The Company established a 401(k) Profit Sharing Plan (the "Plan") which allows qualifying employees electing membership to defer a portion of their income on a pretax basis through contributions to the Plan. For each dollar of employee contributions, the Company makes a discretionary percentage matching contribution to the Plan. In addition, eligible employees share in any additional discretionary contributions which are based upon the profitability of the Company. All contributions made by the Company are determined by the Company's Board of Directors. For the Plan year ended December 31, 1996, the approved matching percentage is twenty-five percent (25%) up to a maximum of $1,250 per employee. The expense recognized for the years ended December 31, 1996, 1995, and 1994 for Company contributions to the Plan totaled $113,000, $99,000, and $76,000 respectively. NOTE J -- RELATED PARTY TRANSACTIONS The West Clinic: The Company's IMPACT Center in Memphis, Tennessee is located adjacent to The West Clinic, P.C., a private practicing oncology group, of which the Company's Chairman is a shareholder. Arrangements exist between the Company and the West Clinic for providing space and other support services to the Company. During the years ended December 31, 1996, 1995, and 1994, the Company expensed $74,000, $59,000 and $108,000, respectively, relating to these arrangements. In addition, during the years ended December 31, 1996, 1995, and 1994, the Company recognized net revenue of $4,653,000, $3,032,000, and $2,026,000, respectively, for sales of pharmaceuticals to The West Clinic and, at December 31, 1996, 1995 and 1994, had a related accounts receivable balance of $829,000, $636,000, and $281,000. The pricing policy with respect to sales of pharmaceuticals to the West Clinic is consistent with sales to physicians at other Centers. NOTE K -- COMMITMENTS AND CONTINGENCIES With respect to professional and general liability risks, the Company currently maintains an insurance policy that provides coverage during the policy period ending August 1, 1997, on a claims-made basis, for $1,000,000 per claim in excess of the Company retaining $25,000 per claim, and $3,000,000 in the aggregate. Costs of defending claims are in addition to the limit of liability. In addition, the Company maintains a $10,000,000 umbrella policy with respect to potential general liability claims. Since inception, the Company has incurred no professional or general liability losses and as of December 31, 1996, the Company was not aware of any pending professional or general liability claims. -35- 36 NOTE L -- SUBSEQUENT EVENTS In February 1997, the $23.5 million Seafield Facility and accrued interest of $.7 million was exchanged for 3,020,536 shares of the Company's common stock at a rate of $8 per share. In March 1997, the Company received a commitment to increase its bank credit facility from $27.5 million to $45.0 million and to extend the expiration date from May 1997 to May 1998. -36- 37 SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS RESPONSE ONCOLOGY, INC. AND SUBSIDIARIES (Amounts in thousands)
Col A Col B Col C - Additions - ------------------------------ ------------- -------------------------------- Charged to Balance at Charged to Other Classification Beginning of Costs and Accounts - Period Expenses Describe - ------------------------------ ------------- ----------- ------------- Year ended December 31, 1996: Deducted from asset accounts: Allowance for doubtful accounts - accounts receivable $2,080 $1,594 ============= =========== Year ended December 31, 1995: Deducted from asset accounts: Allowance for doubtful accounts - accounts receivable $3,935 $2,106 ============= =========== Year ended December 31, 1994: Deducted from asset accounts: Allowance for doubtful accounts - accounts receivable $3,800 $2,528 ============= =========== Col A Col D Col E - ------------------------------ ------------- ----------- Deductions Balance at Classification - Describe End of (1) Period - ------------------------------ ------------- ----------- Year ended December 31, 1996: Deducted from asset accounts: Allowance for doubtful accounts - accounts receivable $1,900 $1,774 ============= =========== Year ended December 31, 1995: Deducted from asset accounts: Allowance for doubtful accounts - accounts receivable $3,961 $2,080 ============= =========== Year ended December 31, 1994: Deducted from asset accounts: Allowance for doubtful accounts - accounts receivable $2,393 $3,935 ============= ===========
(1) Accounts written off, net of recoveries. EX-10.D 2 EMPLOYMENT AGREEMENT 1 Exhibit 10(D) EMPLOYMENT AGREEMENT -------------------- THIS AGREEMENT is made May 6, 1996 effective as of July 1, 1995, by and between RESPONSE ONCOLOGY, INC., a Tennessee corporation (the "Company"), and WILLIAM H. WEST, M.D. (the "Executive"). WHEREAS, the Company is engaged in the business of providing advanced cancer treatment services; and WHEREAS, the Company desires to employ the Executive to devote full time to the business of the Company and to continue as the Chairman and Chief Executive Officer of the Company; and WHEREAS, the Executive desires to be employed on the terms and subject to the conditions hereinafter stated. NOW, THEREFORE, in consideration of the mutual covenants contained in this Employment Agreement, the parties hereby agree as follows: SECTION 1 POSITION AND RESPONSIBILITIES ----------------------------- During the Term of this Employment Agreement, the Executive shall perform such duties for such compensation and subject to such terms and conditions as are hereinafter set forth. SECTION 2 TERMS AND DUTIES ---------------- 2.1 Term; Extension. The term of this Employment Agreement (the "Term of this Employment Agreement") will commence as of July 1, 1995, and shall continue through December 31, 1997. On the first and each successive anniversary of the effective date of this Employment Agreement, the Term of this Employment Agreement shall be extended for an additional one (1) year period, unless either party gives notice no later than such anniversary date of such party's intent not to extend the Term of this Employment Agreement. Termination of the Executive's employment pursuant to this Employment Agreement shall be governed by Sections 4 and 5. 2.2 Duties. The Executive shall devote substantially all of his time and attention and best efforts during normal business hours to the Company's affairs. The Executive shall have such duties and responsibilities as are assigned to him from time to time by the Board of Directors. As of the effective date of this Employment Agreement, the Executive shall continue to possess and assume senior management authority and responsibility as Chairman of the Company, responsible for implementation of the long range growth strategy of the Company, consistent with directions from the Board of Directors. 2.3 Location. The duties of the Executive shall be performed at such locations and places as may be directed by the Board of Directors. SECTION 3 COMPENSATION AND BENEFITS ------------------------- 3.1 Basic Compensation. The Company shall pay the Executive a base salary ("Base Salary") of $225,000 per annum, subject to applicable withholdings. Base Salary shall be payable according to the customary 2 payroll practices of the Company but in no event less frequently than once each month. The Base Salary shall be reviewed annually and shall be subject to increase or decrease according to the policies and practices adopted by the Board of Directors from time to time; provided, however, that in no event shall the Base Salary for any year be decreased by more than five percent (5%) from the immediately preceding year's Base Salary as a result of any such annual review. 3.2 Annual Incentive Awards. The Company will pay the Executive annual incentive compensation of up to 100% of his Base Salary, in accordance with policies and based on performance targets established annually by the Compensation Committee of the Board of Directors. 3.3 Additional Benefits. The Executive will be entitled to participate in all employee benefit plans or programs and receive all benefits and perquisites to which any salaried employees are eligible under any existing or future plans or programs established by the Company for salaried employees. The Executive will participate to the extent permissible under the terms and provisions of such plans or programs in accordance with program provisions. These may include group hospitalization, health, dental care, life or other insurance, tax qualified pension, car allowance, savings, thrift and profit sharing plans, termination pay programs, sick leave plans, travel or accident insurance, disability insurance, and contingent compensation plans, including capital accumulation programs, restricted stock programs, stock purchase programs and stock options plans. Nothing in this Agreement will preclude the Company from amending or terminating any of the plans or programs applicable to salaried employees or senior executives. The Executive will be entitled to an annual paid vacation as established by the Board of Directors. 3.4 Business Expenses. The Company will reimburse the Executive for all reasonable travel and other expenses incurred by the Executive in connection with the performance of his duties and obligations under this Employment Agreement. 3.5 Withholding. The Company may directly or indirectly withhold from any payments under this Employment Agreement all federal, state, city or other taxes that shall be required pursuant to any law or governmental regulation. SECTION 4 DEATH BENEFIT; DISABILITY COMPENSATION; KEY MAN INSURANCE 4.1 Payment in Event of Death. In the event of the death of the Executive during the Term of this Employment Agreement, the Company's obligation to make payments under this Employment Agreement shall cease as of the date of death, except for earned but unpaid Base Salary and incentive compensation which will be paid on a prorated basis for that year. The Executive's designated beneficiary will be entitled to receive the proceeds of any life or other insurance or other death benefit programs provided or referred to in this Employment Agreement, other than "key man" life insurance benefits. 4.2 Disability Compensation. Notwithstanding the disability of the Executive, the Company will continue to pay the Executive pursuant to Section 3 hereof during the Term of this Employment Agreement, unless the Executive's employment is earlier terminated in accordance with this Employment Agreement, unless the Executive's employment is earlier terminated in accordance with this Employment Agreement. In the event the disability continues for a period of three (3) months, the Company may thereafter terminate this Employment Agreement and the Executive's employment. Following such termination, the Company will pay the Executive amounts equal to his regular installments of Base Salary, as of the time of termination, for a period of six (6) months. All other compensation will cease except for earned but unpaid incentive compensation awards which would be payable on a pro-rated basis for the year in which the disability occurred, through the date of termination. 4.3 Responsibilities in the Event of Disability. During the period the Executive is receiving payments following his disability and as long as he is physically and mentally able to do so, the Executive will 2 3 furnish information and assistance to the Company and from time to time will make himself available to the Company to undertake assignments consistent with his position or prior position with the Company and his physical and mental health. If the Company fails to make a payment or provide a benefit required as part of this Employment Agreement, the Executive's obligations to provide information and assistance will end. 4.4 Definition of Disability. For purposes of this Employment Agreement, the term "disability" will have the same meaning as is attributed to such term, or any substantially similar term, in the Company's long term income disability plan as in effect from time to time. 4.5 Key-Man Life Insurance. Upon request by the Company, the Executive agrees to cooperate with the Company in obtaining "key man" life insurance on the life of the Executive, with death benefits payable to the Company. Such cooperation shall include the submission by the Executive to a medical examination and his response to inquiries regarding his medical history. SECTION 5 TERMINATION OF EMPLOYMENT Notwithstanding anything herein to the contrary, this Employment Agreement and the Executive's employment with the Company may be terminated by the Company at any time, subject to the terms and provisions of this Section 5. 5.1 Termination Without Cause (a) Without a Change in Control. If the Executive suffers, a Termination Without Cause (hereinafter defined) and a Change in Control (hereinafter defined) shall not have occurred within one (1) year prior thereto, the Company will continue to pay the Executive amounts equal to his Base Salary, as in effect at the time of the Termination Without Cause, for the remaining Term of this Employment Agreement; provided, however, if the Executive shall give the notice referred to in Section 6.3(c), the Executive shall not be entitled to any amounts for periods after the effective date of such notice. Earned but unpaid Base Salary through the date of termination will be paid in a lump sum at such time, and pro-rated incentive compensation, if any, for the year of termination, to the date of termination, will be paid to the Executive in accordance with the Company's customary practice for payment of incentive compensation. For six (6) months following such Termination Without Cause, the Company shall reimburse the Executive for the cost of the Executive's major medical health insurance as in effect at the date of termination; provided that reimbursement for the costs of such medical insurance shall cease upon the effective date of a notice given by the Executive pursuant to Section 6.3(e). The exercisability of stock options granted to the Executive shall be governed by any applicable stock option agreements and the terms of the respective stock option plans. (b) Upon a Change in Control. If the Executive suffers a Termination Without Cause within one (1) year following a Change in Control, the Company will pay to the Executive in a lump sum upon such termination an amount equal to the lesser of (i) 300% of the Executive's Base Salary as in effect at the time of the termination and (ii) the maximum amount which could be paid and not result in such amount or any other payment in the nature of compensation (within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended, and the regulations thereunder ("Section 280G")) to or for the benefit of the Executive, or any part of such amount or other payment, constituting a "parachute payment" within the meaning of Section 280G. Earned but unpaid Base Salary through the date of termination will be paid in a lump sum at such time and pro rated incentive compensation, if any, for the year of termination, to the date of termination, will be paid to the Executive in accordance with the Company's customary practice for payment of incentive compensation. 3 4 5.2 Termination With Cause; Voluntary Termination. If the Executive suffers a Termination with Cause or the Executive terminates his employment with the Company (a "Voluntary Termination"), then, whether or not there has been a Change in Control, the Company will not be obligated to pay the Executive any amounts of compensation or benefits following the date of termination. However, earned but unpaid Base Salary through the date of termination will be paid in a lump sum at such time, and incentive compensation, if any, for the year during which such termination occurs will be pro rated for the portion of the year prior to the date of termination and paid in accordance with the Company's customary practice for payment of incentive compensation. 5.3 Definitions. For purposes of this Employment Agreement, the following terms have the following meanings: (a) "Change in Control" shall occur if an event or series of events occurs after the effective date of this Employment Agreement which would constitute either a change in ownership of the Company, within the meaning of Section 280G, or a change in the ownership of a substantial portion of the Company's assets, within the meaning of Section 280G, but for purposes of this definition, the fair market value threshold for determining "substantial portion of the Company's assets" shall be "greater than 50%;" provided that neither a distribution of shares of Company stock by Seafield Capital Corporation ("Seafield") to its shareholders nor a sale (including a sale by Seafield) of shares of Company stock in a public offering shall constitute a change in control for purposes of this Employment Agreement. (b) "Termination With Cause" means termination of the Executive's employment by the Company, acting in good faith, by written notice to the Executive specifying the event relied upon for such termination, due to the Executive's conviction for a felony, the Executive's perpetration of a fraud, embezzlement or other act of dishonesty or the Executive's breach of a trust or fiduciary duty which materially adversely affects the Company or its shareholders. (c) "Termination Without Cause" means termination of the Executive's employment by the Company other than due to the Executive's death or disability of Termination With Cause. SECTION 6 OTHER DUTIES OF THE EXECUTIVE DURING AND AFTER THE TERM OF THIS EMPLOYMENT AGREEMENT 6.1 Additional Information. The Executive will, upon reasonable notice, during or after the Term of this Employment Agreement, furnish information as may be in his possession and cooperate with the Company as may reasonably be requested in connection with any claims or legal actions in which the Company is or may become a party. The Executive shall receive reasonable compensation for the time expended by him pursuant to this Section 6.1. 6.2 Confidentiality. The Executive recognizes and acknowledges that all information pertaining to the affairs, business, clients, customers or other relationships of the Company, as hereinafter defined, is confidential and is a unique and valuable asset of the Company. Access to and knowledge of this information are essential to the performance of the Executive's duties under this Employment Agreement. The Executive will not during the Term of this Employment Agreement or thereafter, except to the extent reasonably necessary in the performance of his duties under this Agreement, give to any person, firm, association, corporation or governmental agency any information concerning the affairs, business, clients, customers or other relationships of the Company except as required by law. The Executive will not make use of this type of information for his own purposes or for the benefit of any person or organization other than the Company. The Executive will also use his best efforts to prevent the disclosure of this information by others. All records, memoranda, etc. relating to the business of the Company, whether made by the Executive or otherwise coming into his possession are confidential and will remain the property of the Company. 4 5 6.3 Noncompetition. (a) During the Term of Employment. The Executive will not Compete with the Company (as defined in subsection (d) hereafter) at any time while he is employed by the Company or receiving payments from the Company. (b) Voluntary Termination; Termination With Cause. In the event of a Voluntary Termination or a Termination With Cause, the Executive will not Compete with the Company for a period consisting of the longer of (i) the remaining Term of this Employment Agreement and (ii) one (1) year, provided that if a Voluntary Termination follows a notice by the Company under Section 2.1 that the Term of this Employment Agreement will not be automatically extended, there will be no restriction on the Executive's right to Compete with the Company after the date his employment terminates. (c) Termination Without Cause. In the event of a Termination Without Cause within one (1) year after a Change in Control, there will be no restriction on the Executive's rights to Compete with the Company after the date of his employment terminates. In the event of a Termination Without Cause where there has been no Change in Control or where such Termination Without Cause occurs after one (1) year following a Change in Control, the Executive will not Compete with the Company for a period consisting of the longer of (i) Change in Control, the Executive will not Compete with the Company for a period consisting of the longer of (i) the remaining Term of this Employment Agreement and (ii) one (1) year; provided, however, that in such event, if the Executive gives written notice to the Company that the Executive will forego payment of all amounts and payments otherwise due to him following the effective date of such notice as a result of a Termination Without Cause, there will be no restriction on the Executive's rights to Compete with the Company following such effective date. (d) Definition of "Compete" With the Company. For the purposes of this Section 6, the term "Compete with the Company" means action by the Executive, direct or indirect, for his own account or for the account of others, either as an officer, director, stockholder, owner, partner, member, promoter, employee, consultant, advisor, agent, manager, creditor or in any other capacity, resulting in the Executive having any pecuniary interest, legal or equitable ownership, or other financial or non-financial interest in, or employment, association or affiliation with, any corporation, business trust, partnership, limited liability company, proprietorship or other business or professional enterprise that provides oncology services or management services to any oncology or hematology practice within a fifty mile radius of any location where the Company or any subsidiary or affiliate of the Company performs such services at the date of a termination of the Executive's employment or has performed such services within one year prior to such termination of employment; provided, however, that the term "Compete with the Company" shall not include (i) the commencement or continuation of the private practice of medical oncology by Executive, or (ii) ownership (without any more extensive relationship) of a less than a 5% interest in any publicly-held corporation or other business entity. (e) Reasonableness of Scope and Duration; Remedies. The Executive acknowledges that the covenants contained herein are reasonable as to geographic and temporal scope. The Executive acknowledges that his breach or threatened or attempted breach of any provision of Section 6 would cause irreparable harm to the Company not compensable in monetary damages and that the Company shall be entitled, in addition to all other applicable remedies, to a temporary and permanent injunction and a decree for specific performance of the terms of Section 6 without being required to prove damages or furnish any bond or other security. SECTION 7 CONSOLIDATION, MERGER OR SALE OF ASSETS Nothing in this Employment Agreement shall preclude the Company from consolidating or merging into or with, or transferring all or substantially all of its assets to, another corporation or organization which assumes 5 6 this Employment Agreement and all obligations and undertakings of the Company hereunder. Upon such a consolidation, merger or sale of assets, the term "the Company" as used herein will mean or include the other corporation or organization and this Employment Agreement shall continue in full force and effect. This Section 7 is not intended to modify or limit the rights of the Executive hereunder. SECTION 8 MISCELLANEOUS 8.1 Entire Agreement. This Employment Agreement contains the entire understanding between the Company and the Executive with respect to the subject matter and supersedes any prior employment or severance agreements between the Company and its affiliates, and the Executive. 8.2 Amendment; Waiver. This Employment Agreement may not be modified or amended except in writing signed by the parties. No terms or condition of this Employment Agreement will be deemed to have been waived except in writing by the party charged with waiver. A waiver shall operate only as to the specific term or condition waived and will not constitute a waiver for the future or act on anything other than that which is specifically waived. 8.3 Severability; Modification of covenant. Should any part of this Employment Agreement be declared invalid for any reason, such invalidity shall not affect the validity of any remaining portion hereof and such remaining portion shall continue in full force and effect as if this Employment Agreement had been originally executed without including the invalid part. Should any covenant of this Employment Agreement be unenforceable because of its geographic scope or term, its geographic scope or term shall be modified to such extent as may be necessary to render such covenant enforceable. 8.4 Effect of Captions. Titles and captions in no way define, limit, extend or describe the scope of this Employment Agreement nor the intent of any provision thereof. 8.5 Counterpart Execution. This Employment Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 8.6 Governing Law; Arbitration. This Employment Agreement has been executed and delivered in the State of Tennessee and its validity, interpretation, performance and enforcement shall be governed by the laws of that state. Any dispute among the parties hereto shall be settled by arbitration in Memphis, Tennessee, in accordance with the rules then obtaining of the American Arbitration Association and judgment upon the award rendered may be entered in any court having jurisdiction thereof. All provisions hereof are for the protection and are intended to be for the benefit of the parties hereto and enforceable directly by and binding upon each party. Each party hereto agrees that the remedy at law of the other for any actual or threatened breach of this Employment Agreement would be inadequate and that the other party shall be entitled to specific performance hereof or injunctive relief or both, by temporary or permanent injunction or such other appropriate judicial remedy, writ or orders as may be decided by a court of competent jurisdiction in addition to any damages which the complaining party may be legally entitled to recover together with reasonable expenses of litigation, including attorney's fees incurred in connection therewith, as may be approved by such court. 8.7 Notices. All notices, requests, consents and other communications hereunder shall be in writing and shall be deemed to have been made when delivered or mailed first-class postage prepaid by registered mail, return receipt requested, or when delivered if by hand, overnight delivery service or confirmed facsimile transmission, to the following: 6 7 (i) If to the Company, at 1775 Moriah Woods Boulevard, Memphis, Tennessee 38117, Attention: Chairman of the Compensation Committee, or at such other address as may have been furnished to the Executive by the Company in writing; or (ii) If to the Executive, at 4354 Walnut Grove Road, Memphis, Tennessee 38117 or such other address as may have been furnished to the Company by the Executive in writing. 8.8 Binding Agreements. This Employment Agreement shall be binding on the parties' successors, heirs and assigns. 7 8 IN WITNESS WHEREOF, the undersigned have executed this Employment Agreement as of the date first above written. RESPONSE ONCOLOGY, INC. By: ------------------------------- Frank M. Bumstead Chairman Emeritus EXECUTIVE: ----------------------------------- William H. West, M.D. 8 EX-10.U 3 LOAN AGREEMENT 1 Exhibit 10 (u) ================================================================================ RESPONSE ONCOLOGY, INC. Borrower --------------------------------------- LOAN AGREEMENT $22,000,000.00 REVOLVING ACQUISITION LOAN $5,500,000.00 REVOLVING WORKING CAPITAL LOAN Dated as of May 31, 1996 ---------------------------------------- NATIONSBANK OF TENNESSEE, N.A., AGENT NATIONSBANK OF TENNESSEE, N.A. UNION PLANTERS NATIONAL BANK Lenders ================================================================================ 2 TABLE OF CONTENTS RECITALS........................................................................ 1 I. DEFINITIONS................................................................ 1 1.1 Terms Defined in This Agreement...................... 1 1.2 Terms Generally......................................17 II. LOANS.......................................................................18 2.1 Acquisition Loan.....................................18 2.2 Use of Proceeds of Acquisition Loan..................18 2.3 Acquisition Loan Notes...............................18 2.4 Working Capital Loan.................................18 2.5 Use of Proceeds of Working Capital Loan..............18 2.6 Working Capital Loan Notes...........................18 2.7 Separate Commitments of Lender.......................18 2.8 Advances of Loans....................................18 2.9 Interest.............................................21 2.10 Alternate Rate of Interest if LIBOR Unavailable......22 2.11 Change in Circumstances..............................23 2.12 Change in Legality of LIBOR Loans....................24 2.13 Principal Repayment..................................25 2.14 Prepayment of LIBOR Loans............................25 2.15 Prepayment of Prime Rate Loans.......................26 2.16 Fixed Commitment Fees................................26 2.17 Periodic Commitment Fee Based on Use of Facilities...26 2.18 Agent's Fee..........................................26 III. CONDITIONS PRECEDENT......................................................26 3.1 Conditions to Initial Advance........................26 3.2 Conditions to Subsequent Loans.......................29 IV. REPRESENTATIONS AND WARRANTIES.............................................29 4.1 Capacity.............................................29 4.2 Authorization........................................29 4.3 Binding Obligations..................................29 4.4 No Conflicting Law or Agreement......................30 4.5 No Consent Required..................................30 4.6 Financial Statements.................................30 4.7 Fiscal Year..........................................30
ii 3 4.8 Litigation...........................................30 4.9 Taxes; Governmental Charges..........................30 4.10 Title to Properties..................................31 4.11 No Default...........................................31 4.12 Casualties; Taking of Properties.....................31 4.13 Compliance with Laws.................................31 4.14 Compliance with Fraud and Abuse Laws.................31 4.15 ERISA................................................31 4.16 Full Disclosure of Material Facts....................32 4.17 Accuracy of Projections..............................32 4.18 Investment Company Act...............................32 4.19 Personal Holding Company.............................32 4.20 Solvency.............................................32 4.21 Chief Executive Office...............................32 4.22 Subsidiaries.........................................32 4.23 Ownership of Patents, Licenses, Etc..................32 4.24 Environmental Compliance.............................32 4.25 Labor Matters........................................33 4.26 OSHA Compliance......................................33 4.27 Regulation U.........................................33 4.28 Affiliate Transactions...............................33 V. AFFIRMATIVE COVENANTS.......................................................33 5.1 Payment of Obligations...............................33 5.2 Maintenance of Existence and Business................33 5.3 Financial Statements and Reports.....................34 5.4 Additional Information...............................35 5.5 Certain Additional Reporting Requirements............35 5.6 Taxes and Other Encumbrances.........................36 5.7 Payment of Liabilities...............................37 5.8 Compliance with Laws.................................37 5.9 Maintenance of Property..............................37 5.10 Compliance with Contractual Obligations..............37 5.11 Further Assurances...................................37 5.12 Security Interest; Setoff............................38 5.13 Insurance............................................38 5.14 Accounts and Records.................................38 5.15 Official Records.....................................39 5.16 Banking Relationships................................39 5.17 Right of Inspection..................................39 5.18 ERISA Information and Compliance.....................39 5.19 Indemnity; Expenses..................................39 5.20 Assistance in Litigation.............................40 5.21 Name Changes.........................................41
iii 4 5.22 Estoppel Letters.....................................41 5.23 Environmental Matters................................41 5.24 Opinions of Counsel..................................42 5.25 Additional Collateral Upon Certain Event.............42 VI. NEGATIVE COVENANTS.........................................................43 6.1 Debts, Guaranties, and Other Obligations.............43 6.2 Change of Management.................................44 6.3 Change of Ownership..................................44 6.4 Distributions........................................44 6.5 Encumbrances.........................................44 6.6 Investments..........................................44 6.7 Sales and Leasebacks.................................45 6.8 Change of Control....................................45 6.9 Nature of Business...................................45 6.10 Further Acquisitions, Mergers, Etc...................45 6.11 Advances.............................................45 6.12 Disposition of Assets................................45 6.13 Inconsistent Agreements..............................45 6.14 Fictitious Names.....................................45 6.15 Subsidiaries and Affiliates..........................46 6.16 Place of Business....................................46 6.17 Adverse Action With Respect to Plans.................46 6.18 Transactions With Affiliates.........................46 6.19 Constituent Document Amendments......................46 6.20 Adverse Transactions.................................46 6.21 Margin Securities....................................46 6.22 Accounting Changes...................................46 6.23 Action Outside Ordinary Course.......................46 VII. FINANCIAL COVENANTS.......................................................47 7.1 Current Ratio........................................47 7.2 Total Funded Debt to Capital.........................47 7.3 Total Funded Debt to Consolidated EBITDA.............47 7.4 Fixed Charge Coverage................................47 7.5 Net Worth............................................47 7.6 Capital Expenditures.................................47 VIII. EVENTS OF DEFAULT........................................................47 8.1 Events of Default....................................47 8.2 Remedies.............................................50 IX. AGENT......................................................................50 9.1 Appointment of Agent.................................50
iv 5 9.2 Powers of Agent......................................50 9.3 Duties of Agent......................................51 9.4 Indemnification of Agent.............................53 9.5 No Representations by Agent..........................53 9.6 Independent Investigations by Lenders................53 9.7 Notice of Default....................................54 9.8 Funding of Loans Pursuant to Borrowing Notices.......54 9.9 Agent in its Individual Capacity.....................54 9.10 Holders..............................................54 9.11 Successor Agent......................................55 9.12 Sharing of Payments, etc...............................55 9.13 Separate Liens on Collateral...........................55 9.14 Payments Between Agent and Lenders.....................55 9.15 Assignments and Participations.........................56 9.16 Bankruptcy Provisions..................................56 9.17 Foreclosure of Collateral..............................56 9.18 Procedures for Notices and Approvals.................56 9.19 Amendments to Article IX...............................56 X. GENERAL PROVISIONS..........................................................57 10.1 Notices.................................................57 10.2 Renewal, Extension, or Rearrangement.................58 10.3 Application of Payments..............................58 10.4 Counterparts.........................................58 10.5 Negotiated Document..................................58 10.6 Consent to Jurisdiction; Exclusive Venue.............58 10.7 Not Partners; No Third Party Beneficiaries...........59 10.8 No Reliance on Lenders' Analysis.....................59 10.9 No Marshaling of Assets..............................59 10.10 Impairment of Collateral.............................59 10.11 Business Days........................................59 10.12 Participations.......................................59 10.13 Standard of Care; Limitation of Damages..............59 10.14 Incorporation of Schedules...........................60 10.15 Indulgence Not Waiver................................60 10.16 Cumulative Remedies..................................60 10.17 Amendment and Waiver in Writing......................60 10.18 Assignment...........................................60 10.19 Entire Agreement.....................................60 10.20 Severability.........................................60 10.21 Time of Essence......................................60 10.22 Applicable Law.......................................60 10.23 Captions Not Controlling.............................61 10.24 Arbitration..........................................61 10.25 Facsimile Signatures.................................62
v 6 LOAN AGREEMENT This Loan Agreement is entered into as of the 31st day of May, 1996, by and among RESPONSE ONCOLOGY, INC. ("Borrower"), a Tennessee corporation; NATIONSBANK OF TENNESSEE, N.A. ("NationsBank"), a national banking association, and UNION PLANTERS NATIONAL BANK ("Union Planters"), a national banking association (collectively "Lenders"); and NATIONSBANK OF TENNESSEE, N.A., in its capacity as Agent for Lenders ("Agent"). RECITALS WHEREAS, Lenders have agreed to extend a revolving acquisition loan facility and a revolving working capital facility to Borrower, on certain terms and conditions, as set forth in detail in this Agreement; and WHEREAS, Lenders wish to appoint Agent to administer the loans extended by Lenders to Borrower; and NOW, THEREFORE, as an inducement to cause Lenders to extend credit to Borrower, and for other valuable consideration, the receipt and sufficiency of which are acknowledged, it is agreed as follows: I. DEFINITIONS 1.1 Terms Defined in This Agreement. As used below in this Agreement, the following capitalized terms shall have the following meanings, unless the context expressly requires otherwise: "ACQUISITION EBITDA" means, with respect to a Practice acquired by a Consolidated Entity and covered by a Service Agreement, (i) the pro forma income to the Consolidated Entities that would have arisen under the applicable Service Agreement preceding the effective date of the acquisition, determined based upon the actual financial performance of the acquired Practice over the period for which a calculation of Consolidated EBITDA is made, without adjustment, (ii) less the pro forma amount of expenses (other than interest, taxes, depreciation and amortization) that the Consolidated Entities would have incurred over the same period on account of the acquired Practice (including, but not limited to, additional expense of administrative personnel), in each case calculated as if the Practice had been acquired effective as of the beginning of the relevant financial period. "ACQUISITION LOAN" means the revolving credit facility described by amount and use in Sections 2.1 and 2.2 hereof. 7 "AFFILIATE" means, with respect to any Person, another Person that, directly or indirectly through one or more intermediaries, Controls, or is Controlled by, or is under common Control with, such Person. "AGENT" means NationsBank of Tennessee, N.A., in its capacity as described in Article IX of this Agreement, its lawful corporate successors and any successor agent appointed pursuant to Article IX hereof. "AGREEMENT" means this Loan Agreement (including all schedules and exhibits hereto), as the same may be amended from time to time. "APPLICABLE COMMITMENT FEE," "APPLICABLE LIBO RATE MARGIN," and "APPLICABLE PRIME RATE MARGIN" mean, with respect to Loans advanced under and the commitment fee respecting the Acquisition Loan, during any Effective Period, the percentage rates per annum set forth opposite the appropriate test in the pricing grid below (ratio values shall be rounded to the nearest one-hundredth, with any value of .005 rounded upward):
TOTAL FUNDED DEBT TO PRIME RATE MARGIN LIBOR COMMITMENT CONSOLIDATED EBITDA MARGIN FEE IN BASIS POINTS Less than or equal to 1.00 .25% 1.50% 20bps Greater than or equal to 1.01 .50% 1.75% 25bps and less than or equal to 2.00 Greater than or equal to 2.01 .75% 2.125% 30bps and less than or equal to 3.00 Greater than or equal to 3.01 1.00% 2.625% 35bps
Additionally, with respect to Loans advanced under and the commitment fee respecting the Working Capital Loan, "APPLICABLE COMMITMENT FEE," "APPLICABLE LIBO RATE MARGIN," and "APPLICABLE PRIME RATE MARGIN" mean, during any Effective Period, the percentage rates per annum set forth opposite the appropriate test in the pricing grid below (ratio values shall be rounded to the nearest one-hundredth, with any value of .005 rounded upward):
TOTAL FUNDED DEBT TO PRIME RATE MARGIN LIBOR COMMITMENT FEE CONSOLIDATED MARGIN IN BASIS POINTS EBITDA Less than or equal to 0% 1.25% 15bps 1.00
2 8
TOTAL FUNDED DEBT TO PRIME RATE MARGIN LIBOR COMMITMENT FEE CONSOLIDATED MARGIN IN BASIS POINTS EBITDA Greater than or equal .25% 1.50% 20bps to 1.01 and less than or equal to 2.00 Greater than or equal .50% 1.875% 25bps to 2.01 and less than or equal to 3.00 Greater than or equal .75% 2.375% 30bps to 3.01
The Total Funded Debt to Consolidated EBITDA ratio shall be established by Agent on the basis of the consolidated quarterly financial statements of and schedules prepared by Borrower delivered to Agent pursuant to this Agreement and shall be calculated as set forth in Section 7.3 hereof. Notwithstanding the foregoing, at the end of any Effective Period, and during the existence and continuation of an Event of Default, and during any period of time for which Pricing Values may be set by Agent pursuant to Section 8.1.5 hereof, the Pricing Values with respect to the Loans shall automatically become the highest values provided for in the applicable pricing grid set forth above in respect of the two respective Credit Facilities. Additionally, the Applicable Prime Rate Margin for Prime Rate Loans and the Applicable LIBO Rate Margin for LIBOR Loans shall each be reduced by one-fourth of one percent (1/4%) if Borrower shall receive aggregate Net Equity Proceeds after the Closing Date from the public offering of its equity securities of at least Thirty Million and No/100 Dollars ($30,000,000.00). "ASSUMED DEBT" means Purchase Money Debt assumed by a Consolidated Entity, or Purchase Money Debt secured by a Purchase Money Security Interest in Property acquired by a Consolidated Entity, whether or not the Purchase Money Debt is contractually assumed, occurring in either case in the course of a Permitted Acquisition. "BANKING DAY" means a Business Day, subject to the following additional convention. As to notices or payments received by Agent on a Business Day at or before 12:00 p.m. (noon) Nashville time, the Banking Day shall correspond to the Business Day of receipt. As to notices or payments received by Agent on a Business Day after 12:00 p.m. (noon) Nashville time, the Banking Day of receipt shall be deemed to be the next following Business Day. "BANKRUPTCY CODE" means Title I of the Bankruptcy Reform Act of 1978, as it may be amended from time to time. 3 9 "BEST OF BORROWER'S KNOWLEDGE" means the actual knowledge, information and belief of the Chairman, Chief Executive Officer, Chief Financial Officer, Controller or General Counsel of Borrower, with no duty of inquiry. "BORROWER" means Response Oncology, Inc., a Tennessee corporation, its successors and assigns. This definition does not abrogate the requirements set forth below restricting Borrower's ability to assign any rights under this Agreement. "BORROWER'S PORTION" means the percentage of equity interest that Borrower acquires in an entity acquired in or created in connection with a Permitted Acquisition. Additionally, if an acquisition is of less than all of the interest or assets of a Seller, or if a Seller had a declining number of Practices over the relevant accounting period, the Borrower's Portion shall include only such of the operations of the Seller as were acquired by a Consolidated Entity in a Permitted Acquisition. "BORROWING BASE" means (i) Borrower's Consolidated EBITDA for the most recent four fiscal quarters, as determined by the quarterly financial statements and schedules delivered to Agent from time to time pursuant to this Agreement, (ii) multiplied by 2.5. "BORROWING NOTICE" has the meaning assigned in Section 2.8.1(b) hereof. "BUSINESS DAY" means any day on which Agent is open for the conduct of ordinary business; provided however, that when used in connection with determining the LIBO Rate, the term "Business Day" shall exclude any day on which banks are not open for dealings in U.S. Dollar deposits in the London Interbank Market. "CAPITAL EXPENDITURES" means expenditures, determined according to GAAP on a consolidated basis, that would be capitalized and depreciated over more than one annual accounting period. "CAPITAL LEASE" means a lease that would be characterized as a financed sale or purchase under GAAP. "CHANGE OF CONTROL" means the occurrence, after the date of this Agreement, of (i) any Person or two or more Persons acting in concert acquiring beneficial ownership (within the meaning of Rule 13d-3 of the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended), directly or indirectly, of securities of Borrower (or other securities convertible into such securities) representing 51% or more of the combined voting power of all securities thereof entitled to vote in the election of directors; or (ii) during any period of up to 12 consecutive months, commencing after the date of this Agreement, individuals who at the beginning of such 12-month period were directors of Borrower ceasing for any reason to constitute a majority of the Board of Directors thereof unless the Persons replacing such individuals were nominated by the Board of Directors of Borrower; or (iii) any Person or two or more Persons acting in concert acquiring by contract 4 10 or otherwise, or entering into a contract or arrangement which upon consummation will result in its acquisition of, or control over, securities of Borrower (or other securities convertible into such securities) representing 51% or more of the combined voting power of all securities of Borrower entitled to vote in the election of directors. "CLOSING DATE" means the date of this Agreement. "CMLTD" means scheduled principal payments in respect of long-term Liabilities payable during the 12 months following the date of determination. "COLLATERAL" means all Property now or hereafter securing the Obligations. "COMMITMENT" means the amount of each Lender's commitment to fund the respective Credit Facilities. Each Lender's several Commitment for the Acquisition Loan shall be as follows: NationsBank Sixteen Million and No/100 Dollars ($16,000,000.00) Union Planters Six Million and No/100 Dollars ($6,000,000.00) Each Lender's several Commitment for the Working Capital Loan shall be as follows: NationsBank Four Million and No/100 Dollars ($4,000,000.00) Union Planters One Million Five Hundred Thousand and No/100 Dollars ($1,500,000.00) "CONSOLIDATED CAPITAL" means Consolidated Net Worth plus Total Funded Debt. "CONSOLIDATED CURRENT RATIO" means current assets, determined on a consolidated basis according to GAAP, divided by current liabilities, determined on a consolidated basis according to GAAP. "CONSOLIDATED EBITDA" means the EBITDA of the Borrower, determined on a consolidated basis, and adjusted as follows with respect to acquisitions. The positive Acquisition EBITDA of acquired Practices shall be included in Consolidated EBITDA only if Agent is satisfied, in its reasonable discretion, as to the accuracy and reliability of the financial information related thereto. In assessing the accuracy and reliability of such financial information, (i) unqualified audited financial statements prepared by a regional or national accounting firm shall be acceptable, and (ii) financial statements reviewed (but not audited) by such a firm shall also be acceptable unless Agent in good faith determines that reviewed statements for a particular enterprise are subject to material doubt as to their accuracy. The negative Acquisition EBITDA for any Practice shall be included in Consolidated EBITDA, based upon the best information available. Notwithstanding any other provision hereof, the EBITDA attributed to Non-Corporate Unperfected Subsidiaries shall not be included in 5 11 Consolidated EBITDA if Non-Corporate Unperfected Subsidiaries would account for more than ten percent (10%) of total Consolidated EBITDA. "CONSOLIDATED ENTITIES" means Borrower and all Subsidiaries of Borrower, from time to time. "CONSOLIDATED NET INCOME" means net income, determined on a consolidated basis according to GAAP. "CONSOLIDATED NET WORTH" means shareholders' equity, determined on a consolidated basis according to GAAP. "CONTROL" or "CONTROLLED" means that a Person has the direct or indirect power to conduct or govern the policies of another Person, whether this power exists as a matter of right or through economic compulsion. "CREDIT CEILING" means, with respect to a Credit Facility, the amount determined by subtracting from the Borrowing Base the principal amount outstanding under the other Credit Facility, to the effect that the total principal amount outstanding under the Credit Facilities shall not in total exceed the Borrowing Base at any time. "CREDIT FACILITIES" means the Acquisition Loan and the Working Capital Loan. "DEFAULT RATE" means the Maximum Lawful Amount of interest that can be charged. "EBITDA" means the sum of net income before extraordinary items plus Interest Expense and expenses for taxes, depreciation and amortization, determined according to GAAP. "EFFECTIVE PERIOD" means a period of up to one calendar quarter, determined as follows. Pursuant to other provisions of this Agreement, Borrower's financial information for each quarter-end is to be submitted during the succeeding quarter, except that year-end financial statements are not due until April 30 of the following year. The performance pricing provisions of this Agreement reevaluate pricing quarterly, based upon those quarterly financial results. An Effective Period imposing pricing based upon a quarter other than the quarter ending December 31 shall begin on the later of (i) the first day of the third month of the following fiscal quarter, or (ii) if financial statements are submitted later than required under this Agreement and Agent waives any Event of Default arising therefrom, five (5) Business Days after the submission of required financial statements. An Effective Period imposing pricing based upon the quarter ending December 31 shall begin "as of" the first day of the third month of the following fiscal quarter, with a retroactive adjustment of interest to be made when the year-end financial statements are timely submitted, if necessary to reflect an increase or decrease of the interest rates or fees based upon performance for the period ending 6 12 December 31. If year-end financial statements are not timely submitted, but are nonetheless accepted by Agent and Agent waives any Event of Default arising therefrom, the Effective Period imposing pricing based upon the quarter ending December 31 shall begin "as of" five (5) Business Days after the submission of the required annual financial statements. The Effective Period shall end on the last day of the second month of each fiscal quarter following the quarter in which the Effective Period was scheduled to begin. Therefore, assuming the timely delivery of all required financial statements, the Effective Periods will be determined as follows: Financial Statements Due By Effective Period --------------------------- ---------------- May 15 June 1 - August 31 August 15 September 1 - November 30 November 15 December 1 - February 28/29 April 30 March 1 (retroactive) - May 31 An initial Effective Period shall commence on the Closing Date and continue through the last day of August, 1996, and Pricing Values shall be determined during this initial Effective Period based on the financial reports as of and for the period ended March 31, 1996. "ENCUMBRANCE" means any interest in Property in favor of one not the owner thereof, whether voluntary or involuntary, including, but not limited to, (i) the lien or security interest arising from a deed of trust, mortgage, pledge, security agreement, conditional sale, Capital Lease, consignment, or bailment for security purposes, and (ii) reservations, exceptions, encroachments, easements, rights-of-way, covenants, conditions, restrictions, leases, and other such title encumbrances. "ENVIRONMENTAL LAWS" means the Environmental Protection Act, the Resource Conservation and Recovery Act of 1976, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, the Hazardous Materials Transportation Act and any other federal, state or municipal law, rule or regulation relating to air emissions, water discharge, noise emissions, solid or liquid waste disposal, hazardous or toxic waste or materials, or other environmental or health matters. "ERISA" means the Employee Retirement Income Security Act of 1974, as amended from time to time, including (unless the context otherwise requires) any rules or regulations promulgated thereunder. "ERISA AFFILIATE" means any Person who for purposes of Title IV of ERISA is a member of Borrower's controlled group, or under common control with Borrower, within the meaning of Section 414 of the IRC, the regulations promulgated pursuant thereto and the published revenue rulings issued thereunder. 7 13 "ERISA EVENT" means (i) the occurrence of a reportable event, within the meaning of Section 4043 of ERISA, unless the 30-day notice requirement with respect thereto has been waived by the PBGC; (ii) the provision by the administrator of any Plan of a notice of intent to terminate such Plan, pursuant to Section 4041(a)(2) of ERISA (including any such notice with respect to a plan amendment referred to in Section 4041(e) of ERISA); (iii) the cessation of operations at a facility in the circumstances described in Section 4068(f) of ERISA; (iv) the withdrawal by Borrower or an ERISA Affiliate from a Multiple Employer Plan during a plan year for which it was a substantial employer, as defined in 4001(a)(2) of ERISA; (v) the failure by Borrower or any ERISA Affiliate to make a material payment to a Plan required under Section 302(f)(1) of ERISA; (vi) the adoption of an amendment to a Plan requiring the provision of initial or additional security to such Plan, pursuant to Section 307 of ERISA; or (vii) the institution by the PBGC of proceedings to terminate a Plan, pursuant to Section 4042 of ERISA, or the occurrence of any event or condition which might constitute grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, a Plan. "EVENT OF DEFAULT" means the occurrence of any of the events specified in Section 8.1 hereof, as to which any requirement for notice or lapse of time has been satisfied. "FINANCIAL PROJECTIONS" means the financial projections prepared by Borrower, a copy of which is attached hereto as Exhibit 1.1. "FINANCIAL STATEMENTS" means the audited consolidated balance sheet, income statement, and statement of cash flows for Borrower dated December 31, 1995 and the unaudited consolidated financial statements dated March 31, 1996 delivered by Borrower to Lender, and all notes thereto. "FIXED CHARGE COVERAGE RATIO" means (i) Consolidated EBITDA, plus expenses incurred under Operating Leases, and less a charge of Ten Thousand and No/100 Dollars ($10,000.00) per year per wholly-owned IMPACT Center and Five Thousand and No/100 Dollars ($5,000.00) per year for each IMPACT Center that is not wholly-owned by a Consolidated Entity to allow for maintenance Capital Expenditures, and less loans advanced to Providers, divided by (ii) the sum of Interest Expense plus CMLTD (including implied amortization calculated as one-seventh of the outstanding principal amount of the Credit Facilities as of the end of the applicable period), plus expenses incurred under Operating Leases. The values for the fixed charges used in the calculation of this ratio will be determined on a pro forma basis as though the acquisitions occurring during the period over which the Fixed Charge Coverage Ratio is being determined had occurred as of the beginning of that period, with such calculations to take into account, along with other adjustments that Agent may approve, in its reasonable discretion, (i) the exclusion of Interest Expense, CMLTD, Capital Lease expense and Operating Lease expense of the target related to debts, leases and obligations that were extinguished in connection with the acquisition, (ii) the inclusion of Interest Expense, CMLTD, Capital Lease expense and Operating Lease expense obligations of the target that survived the acquisition, and (iii) the inclusion of Interest 8 14 Expense, CMLTD, Capital Lease expense and Operating Lease Expense arising from obligations incurred in connection with the acquisition (including, but not limited to, added Interest Expense arising from Seller Debt or from Loans advanced under this Agreement incidental to the acquisition). "FRAUD AND ABUSE LAWS" means Section 1128B(b) of the Social Security Act, 42 U.S.C. Section 1320a-7b(b) and Section 1877 of the Social Security Act, 42 U.S.C. Section 1877, as from time to time amended; any successor statute(s) thereto; all rules and regulations promulgated thereunder; and any other Law relating to the ownership of medical facilities by providers of medical services or the referral of patients to medical facilities owned by providers of medical services. "GAAP" means generally accepted accounting principles pronounced by the Financial Accounting Standards Board or any successor thereto, as in effect from time to time. "GOVERNMENTAL AUTHORITY" means any governmental or quasi-governmental entity, court or tribunal including, without limitation, any department, commission, board, bureau, agency, administration, service or other instrumentality of any foreign or domestic governmental entity. "HAZARDOUS SUBSTANCES" means those substances included from time to time within the definition of hazardous substances, hazardous materials, toxic substances, or solid waste under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 as amended, 42 U.S.C. ss. 9601 et seq.; the Resource Conservation and Recovery Act of 1976, 42 U.S.C. ss. 6901 et seq.; the Hazardous Materials Transportation Act, 49 U.S.C. ss. 1801 et seq.; the Clean Water Act, 33 U.S.C. Section 1251 et. seq.; the Toxic Substances Control Act, 15 U.S.C. Section 2601 et. seq., and in the regulations promulgated pursuant to such acts and laws; and such other substances that are or become regulated under any applicable local, state, or federal law or regulation addressing environmental hazards. "IMPACT CENTER" means a high dose chemotherapy cancer treatment center operated by a Consolidated Entity. "INTEREST EXPENSE" means expenses for interest (and including the interest portion of current charges on Capital Leases) and expenses for any interest rate swaps or similar derivative contracts used for the management of interest expense. "INTEREST PAYMENT DATE" means, (i) as to Prime Rate Loans, the first day of each month, and (ii) as to any LIBOR Loan, the last day of the Interest Period applicable to such Loan and, in addition, in the case of a LIBOR Loan with an Interest Period of six (6) or twelve (12) months' duration, the numerically corresponding day (or, if there is no numerically corresponding day, on the last day) in the calendar month that is 3, 6, 9 and 12 months, as applicable, after the commencement of the Interest Period. 9 15 "INTEREST PERIOD" means, as to any LIBOR Loan, the period commencing on the date of such LIBOR Loan and ending on the numerically corresponding day (or, if there is no numerically corresponding day, on the last day) in the calendar month that is 1, 2, 3, 6 or 12 months thereafter, as Borrower may elect; provided, however, that (x) if any Interest Period would end on a day that is not a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless, with respect to LIBOR Loans, such next succeeding Business Day would fall in the next calendar month, in which case such Interest Period shall end on the next preceding Business Day and (y) no Interest Period with respect to any Loan shall end later than the Maturity Date. Interest shall accrue from and including the first Banking Day of an Interest Period to but excluding the last Banking Day of such Interest Period. "IRC" means the Internal Revenue Code of 1986, as amended from time to time. "LAW" or "LAWS" means all applicable constitutional provisions, statutes, codes, acts, ordinances, orders, judgments, decrees, injunctions, rules, regulations, and requirements of all Governmental Authorities. "LENDERS" means NationsBank and Union Planters, their respective successors and assigns. "LIABILITY" means, with respect to any Person, an obligation, contingent or otherwise, that would be classified under GAAP as a liability of that Person including, but not limited to, any nonrecourse obligation secured by Property of that Person. "LIBO RATE" means, for any given Interest Period with respect to a given LIBOR Loan, the rate per annum appearing on Telerate Page 3750 (or any successor page) as the London interbank offered rate for deposits in Dollars at approximately 11:00 a.m. (London time) two Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period. If for any reason such rate is not available, the term LIBO Rate shall mean, for any given Interest Period with respect to a given LIBOR Loan, the rate per annum appearing on Reuters Screen LIBO Page as the London interbank offered rate for deposits in Dollars at approximately 11:00 a.m. (London time) two Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period; provided, however, if more than one rate is specified on Reuters Screen LIBO Page, the applicable rate shall be the arithmetic mean of all such rates. "LIBO RATE RESERVE PERCENTAGE" means the reserve percentage applicable during any Interest Period (or if more than one such percentage shall be so applicable, the daily average of such percentages for those days in such Interest Period during which any such percentage shall be so applicable) under regulations issued from time to time by the Board of Governors of the Federal Reserve System (or any successor) for determining the maximum 10 16 reserve requirement (including, without limitation, any emergency, supplemental or other marginal reserve requirement) for Lenders with respect to liabilities or assets consisting of or including LIBOR Liabilities having a term equal to such Interest Period. "LIBOR LIABILITIES" means deposit liabilities incurred through the London Interbank Market. "LIBOR LOAN" means a Loan for which Borrower has elected application of an interest rate based on the LIBO Rate. "LOAN" means a loan advanced under the Credit Facilities. "LOAN DOCUMENTS" means, collectively, each writing delivered at any time by Borrower to Lenders or Agent relating to the Credit Facilities. "MATERIAL ADVERSE CHANGE" means any material and adverse change in the business, Properties, or operations of the Consolidated Entities. "MATERIAL ADVERSE EFFECT" means any event or condition which, singly or in the aggregate with other events or conditions, materially and adversely affects the business, Properties, or operations of the Consolidated Entities, considered collectively. "MATURITY DATE" means May 31, 1998, with respect to the Acquisition Loan, and May 31, 1997, with respect to the Working Capital Loan; provided, however, that Borrower may extend the Maturity Date for the Working Capital Loan to May 31, 1998, by giving Agent written notice of such election in the form set forth in Exhibit 1.2 hereto and paying an extension fee of Thirteen Thousand Seven Hundred Fifty and No/100 Dollars ($13,750.00), to be apportioned to Lenders Pro Rata in accordance with their respective Commitments for the Working Capital Loan. "MAXIMUM LAWFUL AMOUNT" means the maximum lawful amount of interest, loan charges, commitment fees or other charges that may be assessed under Tennessee law or, if higher, under applicable federal law. "MIAMI DEBT" means the obligations of Borrower under that Non-Negotiable Promissory Note made by Borrower dated January 2, 1996 in the original principal amount of Five Million Nine Hundred Fifty-Nine Thousand Nine Hundred Seventy-Two and No/100 Dollars ($5,959,972.00), and any modification, extension or renewal thereof approved by Agent. "NATIONSBANK" means NationsBank of Tennessee, N.A., its successors and assigns. 11 17 "NET EQUITY PROCEEDS" means the Net Proceeds of issuances of equity by Borrower, less any amount of such Net Proceeds used to redeem existing, outstanding equity securities of Borrower. "NET PROCEEDS" means gross proceeds of a transaction less reasonable and customary underwriter and brokerage fees and commissions, the fees and expenses of trustees and attorneys, and other reasonable and customary closing fees and expenses. "NON-CORPORATE SUBSIDIARY" means a Permitted Subsidiary that is other than a corporation. "NON-CORPORATE UNPERFECTED SUBSIDIARY" means a Non-Corporate Subsidiary, Borrower's interest in which is not subject to a perfected security interest to secure the Obligations. "NOTE" means any of the Acquisition Loan Notes or the Working Capital Loan Notes referred to in Sections 2.3 and 2.6 hereof, respectively. "OBLIGATIONS" means the obligations of Borrower to Lenders to repay the Credit Facilities and all other obligations of Borrower and the Consolidated Entities to Lenders and to Agent under this Agreement and the other Loan Documents. "OPERATING LEASES" means leases that are not Capital Leases. "PBGC" means the Pension Benefit Guaranty Corporation and any entity succeeding to any or all of its functions under ERISA. "PERMITTED ACQUISITION" means the acquisition (by asset purchase, stock purchase, merger or otherwise, subject to the other requirements of this definition set forth below) by Borrower of the assets of a Practice in the ordinary course of business (it being acknowledged that medical records and certain other professional assets that are required by Law to be owned by a physician Provider are not acquired in these transactions), which purchase meets all of the following criteria: (a) The form of the acquisition shall have been of the assets of a Practice or, if for stock or other equity interest, the target acquired shall become a Permitted Subsidiary concurrently with the closing of the acquisition. (b) Borrower shall have delivered to Lender, prior to closing the acquisition, unaudited pro forma financial statements or certificates demonstrating continued compliance with all covenants in this Agreement following the acquisition. 12 18 (c) Agent shall have given its written consent to the acquisition prior to the closing thereof, in the cases of those acquisitions (i) for which the total consideration is greater than seven (7) times Acquisition EBITDA over the previous twelve (12) months (with Acquisition EBITDA determined for the purpose of this Subsection (i) only based upon the pro forma financial performance of the acquired Practice over the twelve (12) - month period, including adjustment for cost savings that Borrower can establish will occur immediately following the transaction), (ii) for which the portion of the purchase price consisting of cash, Assumed Debt and Seller Debt exceeds three percent (3%) of Borrower's total assets as reported by Borrower pursuant to this Agreement most recently prior to the date of determination, (iii) in which the Acquisition EBITDA of the target is negative for either of the previous two (2) fiscal years, (iv) of more than three (3) Practices in a single transaction, or (v) which, together with previous acquisitions within a single calendar year, total seven (7) or more Practices. "PERMITTED ENCUMBRANCES" means all of the following: (a) Encumbrances securing the payment of any of the Obligations. (b) Encumbrances securing taxes, assessments, or other governmental charges not yet due or which are being contested in good faith by appropriate action promptly initiated and diligently conducted, if Borrower has made reserve therefor as required by GAAP. (c) Mechanics', repairmen's, materialmen's, warehousemen's, landlords' and other like liens arising by operation of law securing accounts that are not delinquent. (d) Encumbrances on real property used by Borrower not securing monetary obligations, provided that the Encumbrances are of a type customarily placed on real property and do not materially impair the value of the affected property. (e) Pledges or deposits in the ordinary course of business to secure nondelinquent obligations under workman's compensation or unemployment laws or similar legislation or to secure the performance of leases or contracts entered into in the ordinary course of business. 13 19 (e) Purchase Money Security Interests, to the extent permitted by Section 6.1.7 hereof. "PERMITTED SUBSIDIARY" means a Subsidiary that (i) is now or hereafter becomes a Borrower or a guarantor under this Agreement, (ii) is owned, in both economic interest and voting rights, by Borrower in an amount exceeding 50%, (iii) is owned by Borrower in a proportion sufficient to allow Borrower to Control the Subsidiary, including the right to cause the Subsidiary to make lawful distributions of income, and the financial interest of Borrower therein is, in Agent's reasonable judgment, freely alienable by Borrower through a security interest granted therein or otherwise, and (iv) as to which Borrower has granted to Agent as additional security for the Loans, a first priority perfected security interest in its stock or other equity interest in the Subsidiary pursuant to documentation in form and substance acceptable to Agent and its counsel, with the validity and perfection of the security interest and other matters as Agent may reasonably require confirmed to Agent by an opinion of Borrower's outside counsel satisfactory to Agent in all respects, and with all expenses related to such documentation (including, but not limited to, filing fees and taxes and the reasonable fees and expenses of Lenders' and Agent's attorneys) to be paid by Borrower; provided, however, that Borrower need not grant a perfected security interest in its equity interest in a Non-Corporate Subsidiary in order for such Subsidiary to be a Permitted Subsidiary. "PERSON" means any individual, corporation, partnership, joint venture, association, joint stock company, trust, unincorporated organization, government, governmental agency or political subdivision thereof, or any other form of entity. "PLAN" means any employee benefit or other plan established or maintained, or to which contributions have been made, by Borrower or any Subsidiary and covered by Title IV of ERISA or to which Section 412 of the IRC applies. "PRACTICE" means an oncology or hematology treatment center or an oncology or hematology medical practice. Whenever in this Agreement "Practice" is used in describing an acquisition by Borrower, and if the reference relates to a medical practice, such reference is to the acquisition of the assets used in the operation of the Practice that can lawfully be acquired by Borrower or to the acquisition of an interest in an entity that owns, as of the time of purchase, only those assets that can be lawfully acquired by Borrower. "PRICING VALUES" means the Applicable LIBO Rate Margin and Applicable Prime Rate Margin for both of the Credit Facilities and the Applicable Commitment Fee. "PRIME RATE" shall be that rate announced by Agent from time to time as its Prime Rate and is one of several interest rate bases used by Agent. Lenders and Agent lend at rates both above and below Agent's Prime Rate and Borrower acknowledges that the Prime Rate is not represented or intended to be the lowest or most favorable rate of interest offered by any Lender or Agent. 14 20 "PRIME RATE LOAN" means a Loan for which Borrower has elected application of an interest rate based on the Prime Rate. "PRO RATA" OR "PRO RATA SHARE" refer to the apportionment among Lenders according to their respective total Commitments at the time of determination; provided, however, if at a time of determination there are principal amounts outstanding under either or both of the Credit Facilities, and if any Lender has failed to fund any unrepaid Loan that was funded by any other Lender or Lenders, this apportionment shall be determined according to the respective total principal amounts of the Credit Facilities held by the respective Lenders rather than by their Commitments. "PROPERTY" or "PROPERTIES" means any interest in any kind of property, whether real, personal, or mixed, or tangible or intangible. "PROVIDER" means an oncologist, hematologist, radiologist or other medical doctor whose specialty is complementary to the practice of oncology or hematology and who performs professional services respecting a Practice that is either managed by Borrower or the assets of which are owned by Borrower. "PURCHASE MONEY DEBT" means a Liability that is secured by a Purchase Money Security Interest. "PURCHASE MONEY SECURITY INTEREST" means an Encumbrance on specific equipment (including the Encumbrance arising under a Capital Lease), provided that (i) the Liability secured by any such Encumbrance shall have arisen at the time of the acquisition thereof and shall not exceed 100% of the cost of the equipment to the entity acquiring the same, and (ii) each such Encumbrance shall attach only to the equipment so acquired with the proceeds of the Liability secured thereby. "REQUIRED LENDERS" means Lenders holding at least 66 2/3% of the total Commitments for the Credit Facilities; provided, however, if at a time of determination there are principal amounts outstanding under either or both of the Credit Facilities, and if any Lender has failed to fund any unrepaid Loan that was funded by any other Lender or Lenders, this determination shall be made according to Lenders holding the required percentage of principal amounts of the Credit Facilities rather than by the outstanding Commitments. "SEAFIELD POSITION" means the equity interest of Seafield Capital Corporation in Borrower. "SELLER" means the former owner of a Practice that is acquired by a Consolidated Entity. "SELLER DEBT" means a Liability incurred in favor of one or more Sellers representing part of the purchase price of a Practice. 15 21 "SERVICE AGREEMENT" means one of those service or management agreements now in effect or hereafter entered into by Borrower and Providers in connection with the management of oncology practices and/or IMPACT Centers. "SIGNIFICANT CONSOLIDATED ENTITY" means (i) Borrower, or (ii) any Consolidated Entity other than Borrower that accounts for more than five percent (5%) of either Borrower's total assets determined on a consolidated basis as of the end of the most recent fiscal quarter or of Borrower's Consolidated EBITDA for the most recent fiscal quarter, from time to time; provided, however, that for as long as any facts that would otherwise constitute Events of Default exist with respect to more than one Consolidated Entity at any time, such that the total contribution of all affected Consolidated Entities exceeds more than five percent (5%) of either Borrower's total assets determined on a consolidated basis as of the end of the most recent fiscal quarter or of Borrower's Consolidated EBITDA for the most recent fiscal quarter, each Consolidated Entity shall be considered a Significant Consolidated Entity. "SOLVENT" shall mean, as to any Person, that as of any date of determination, (i) the then fair value of the assets of such Person is (a) greater than the then total amount of liabilities (including subordinated liabilities) of such Person and (b) greater than the amount that will be required to pay such Person's probable liability on such Person's then existing debts as they become absolute and matured, (ii) such Person's capital is not unreasonably small in relation to its business, and (iii) such Person has not incurred and does not intend to incur, or believe or reasonably should believe that it will incur, debts beyond its ability to pay such debts as they become due. "SUBORDINATED DEBT" means any unsecured Liability that is subordinated as to payment, liquidation, collection and collection in bankruptcy to the obligations of Borrower to Lenders pursuant to subordination documentation in form and substance acceptable to Agent and which has a maturity of no earlier than six (6) months following the latest applicable Maturity Date. The Miami Debt shall be regarded as Subordinated Debt for all purposes in this Agreement at any time that the average (mean) closing bid price for Borrower's stock is greater than Seventeen and 50/100 Dollars ($17.50) for the ten market days prior to the date of determination. "SUBSIDIARY" means any present or future corporation, joint venture, limited liability company, or partnership, at least a majority of whose outstanding voting stock or other voting securities or interests shall at the time be owned directly or indirectly by Borrower. "TAXES" means all taxes and assessments, whether general or special, ordinary or extraordinary, or foreseen or unforeseen, which at any time may be assessed, levied, confirmed or imposed on the Consolidated Entities or on any of their properties or assets or any part thereof or in respect of any of their franchises, businesses, income or profits. 16 22 "TOTAL FUNDED DEBT" means all obligations for borrowed money, including, but not limited to, advances under the Credit Facilities, all Seller Debt and all Capitalized Leases, whether short-term or long-term. Subordinated Debt is not included in Total Funded Debt. "UCC" means the Uniform Commercial Code as adopted in Tennessee, as it may be amended from time to time. "UNION PLANTERS" means Union Planters National Bank, its successors and assigns. "UNMATURED DEFAULT" means any event or condition that, but for the giving of any required notice by Agent and/or the passing of time, would be an Event of Default hereunder. "WORKING CAPITAL LOAN" means the revolving credit facility described in Sections 2.4 and 2.5 hereof. 1.2 Terms Generally. 1.2.1 Computations; Accounting Principles. Where the character or amount of any asset or liability or item of income or expense is required to be determined, or any consolidation or other accounting computation is required to be made for the purposes of this Agreement, such determination or calculation, to the extent applicable and except as otherwise specified in this Agreement, shall be made in accordance with GAAP. If a change in GAAP after the date of this Agreement would require a change affecting the calculation of any requirement under this Agreement, then Agent and Borrower shall negotiate in good faith for the amendment of the affected requirements; provided, however, until and unless such an amendment is agreed upon, the requirements of this Agreement shall remain as written and compliance therewith shall be determined according to GAAP as in effect prior to the change. 1.2.2 Gender and Number. Words used herein indicating gender or number shall be read as context may require. 1.2.3 References Include Successors. References herein to specific Laws, regulatory bodies, parties or agreements also refer to any successor Laws, regulatory bodies, and parties, and to all modifications, extensions, renewals and restatements of agreements. 1.2.4 References to This Agreement. "Herein," "hereof" and words of similar import refer to this Agreement as a whole and not to any particular provision hereof, unless otherwise expressly stated. 17 23 1.2.5 Limitations of Knowledge. Certain representations and warranties are made herein the Best of Borrower's Knowledge. These limitations reflect only Borrower's special interest in disclosing that no targeted diligence has been performed as to these matters in connection with this Agreement. Should any matter so represented or warranted be discovered to be false, then, irrespective of the knowledge qualification, the representation or warranty shall be deemed breached and shall constitute an Event of Default or Unmatured Default hereunder, as may apply. II. LOANS Concurrently with the execution of this Agreement, Lenders agree on a several basis, and not on a joint basis, in accordance with their respective Commitments, to make the Acquisition Loan and the Working Capital Loan to Borrower, under the following terms and conditions: 2.1 Acquisition Loan. The principal indebtedness of Borrower to Lenders under the Acquisition Loan shall not exceed the lesser of (i) Twenty-Two Million and No/100 Dollars ($22,000,000.00), or (ii) the Credit Ceiling in effect from time to time. 2.2 Use of Proceeds of Acquisition Loan. The proceeds of the Acquisition Loan shall be used by Borrower for (i) Permitted Acquisitions, (ii) other Capital Expenditures, and (iii) the development of IMPACT Centers. 2.3 Acquisition Loan Notes. Borrower's obligations under the Acquisition Loan shall be evidenced by Acquisition Loan Notes in favor of the respective Lenders in the form included as Exhibit 2.3 hereto payable to each Lender for its Commitment under the Acquisition Loan. 2.4 Working Capital Loan. The principal indebtedness of Borrower to Lenders under the Working Capital Loan shall not exceed the lesser of (i) Five Million Five Hundred Thousand and No/100 Dollars ($5,500,000.00), or (ii) the Credit Ceiling in effect from time to time. 2.5 Use of Proceeds of Working Capital Loan. The proceeds of Loans advanced under the Working Capital Loan shall be used by Borrower for (i) working capital purposes, and (ii) to the extent that the Acquisition Loan may be fully drawn, for the same purposes permitted under the Acquisition Loan. 2.6 Working Capital Loan Notes. Borrower's obligations under the Working Capital Loan shall be evidenced by Working Capital Loan Notes in favor of the respective Lenders in the form included as Exhibit 2.6 hereto payable to each Lender for its Commitment under the Working Capital Loan. 18 24 2.7 Separate Commitments of Lenders. Borrower acknowledges that each Lender's commitment to fund its portion of the Credit Facilities is made by each Lender severally, and neither Agent nor any Lender shall be liable for the failure of another Lender to timely perform under this Agreement. 2.8 Advances of Loans. Subject to the terms and conditions of this Agreement, Borrower may borrow, repay and reborrow Loans under the Credit Facilities, provided that the outstanding principal balance of the Acquisition Loan and the Working Capital Loan, respectively, shall not at any time exceed the amounts permitted under Sections 2.1 and 2.4 above. Loans shall be disbursed as follows: 2.8.1 Loans Advanced Pursuant to Borrowing Notices. 2.8.1(a) Applicability. Loans under the Credit Facilities may be LIBOR Loans, Prime Rate Loans, or a combination thereof, and the funding thereof shall be subject to this Section 2.8.1. 2.8.1(b) Borrowing Notices. As long as Borrower meets the conditions for funding stated in this Agreement, Borrower may submit requests for Loans ("Borrowing Notices") to Agent. All requests shall be made in writing (or by telephone, subject to such security procedures as Agent may require from time to time, provided that all telephonic notices shall be confirmed by written Borrowing Notices within one (1) Business Day) and shall specify the proposed disbursement date for the requested Loan; the Credit Facility from which the Loan is requested; the amount of the Loan; the purpose of the Loan (characterized in accordance with Sections 2.2 and 2.5 above); the type of Loan, i.e., LIBOR Loan or Prime Rate Loan; and if a LIBOR Loan, the designated Interest Period. Each Borrowing Notice shall irrevocably obligate Borrower to accept the Loan requested thereby. Borrowing Notices shall be in the form of Exhibit 2.8.1(b) hereto or such other form as Agent may from time to time require. 2.8.1(c) Funding of Loans. Lenders shall fund their respective portions of requested Loans on the next following Banking Day after the Banking Day of Agent's receipt of the Borrowing Notice, in the case of Prime Rate Loans, and on the second (2nd) Banking Day following the Banking Day of Agent's receipt of the Borrowing Notice, in the case of LIBOR Loans. All funds shall be disbursed directly into an account maintained by Borrower with Agent. Borrower agrees that if any Lender elects to fund any requested Loan(s) sooner after requested than is required hereunder, the Lender may nevertheless use the entire response period allowed hereunder upon receipt of any subsequent request, at the Lender's sole option. 19 25 2.8.1(d) Prime Rate Loan Limitations. Individual Prime Rate Loans shall be in the minimum amount of One Hundred Thousand and No/100 Dollars ($100,000.00) each. Any number of Prime Rate Loans may be outstanding at any one time. 2.8.1(e) LIBOR Loan Limitations. Individual LIBOR Loans shall be in the minimum amount of Five Hundred Thousand and No/100 Dollars ($500,000.00) each. No more than three (3) LIBOR Loans may be outstanding under either of the Credit Facilities (for a maximum total of six (6)) at any one time. 2.8.1(f) Additional Limitation on LIBOR Interest Periods. Notwithstanding anything to the contrary in this Agreement, if an Event of Default shall have occurred and be continuing, no additional LIBOR Loans may be created or continued and no Prime Rate Loan may be converted into a LIBOR Loan. 2.8.2 Conversion of Loans. Borrower shall have the right, on prior irrevocable written notice to Agent given two (2) Banking Days prior to the date of any requested conversion, to convert any Prime Rate Loan or LIBOR Loan into a Loan of another type, or to continue any LIBOR Loan for another Interest Period, subject in each case to the following: 2.8.2(a) Application of Loans. Each conversion shall be effected by applying the proceeds of the new LIBOR Loan and/or Prime Rate Loan, as the case may be, to the Loan (or portion thereof) being converted. 2.8.2(b) Notices of Conversions. Each notice pursuant to this Section 2.8.2(b) shall be irrevocable and shall refer to this Agreement and specify the identity and principal amount of the particular Loan that Borrower requests be converted or continued; if such notice requests conversion, the date of such conversion (which shall be a Business Day); and if a Loan is to be converted to a LIBOR Loan or a LIBOR Loan is to be continued, the Interest Period with respect thereto. No LIBOR Loan shall be converted at any time other than at the end of the Interest Period applicable thereto, except in accordance with Section 2.9 hereof. Conversion notices shall be in the form attached as Exhibit 2.8.1(b) hereto. 2.8.3 Absence of Election. If Borrower fails to give Agent notice to continue any LIBOR Loan for a subsequent period, such LIBOR Loan (unless repaid) shall automatically be converted into a Prime Rate Loan. If Borrower fails to specify in any Borrowing Notice the type of borrowing or, in the case of 20 26 a LIBOR Loan, the applicable Interest Period, Borrower will be deemed to have requested a Prime Rate Loan. 2.8.4 Implied Representations Upon Request for Loan. Upon making any request for any Loan, Borrower shall be deemed to have warranted to Agent and Lenders that all conditions to funding set forth in Article III hereof are satisfied. 2.8.5 Advance Not Waiver. Either Lender's making of any Loan that it is not obligated to make under any provision of Article III hereof or any other provision hereof shall not be construed as a waiver of the Lender's right to withhold future Loans, declare an Event of Default, or otherwise demand strict compliance with this Agreement, acting through Agent as permitted by the terms hereof. 2.8.6 Draws by Debit Memorandum. Agent may cause Lenders to draw amounts that may be available under the Credit Facilities to pay any Obligation that is not otherwise timely paid. 2.9 Interest. Interest shall accrue on each Loan as follows: 2.9.1 Prime Rate Loans. Interest shall accrue on each Prime Rate Loan at an annual rate equal to the Prime Rate plus the Applicable Prime Rate Margin, said rate to change contemporaneously with any change in the Prime Rate. 2.9.2 LIBOR Loans. Interest shall accrue on each LIBOR Loan at a rate equal to the LIBO Rate for the selected Interest Period plus the Applicable LIBO Rate Margin. 2.9.3 Additional Interest on LIBOR Loans. In addition to the interest described above, Borrower shall pay to Lenders, if and so long as Lenders shall be required under regulations of the Board of Governors of the Federal Reserve System to maintain reserves with respect to liabilities or assets consisting of or including LIBOR Liabilities, additional interest on the unpaid principal amount of each LIBOR Loan, from the date of such advance until said principal amount is paid in full, at an interest rate per annum equal at all times to the remainder obtained by subtracting (i) the LIBO Rate for the Interest Period from (ii) the rate obtained by dividing the LIBO Rate by a percentage equal to 100% minus the LIBO Rate Reserve Percentage for such Interest Period. This additional interest shall be payable on each date on which interest is payable. The amount of additional interest shall be determined by each Lender, who shall notify Borrower and Agent thereof and whose determination shall be conclusive, absent manifest error. 21 27 2.9.4 Calculation of Interest. Interest for both Prime Rate Loans and LIBOR Loans shall be computed on the basis of a 360-day year counting the actual number of days elapsed. Interest shall accrue on the Business Day a Loan is extended and shall accrue through the Business Day on which it is repaid. 2.9.5 Default Rate. Notwithstanding the foregoing, upon the occurrence of an Event of Default and during the continuation of such Event of Default, interest shall be charged at the Default Rate, regardless of whether Lenders have elected to exercise any other remedies available to Lender, including, without limitation, acceleration of the maturity of the outstanding principal of the Credit Facilities. All such interest shall be paid without demand on the Interest Payment Dates applicable to Prime Rate Loans. 2.9.6 Payment of Interest. Interest for Prime Rate Loans and LIBOR Loans shall be due and payable in arrears, without notice, on each Interest Payment Date. 2.9.7 Usury Savings Provision. It is the intention of the parties that all charges under or in connection with this Agreement and the Obligations, however denominated, and including (without limitation) all interest, commitment fees, late charges and loan charges, shall be limited to the Maximum Lawful Amount. Such charges hereunder shall be characterized and all provisions of the Loan Documents shall be construed as to uphold the validity of charges provided for therein to the fullest possible extent. Additionally, all charges hereunder shall be spread over the full permitted term of the Obligations for the purpose of determining the effective rate thereof to the fullest possible extent, without regard to prepayment of or the right to prepay the Obligations. If for any reason whatsoever, however, any charges paid or contracted to be paid in respect of the Obligations shall exceed the Maximum Lawful Amount, then, without any specific action by Lenders, Agent or Borrower, the obligation to pay such interest and/or other charges shall be reduced to the Maximum Lawful Amount in effect from time to time, and any amounts collected by Lenders that exceed the Maximum Lawful Amount shall be applied to the reduction of the principal balance of the Obligations and/or refunded to Borrower so that at no time shall the interest or loan charges paid or payable in respect of the Obligations exceed the Maximum Lawful Amount. This provision shall control every other provision herein and in any and all other agreements and instruments now existing or hereafter arising between Borrower and Lenders with respect to the Obligations. 2.10 Alternate Rate of Interest if LIBOR Unavailable. In the event, and on each occasion, that on the date of commencement of any Interest Period for a LIBOR Loan, a Lender shall have determined (i) that dollar deposits in the amount of the requested principal 22 28 amount of such LIBOR Loan are not generally available in the London Interbank Market; (ii) that the rate at which such dollar deposits are being offered will not adequately and fairly reflect the cost to the Lender of making or maintaining such LIBOR Loan during such Interest Period; or (iii) that reasonable means do not exist for ascertaining the LIBO Rate, the Lender shall, as soon as practicable thereafter, give written or telephonic notice of such determination to Borrower. In the event of any such determination, any request by Borrower for a LIBOR Loan under this Agreement shall, until the circumstances giving rise to such notice no longer exist, be deemed to be a request for a Prime Rate Loan. Each determination by the Lender hereunder shall be conclusive absent manifest error. 2.11 Change in Circumstances. 2.11.1 Imposition of Requirements. Notwithstanding any other provision herein, if after the date of this Agreement any change in applicable Laws or in the interpretation or administration thereof by any Governmental Authority charged with the interpretation or administration thereof (whether or not having the force of Law) shall change the basis of taxation of payments to a Lender under any LIBOR Loan made by the Lender or any other fees or amounts payable hereunder (other than taxes imposed on the overall net income, gross receipts or added value of a Lender by the country in which the Lender is located, or by the jurisdiction in which a Lender has its principal office, or by any political subdivision or taxing authority therein), or shall impose, modify or deem applicable any reserve requirement, special deposit, insurance charge (including FDIC insurance on LIBOR Liabilities) or similar requirement against assets of, deposits with or for the account of, or credit extended by, a Lender or shall impose on a Lender or the London Interbank Market any other condition affecting this Agreement or LIBOR Loans made by a Lender, and the result of any of the foregoing shall be to increase the cost to the Lender of making or maintaining its LIBOR Loan or to reduce the amount of any sum received or receivable by a Lender hereunder (whether of principal, interest or otherwise) in respect thereof by an amount deemed by the affected Lender to be material, then Borrower will pay to such Lender such additional amount or amounts as will compensate the Lender for such additional costs of reduction. 2.11.2 Other Changes. If either (i) the introduction of, or any change in, or in the interpretation of, any United States or foreign Law; or (ii) compliance with any directive, guidelines or request from any central bank or other United States or foreign Governmental Authority (whether or not having the force of law) promulgated or made after the date hereof, affects or would affect the amount of capital required or expected to be maintained by a Lender (or any lending office of a Lender) or any corporation directly or indirectly owning or controlling a Lender (or any lending office of a Lender) based upon the existence of this Agreement, and the Lender shall have determined that such introduction, change or compliance has or would have the effect of reducing the 23 29 rate of return on the Lender's capital or on the capital of such owning or controlling corporation as a consequence of its obligations hereunder (including its commitment) to a level below that which the Lender or such owning or controlling corporation could have achieved but for such introduction, change or compliance (after taking into account that Lender's policies or the policies of such owning or controlling corporation, as the case may be, regarding capital adequacy) by an amount deemed by the Lender (in its sole discretion) to be material, then, from time to time, Borrower shall pay to the Lender such additional amount or amounts as will compensate the Lender for such reduction attributable to making, funding and maintaining its commitment and Loans hereunder. 2.11.3 Computation of Amounts. A certificate of a Lender setting forth the basis and method of computation of such amount or amounts specified in Sections 2.11.1 and 2.11.2 hereof as shall be necessary to compensate the Lender (or its participating banks) as specified above, as the case may be, shall be delivered to Borrower and shall be conclusive absent manifest error; provided however, that Borrower shall be responsible for compliance herewith and the payment of increased costs only to the extent that (i) any change in Laws giving rise to increased costs occurs after the date of this Agreement; and (ii) the Lender gives notice of the change giving rise to increased costs within one hundred eighty (180) Business Days after the Lender has, or with reasonable diligence should have had, knowledge of the change, or else Lender can only collect costs from and after the date of the notice. Subject to the foregoing, Borrower shall pay the affected Lender the amount shown as due on any such certificate within ten (10) Business Days after its receipt of such certificate. 2.11.4 No Duty to Contest. The protection of this Section 2.11 shall be available to a Lender regardless of any possible contention of invalidity or inapplicability of the Law or condition that shall have been imposed. Should a Lender assess any charge to Borrower under this Section 2.11, and provided that Borrower pays the assessment to the Lender, Borrower may thereafter undertake, at Borrower's own expense, any contest of the matters giving rise to the charge that may, in the opinion of Borrower's independent counsel issued to the affected Lender, and concurred in by counsel to the Lender, have a reasonable chance of success, provided further that the contest would not require the assertion of any position contrary to a position taken by the Lender generally with taxing authorities or any other involved parties and that there does not exist any other circumstance that would disadvantage the Lender in the event of such contest, as the affected Lender may determine in its discretion. The affected Lender shall offer reasonable participation to Borrower for the purpose of enabling Borrower to pursue the contest of such issue, with all 24 30 expenses, including fees and expenses of the affected Lender's counsel, to be paid by Borrower. 2.12 Change in Legality of LIBOR Loans. Notwithstanding anything to the contrary herein contained, if any change in any Law or in interpretation thereof by any Governmental Authority charged with the administration or interpretation thereof shall make it unlawful for a Lender to make or maintain any LIBOR Loan or to give effect to its obligations as contemplated hereby, then, by written notice to Borrower, the Lender may (i) declare that LIBOR Loans will not thereafter be made by the Lender hereunder, whereupon Borrower shall be prohibited from requesting LIBOR Loans from the Lender hereunder unless such declaration is subsequently withdrawn; and (ii) require that all outstanding LIBOR Loans made by it be converted to Prime Rate Loans, in which event (a) all such LIBOR Loans shall be automatically converted to Prime Rate Loans (but without imposition of any additional charge that would normally become due under Section 2.11 hereof) as of the effective date of such notice, and (b) all payments and prepayments of principal that would otherwise have been applied to repay the converted LIBOR Loans shall instead be applied to repay the Prime Rate Loans resulting from the conversion of such LIBOR Loans. For purposes of this Section 2.12, a notice to Borrower by the Lender pursuant to (a) above shall be effective, if lawful, on the last day of the then current Interest Period; in all other cases, such notice shall be effective on the date of receipt by Borrower. 2.13 Principal Repayment. Principal payments under the Credit Facilities shall become due immediately and without notice at such time that the outstanding principal balance of the Credit Facilities may exceed the Credit Ceiling, in an amount sufficient to reduce the outstanding principal balance to an amount no greater than the Credit Ceiling. All remaining principal outstanding under the Credit Facilities shall become due on the Maturity Date or the earlier acceleration of the Credit Facilities in accordance with the terms of this Agreement. 2.14 Prepayment of LIBOR Loans. 2.14.1 Notice of LIBOR Loan Prepayment. Borrower may, upon two (2) Banking Days' prior written notice to Agent, and upon payment of all applicable premiums set forth in Section 2.14.3 hereof, prepay any outstanding LIBOR Loans prior to any Interest Payment Date for such LIBOR Loans, in whole or in part. Each notice of prepayment of any LIBOR Loan shall specify the date and amount of such prepayment and shall be irrevocable. 2.14.2 Amount of LIBOR Loan Prepayment. Each partial prepayment of any LIBOR Loan shall be in an aggregate principal amount which is the lesser of (i) the then outstanding principal balance of the one or more LIBOR Loans to be prepaid, or (ii) Five Hundred Thousand and No/100 Dollars ($500,000.00) or an integral multiple thereof. Interest on the amount prepaid accrued to the prepayment date shall be paid on such date. 25 31 2.14.3 LIBOR Loan Prepayment Premium. Upon prepayment of any LIBOR Loan on a date other than the relevant Interest Payment Date for such borrowing, Borrower shall pay to Lenders, in addition to all other payments then due and owing Lenders, premiums which shall be equal to an amount, if any, reasonably determined by Agent to be the difference between the rate of interest then applicable to the relevant LIBOR Loan and the yield Lenders would receive upon reinvestment of so much of the relevant LIBOR Loans as is prepaid for the remainder of the term of the relevant LIBOR Loan or Loans. Anything in this Section 2.14.3 to the contrary notwithstanding, the premiums payable upon any such prepayment shall not exceed the amount, if any, determined by Agent to be the difference between the rate of interest then applicable to the relevant LIBOR Loan and the yield that Lenders could receive upon reinvestment in the "Floor Reinvestment" of so much of the relevant LIBOR Loan as is prepaid for the remainder of the term of the relevant LIBOR Loan. For purposes hereof, "Floor Reinvestment" shall mean an investment for the time period from the date of such prepayment to the end of the relevant Interest Period applicable to such LIBOR Loan at an interest rate per annum equal to the federal funds "offered" rate as published in the Wall Street Journal on the date of such prepayment. All determinations, estimates, assumptions, allocations and the like required for the determination of such premiums shall be made by Agent in good faith and shall be presumed correct absent manifest error. 2.15 Prepayment of Prime Rate Loans. Borrower may at any time prepay any outstanding Prime Rate Loans prior to the Maturity Date in whole or in part without premium or penalty. 2.16 Fixed Commitment Fees. Borrower shall pay a commitment fee to Lenders on a Pro Rata basis upon the execution of this Agreement (i) with respect to the Acquisition Loan, in the amount of One Hundred Ten Thousand and No/100 Dollars ($110,000.00) and (ii) with respect to the Working Capital Loan, in the amount of Thirteen Thousand Seven Hundred Fifty and No/100 Dollars ($13,750.00). An additional commitment fee shall become due with respect to the Working Capital Loan under certain circumstances as set forth in the definition of "Maturity Date" above in this Agreement. These commitment fees are not refundable or proratable. 2.17 Periodic Commitment Fee Based on Use of Facilities. Borrower shall pay to Agent for distribution to Lenders Pro Rata an additional commitment fee for the unused portion of the Credit Facilities. This fee shall be determined by applying the Applicable Commitment Fee to the average daily unused balance of the Credit Facilities. The commitment fee shall be paid in arrears on each Interest Payment Date applicable to Prime Rate Loans. This commitment fee is not refundable or proratable. 26 32 2.18 Agent's Fee. On the Closing Date, and on each subsequent anniversary thereof excepting only an anniversary corresponding to the Maturity Date, Borrower shall pay to Agent a fee of Five Thousand and No/100 Dollars ($5,000.00) for each Lender (inclusive of Agent) then a party to this Agreement. If any additional Lender becomes a party to this Agreement between anniversary dates as to increase the total number of Lenders, a like fee shall be paid to Agent with respect to that Lender upon its entry, prorated to reflect the balance of the year remaining until the next anniversary of the Closing Date. III. CONDITIONS PRECEDENT 3.1 Conditions to Initial Advance. Lenders shall not be obligated to make their initial Loan pursuant to this Agreement unless and until Borrower satisfies the following conditions: 3.1.1 Loan Documents. Borrower shall have delivered to Lenders and to Agent the following documents, fully executed and in form and substance acceptable to the Agent: 3.1.1(a) Loan Agreement. This Agreement. 3.1.1(b) Acquisition Loan Notes. The Acquisition Loan Notes made by Borrower payable to the order of the respective Lenders in the maximum principal amounts of Sixteen Million and No/100 Dollars ($16,000,000.00) and Six Million and No/100 Dollars ($6,000,000.00), respectively. 3.1.1(c) Working Capital Loan Notes. The Working Capital Loan Notes made by Borrower payable to the order of the respective Lenders in the maximum principal amounts of Four Million and No/100 Dollars ($4,000,000.00) and One Million Five Hundred Thousand and No/100 Dollars ($1,500,000.00), respectively. 3.1.1(d) Guaranties of Subsidiaries. Unconditional Continuing Guaranties executed by all Subsidiaries of Borrower other than Non-Corporate Subsidiaries. 3.1.1(e) Pledge of Stock of Subsidiaries. Stock Pledge Agreement, Irrevocable Proxies and Blank Stock Powers evidencing a first priority perfected security interest in all of the stock of Borrower's corporate Subsidiaries and all dividends, distributions and other property related thereto, together with the original certificates evidencing the pledged stock. 27 33 3.1.1(f) Charters. Certified Copies of the Consolidated Entities' corporate charters and all amendments thereto, issued by the Secretaries of State for their states of domicile. 3.1.1(g) Bylaws. Certified Copies of Bylaws for the Consolidated Entities. 3.1.1(h) Certificates of Good Standing. Certificates of good standing or existence, as applicable, issued as to the Consolidated Entities by the Secretaries of State for the states of their domicile. 3.1.1(i) Foreign Qualification. Certificates of Qualification issued by the Secretaries of State for each state in which a Consolidated Entity is required to qualify as a foreign corporation. 3.1.1(j) Resolutions. Certified Copies of Resolutions authorizing the execution of all applicable Loan Documents on behalf of Consolidated Entities. 3.1.1(k) Opinions of Borrower's Counsel. Opinions of counsel to the Consolidated Entities addressed to Agent and Lenders, addressing matters reasonably required by Lenders, Agent and their counsel. 3.1.1(l) UCC Searches. UCC search reports on Borrower from such jurisdictions and filing offices as Lenders and Agent may require. 3.1.1(m) Closing Statement and Funding of Expenses. Loan Closing Statement describing expenses and fees due in connection with the closing of the Credit Facilities and payment thereof in immediately available funds. 3.1.1(n) Other Documents. Such other documents as Lenders or Agent may reasonably require. 3.1.1(o) Completion of Exhibits and Schedules. The completion of all exhibits and schedules to this Agreement, which shall be satisfactory to Agent, in its sole discretion. 3.1.2 Additional Conditions. Borrower shall have satisfied the following additional conditions, to Lenders' and Agent's satisfaction: 28 34 3.1.2(a) Warranties. All warranties made in the Loan Documents must be true in all material respects and shall be true in all material respects taking into account the funding of the requested Loan. 3.1.2(b) Covenants. All covenants made in the Loan Documents must have been complied with and shall have been complied with taking into account the funding of the requested Loan. 3.1.2(c) Absence of Unmatured Default. No Event of Default or Unmatured Default shall exist under this Agreement. 3.1.2(d) No Adverse Change. There must be no Material Adverse Change since the date of the Financial Statements. 3.1.2(e) Regulatory Diligence. The completion of healthcare regulatory diligence to the satisfaction of Agent and its counsel. 3.2 Conditions to Subsequent Loans. Lenders shall not be obligated to make any Loan unless all of the following conditions are satisfied as of the time of the request and of funding: 3.2.1 Conditions to Initial Advance. All of the conditions in Section 3.1 hereof must have been satisfied. 3.2.2 Warranties. All warranties made in the Loan Documents must be true in all material respects and shall be true in all material respects taking into account the funding of the requested Loan. 3.2.3 Covenants. All covenants made in the Loan Documents must have been complied and shall have been complied with taking into account the funding of the requested Loan. 3.2.4 Absence of Unmatured Default. No Event of Default or Unmatured Default shall exist under this Agreement. 3.2.5 Material Adverse Change. There shall not have occurred a Material Adverse Change. IV. REPRESENTATIONS AND WARRANTIES Borrower represents and warrants to Lenders and Agent that: 4.1 Capacity. Each Consolidated Entity is a corporation or other entity as set forth in Schedule 4.1 hereof, and is duly organized, validly existing and in good standing 29 35 under the laws of the state of its domicile as set forth in Schedule 4.1. Each Consolidated Entity is qualified or authorized to do business in all jurisdictions in which its ownership of property or conduct of business requires such qualification or authorization or where the failure to be so qualified or authorized would not have a Material Adverse Effect. Each Consolidated Entity has the power and authority to own its Properties and to carry on its business as now being conducted and as proposed to be conducted after the execution hereof, to execute and deliver this Agreement and the other Loan Documents, and to perform its obligations hereunder and under the other Loan Documents. 4.2 Authorization. The execution, delivery and performance of this Agreement and the other Loan Documents by each Consolidated Entity executing such documents has been duly authorized by all requisite action. 4.3 Binding Obligations. This Agreement is and the other Loan Documents, when executed and delivered to Lender, will be, legal, valid and binding upon each Consolidated Entity who is a party thereto, enforceable in accordance with its respective terms, subject only to principles of equity and laws applicable to creditors generally, including bankruptcy laws. 4.4 No Conflicting Law or Agreement. The execution, delivery and performance of this Agreement and the other Loan Documents by each Consolidated Entity does not constitute a breach of or default under, and will not violate or conflict with, any provisions of the corporate charter or other constituent documents of a Consolidated Entity; any contract, financing agreement, lease, or other agreement to which a Consolidated Entity is a party or by which its Properties may be affected, the violation of which could have a Material Adverse Effect; or any Law to which a Consolidated Entity is subject or by which its Properties may be affected, the violation of which could have a Material Adverse Effect; nor will the same result in the creation or imposition of any Encumbrance upon any Property of any Consolidated Entity, other than those contemplated by the Loan Documents. 4.5 No Consent Required. The execution, delivery, and performance of this Agreement and the other Loan Documents by the Consolidated Entities do not require the consent or approval of or the giving of notice to any Person except for those consents which have been duly obtained and are in full force and effect on the date hereof and others, if any, which by their omission could not result in a Material Adverse Effect. 4.6 Financial Statements. The Financial Statements are complete and correct, have been prepared in accordance with GAAP, and present fairly the financial condition and results of operations of the Consolidated Entities as of the date and for the period stated therein, subject to year-end adjustments. No Material Adverse Change has occurred since the date of the Financial Statements. Borrower acknowledges that Lenders have advanced (or shall advance) the Credit Facilities in reliance upon the Financial Statements. 30 36 4.7 Fiscal Year. Each Consolidated Entity's fiscal year ends on December 31 of each year. 4.8 Litigation. Except as disclosed on Schedule 4.8 hereto, (i) there is no litigation, arbitration, legal or administrative proceeding, tax audit, investigation, or other action or proceeding of any nature pending against any Consolidated Entity or any of its Properties, and (ii) there is no litigation, arbitration, legal or administrative proceeding, tax audit, investigation, or other action or proceeding of any nature threatened in writing against a Consolidated Entity which, if adversely determined, could have a Material Adverse Effect. No Consolidated Entity is subject to any outstanding court, arbitral or administrative order, writ or injunction. To the Best of Borrower's Knowledge, no facts exist under which third parties have unasserted claims against any Consolidated Entity which, if adversely determined, could have a Material Adverse Effect. 4.9 Taxes; Governmental Charges. Each Consolidated Entity has filed or caused to be filed or has lawfully extended the deadline for filing all tax returns and reports required to be filed. Each Consolidated Entity has paid, or made adequate provision for the payment of, all Taxes that have or may have become due pursuant to such returns or otherwise, or pursuant to any assessment received by it, except such Taxes, if any, as are being contested in good faith by appropriate proceedings and for which adequate reserves have been provided. To the Best of Borrower's knowledge, there is no proposed material tax assessment against any Consolidated Entity. No extension of time for the assessment of federal, state or local taxes of any Consolidated Entity is in effect or has been requested, except as disclosed in Schedule 4.9 hereto. Each Consolidated Entity has timely made all required remittances of withholding deposits and other assessments against payroll expenditures. 4.10 Title to Properties. Each Consolidated Entity has good and marketable title to its Properties, free and clear of all Encumbrances except for Permitted Encumbrances. 4.11 No Default. No Consolidated Entity is in default in any respect that affects its business, Properties, operations, or condition, financial or otherwise, under any indenture, mortgage, deed of trust, obligation to equity holders, credit agreement, note, agreement, lease, sale agreement or other instrument to which any Consolidated Entity is a party or by which its Properties are bound, which default could have a Material Adverse Effect. To the Best of Borrower's Knowledge, no other party to any contract with any Consolidated Entity under which a default could have a Material Adverse Effect is in default or breach thereof and no circumstances exist which, with the giving of notice and/or the passing of time would constitute such default or breach. No Event of Default or Unmatured Default exists under this Agreement. 4.12 Casualties; Taking of Properties. Neither the business nor the Property of any Consolidated Entity is presently impaired as a result of any fire, explosion, earthquake, flood, drought, windstorm, accident, strike or other labor disturbance, embargo, requisition or 31 37 taking of property, cancellation of contracts, permits, concessions by any domestic or foreign government or any agency thereof, riot, activities of armed forces or acts of God or of any public enemy, in any case as could have a Material Adverse Effect. 4.13 Compliance with Laws. No Consolidated Entity is in violation of any Law to which it, its business or any of its Properties are subject, the violation of which would likely have a Material Adverse Effect, and, to the Best of Borrower's Knowledge, there are no outstanding citations, notices or orders of noncompliance issued to any Consolidated Entity under any such Law, the violation of which would likely have a Material Adverse Effect. Each Consolidated Entity has obtained all licenses, permits, franchises, or other governmental authorizations necessary to the ownership of its Properties or to the conduct of its business, except for those which, if not obtained, could not have a Material Adverse Effect. 4.14 Compliance with Fraud and Abuse Laws. Without limiting any other provision of this Agreement, no Consolidated Entity and no Provider is in violation of any Fraud and Abuse Law, the violation of which could have a Material Adverse Effect. 4.15 ERISA. No ERISA Event has occurred with respect to any Plan or is reasonably expected to occur with respect to any Plan. 4.16 Full Disclosure of Material Facts. Borrower has fully advised Lenders of all matters involving the financial condition, business, operations and Properties of the Consolidated Entities that would be reasonably expected to have a Material Adverse Effect. No information, exhibit, or report furnished or to be furnished by Borrower to Lenders in connection with this Agreement contains, as of the date thereof, any misrepresentation of fact or failed or will fail to state any material fact, the omission of which would render the statements therein materially false or misleading. 4.17 Accuracy of Projections. With respect to all business plans and other forecasts and projections furnished by or on behalf of Borrower and made available to Lenders relating to the financial condition, business, operations or Properties of the Consolidated Entities, all facts stated as such therein were true and complete in all material respects as of the time made and all estimates and assumptions were made in good faith and believed to be reasonable at the time made. As of the Closing Date, nothing has since come to the attention of Borrower that has changed its assessment of any such matters, except for changes that could not have a Material Adverse Effect. 4.18 Investment Company Act. No Consolidated Entity is an "investment company" under the Investment Company Act of 1940, as amended. 4.19 Personal Holding Company. No Consolidated Entity is a "personal holding company" as defined in Section 542 of the IRC. 32 38 4.20 Solvency. Each Consolidated Entity is Solvent as of the Closing Date and will remain Solvent upon the consummation of the transactions contemplated hereby. 4.21 Chief Executive Office. The address designated herein to which notices are to be sent under this Agreement is the Borrower's chief executive office within the meaning of Tennessee Code Annotated Section 47-9-103(3)(d). 4.22 Subsidiaries. Borrower has no Subsidiaries, except for those listed on Schedule 4.22 hereto. 4.23 Ownership of Patents, Licenses, Etc. The Consolidated Entities own all licenses, permits, franchises, registrations, patents, copyrights, trademarks, trade names or service marks, or the rights to use the foregoing, that are necessary for the continued operation of their business except for such licenses, etc., which, if not held or owned, could not have a Material Adverse Effect. 4.24 Environmental Compliance. Each Consolidated Entity has duly complied with, and their Properties are owned and operated in compliance with, all Environmental Laws, the violation of which could have a Material Adverse Effect. There have been no citations, notices or orders of non-compliance issued to any Consolidated Entity or, to the Best of Borrower's knowledge, relating to their business or Properties pursuant to any Environmental Law. Each Consolidated Entity has obtained all required federal, state and local licenses, certificates or permits relating to them and their Properties as required by applicable Environmental Laws, except for those which, if not obtained, could not have a Material Adverse Effect 4.25 Labor Matters. No Consolidated Entity is subject to any collective bargaining agreements or any decrees or orders requiring them to recognize, deal with or employ any Person. No demand for collective bargaining has been asserted against any Consolidated Entity by any union or organization. No Consolidated Entity has experienced any strike, labor dispute, slowdown or work stoppage due to labor dispute and, to the best knowledge of Borrower, there is no such strike, dispute, slowdown or work stoppage threatened against any Consolidated Entity. All Consolidated Entities are in compliance in all material respects with the Fair Labor Standards Act of 1938, as amended. 4.26 OSHA Compliance. All Consolidated Entities are in compliance in all material respects with the Federal Occupational Safety and Health Act, as amended, and all regulations under the foregoing. 4.27 Regulation U. No Consolidated Entity is engaged in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulation U issued by the Board of Governors of the Federal Reserve System). No proceeds of any Loan will be used to purchase or carry any margin stock (within the meaning of Regulation U issued by the Board of Governors of the Federal Reserve System) in violation of 33 39 applicable law, including, without limitation, Regulation U issued by the Board of Governors of the Federal Reserve System. 4.28 Affiliate Transactions. No Consolidated Entity is a party to any transaction, contract or agreement with any Affiliate, except for Service Agreements, lease agreements and other agreements among Borrower and its Subsidiaries and those other agreements described in Schedule 4.28 hereof. V. AFFIRMATIVE COVENANTS Borrower covenants that, during the term of this Agreement (and thereafter where expressly stated herein): 5.1 Payment of Obligations. Borrower shall pay all amounts owed under the Obligations when due. 5.2 Maintenance of Existence and Business. Except for transactions among Consolidated Entities permitted under this Agreement, each Consolidated Entity shall maintain its fundamental existence, name, rights, and franchises, and shall maintain its qualification and good standing in all states in which such qualification is necessary, and shall continue to operate in the same type of business as such Consolidated Entity engages in as of the date hereof. 5.3 Financial Statements and Reports. Borrower shall furnish to Agent the following, all of which must be in form and substance satisfactory to Lender (the financial reports below and all other reports required of Borrower under this Agreement shall be delivered in sufficient counterparts that each Lender and Agent may have an original counterpart thereof): 5.3.1 Monthly Financial Reports. As soon as available, and in any event by the thirtieth (30th) day following the end of a month, Borrower shall deliver to Agent a balance sheet, income statement and statement of cash flows of Borrower for and as of the end of the preceding month, all prepared by Borrower on a consolidated basis and certified by Borrower's president or chief financial officer to be complete and correct and to present fairly, in accordance with GAAP (excluding year-end adjustments and required footnote disclosures), the consolidated financial condition of Borrower as of the date of such statements and the consolidated results of its operations and its cash flow for such period. Notwithstanding the foregoing, if as of May 31, 1997, Borrower has met the Financial Projections since the date hereof, the requirements of this Section 5.3.1 will terminate and monthly financial statements shall no longer be required. 34 40 5.3.2 Quarterly Financial Reports. As soon as available, and in any event by the forty-fifth (45th) day of each fiscal quarter except the fourth fiscal quarter, Borrower shall prepare and deliver to Agent a consolidated balance sheet, income statement and statement of cash flows of Borrower for and as of the end of the preceding fiscal quarter, certified by Borrower's President or Chief Financial Officer to be complete and correct and to present fairly, in accordance with GAAP (excluding year-end adjustments and required footnote disclosures), the consolidated financial condition of Borrower as of the date of such statements and the consolidated results of its operations and its cash flow for such period. Supplemental to such basic financial statements, Borrower shall deliver to the Agent calculations of all financial ratios; the certification of Borrower's President or Chief Financial Officer as to the absence of any Event of Default or Unmatured Default; a Borrowing Base certificate; and by- Practice financial summaries addressing Practice revenues, expenses and fees to Consolidated Entities in form and substance acceptable to Agent. 5.3.3 Annual Financial Reports. As soon as available, and in any event within ninety (90) days after the end of each fiscal year, Borrower shall deliver to Agent the audited consolidated balance sheet of Borrower as of the end of such year and the related audited consolidated statements of income, retained earnings and cash flows for such year, together with supporting schedules, all such statements prepared in accordance with GAAP and accompanied by an unqualified audit report prepared by an independent "big six" certified public accountant acceptable to Agent showing the consolidated financial condition of Borrower at the close of such year and the consolidated results of its operations, changes in its retained earnings and its cash flows for such year. Supplemental to the audited year-end financial statements, Borrower shall deliver to Agent calculations of all financial ratios as determined based upon the audited financial statements and the certification of Borrower's President or Chief Financial Officer as to the absence of any Event of Default or Unmatured Default. 5.3.4 Accountant Reports. Promptly upon the receipt thereof, Borrower shall deliver to Agent a copy of each other report (other than work papers) submitted to Borrower or any Subsidiary by its accountants in connection with any annual, interim or special audit made by them, but Borrower shall be obligated to deliver such report only if (i) the report advises Borrower of a material weakness in internal controls, or (ii) Agent has requested the report in writing based upon Agent's good faith belief that, based upon its review of Borrower's financial statements or other information relating to the operations and condition of the Consolidated Entities, a copy of such report is needed in order for Agent and/or Lenders to thoroughly assess the financial condition of the Consolidated Entities and/or their continued compliance with this Agreement. 35 41 5.3.5 Acquisition Certification. In connection with any draw, Borrower shall submit a Borrowing Base certificate to confirm the sufficiency of the Borrowing Base for the requested advance. 5.3.6 Other Information. Borrower shall provide Agent with such additional information regarding the financial condition, properties, operations and prospects of the Consolidated Entities and their consolidated entities as Agent may reasonably require. 5.4 Additional Information. Borrower shall provide such other information respecting the condition or operations, financial or otherwise, of the Consolidated Entities as Agent may from time to time reasonably request. 5.5 Certain Additional Reporting Requirements. 5.5.1 Owner Mailings. Promptly upon the sending thereof, Borrower shall deliver to Agent a copy of each statement, report or notice sent to its shareholders. 5.5.2 SEC Filings. Promptly upon the filing thereof, should such filings become applicable, Borrower shall deliver to Agent copies of all regular, periodic and special reports that any Consolidated Entity files with the United States Securities and Exchange Commission or any successor thereto, or any national securities exchanges or the National Association of Securities Dealers. 5.5.3 Change in Accounting Policies. Borrower shall promptly notify Agent in writing upon any material change in accounting policies or financial reporting practices on the part of any Consolidated Entity. 5.5.4 Notice to Agent Upon Perceived Breach. Borrower agrees to give Lender prompt written notice of any action or inaction by or on behalf of Lender in connection with this Agreement or the Obligations that Borrower believes may be actionable against Lenders or Agent or a defense to payment of any or all Obligations for any reason, including, but not limited to, commission of a tort or violation of any contractual duty or duty implied by law provided, however, that Borrower's failure to give such notice, if such failure is unintentional and does not arise from Borrower's gross negligence, shall not foreclosure any such action or defense to be asserted by Borrower. 5.5.5 Changes in Constituent Documents. Borrower shall promptly notify Agent in writing of any change in the corporate charter or bylaws of Borrower or the fundamental documents of any Subsidiary following the encumbrance of the stock thereof in favor of Agent to secure Lenders as required under this Agreement, and shall provide Agent with a copy of such 36 42 change (Consolidated Entities are restricted in the adoption of such amendments as provided elsewhere in the Loan Documents, and nothing contained in this Section shall be deemed a waiver of such restrictions). 5.5.6 Notice of Litigation. Borrower shall give Agent prompt written notice of any litigation, arbitration, tax audit, administrative proceeding or investigation that may hereafter be instituted or threatened in writing in which Borrower would be a party or which otherwise may affect any Consolidated Entity or any of their business, operations or Properties, except for (i) actions seeking only monetary damages in an amount of less than the amount equal to one-half percent (1/2%) of Borrower's Consolidated EBITDA for the most recent four (4) fiscal quarters for which Borrower has submitted financial statements to Agent, as of the time of determination, and (ii) matters arising from premises or vehicular liability seeking only monetary damages and which are fully covered by insurance, subject only to any applicable deductible. 5.5.7 Other Notices. Borrower shall promptly notify Agent in writing if Borrower learns of the occurrence of (i) any event that constitutes an Event of Default or an Unmatured Default, together with a detailed statement of the steps being taken as a result thereof, or (ii) any Material Adverse Change. 5.6 Taxes and Other Encumbrances. Each Consolidated Entity shall make due and timely payment or deposit of all federal, state and local taxes, assessments or contributions required of it by law, and execute and deliver to Agent, on demand, appropriate certificates attesting to the payment or deposit thereof; provided, however, that the Consolidated Entities shall not be required to pay or discharge any such tax, assessment, charge or claim for as long as it is being diligently contested in good faith by proper proceedings and for which appropriate reserves are being maintained. 5.7 Payment of Liabilities. Each Consolidated Entity shall pay all of its Liabilities as and when the same becomes due in accordance with its terms. 5.8 Compliance with Laws. Each Consolidated Entity shall observe and comply with all Laws (including, but not limited to, Fraud and Abuse Laws), and shall maintain all certificates, franchises, permits, licenses, and authorizations necessary to the conduct of its business or the operation of its Properties, except for such Laws, certificates, etc., which, if violated or not obtained and full penalties were imposed for such violation, could not cause a Material Adverse Effect. Each Consolidated Entity shall further use its best efforts to assure the compliance by all Providers with all applicable Laws, including, but not limited to, medical licensure and Fraud and Abuse Laws, relating to their providing of professional services, except for those which, if violated and full penalties were imposed for such violation, could not cause a Material Adverse Effect. 37 43 5.9 Maintenance of Property. All Consolidated Entities shall maintain their Property (and any Property leased by or consigned or held under title retention or conditional sales contracts) in good and workable condition at all times, subject to ordinary wear and tear, normal discards and replacements due to functional and useful-life obsolescence, and shall make all repairs, replacements, additions, and improvements to their Property reasonably necessary and proper to ensure that the business carried on in connection with their Property may be conducted properly and efficiently at all times. 5.10 Compliance with Contractual Obligations. Each Consolidated Entity will perform all of its obligations in respect of all material contracts to which it is a party and will use its best efforts to keep, and to take all action to keep, such contracts in full force and effect and not allow any such contract to lapse or be terminated or any rights to renew such to be forfeited or canceled, if such lapse, etc. could have a Material Adverse Effect; provided, however, that any such contract may lapse or be terminated or such renewal rights may be forfeited or canceled if in the reasonable business judgment of the Consolidated Entities it is in their best interests to allow or cause such lapse, termination, forfeiture or cancellation. 5.11 Further Assurances. The Consolidated Entities shall promptly cure any defects in the creation, issuance, or delivery of the Loan Documents. The Consolidated Entities at their expense will execute (or cause to be executed) and deliver to Agent upon request all such other and further documents, agreements, and instruments in compliance with or accomplishment of the covenants and agreements applicable to them in the Loan Documents, or to evidence further and to describe more fully any Collateral intended as security for the Obligations, or to correct any omissions in the Loan Documents, or to state more fully the Obligations and agreements set out in any of the Loan Documents, or to perfect, protect, or preserve any Encumbrances created pursuant to any of the Loan Documents, or to make any recordings, to file any notices, or to obtain any consents, all as may be reasonably necessary or appropriate in connection therewith. Borrower appoints Agent as Borrower's attorney-in-fact to execute any financing statements or other instruments of perfection with respect to the Collateral. 5.12 Security Interest; Setoff. In order to further secure the payment of the Obligations, Borrower hereby grants to Agent and to each Lender a security interest and right of setoff against all of Borrower's presently owned or hereafter acquired monies, items, credits, deposits and instruments (including certificates of deposit) presently or hereafter in the possession of any Lender or Agent. By maintaining any such accounts or other property with a Lender or Agent, Borrower acknowledges that Borrower voluntarily subjects the property to the security interest arising hereunder. Subject to the provisions in Article IX hereof, a Lender may exercise its rights under this Section without prior notice (but with prompt notice following the setoff) following an Event of Default. Borrower agrees that neither Lenders nor Agent shall be liable for the dishonor of any instrument after notice of setoff shall have been duly given resulting from a Lender's exercise of its rights under this Section. 38 44 5.13 Insurance. 5.13.1 General Insurance Requirements. In addition to the other specific requirements set forth in this Agreement and in other Loan Documents, the Consolidated Entities shall maintain insurance on all insurable Properties now or hereafter owned by them against such risks and to the extent customary in their industry, and shall maintain or cause to be maintained public liability and worker's compensation insurance to the extent customary in the industry. 5.13.2 Practice-Related Insurance Requirements. The Consolidated Entities shall maintain insurance for claims, however characterized, against them in connection with the provision of medical services by Providers and/or ancillary services provided by them at Practices covered by Service Agreements, in an amount of at least Five Hundred Thousand and No/100 Dollars ($500,000.00) per occurrence and One Million and No/100 Dollars ($1,000,000.00) in the aggregate for Providers who are physicians, which insurance shall name Lenders (or Agent on behalf of Lenders) as additional insureds. The Consolidated Entities shall further cause each Provider to maintain medical malpractice insurance of at least Five Hundred Thousand and No/100 Dollars ($500,000.00) per occurrence and One Million and No/100 Dollars ($1,000,000.00) in the aggregate. 5.14 Accounts and Records. The Consolidated Entities shall maintain current books of record and account, in which full, true, and correct entries will be made of all transactions. 5.15 Official Records. The Consolidated Entities shall maintain current corporate and official records, minute books and stock ledgers and other records appropriate to their form of organization. 5.16 Banking Relationships. The Consolidated Entities shall maintain their deposit accounts with Lenders or with other FDIC-insured depository institutions. 5.17 Right of Inspection. The Consolidated Entities shall permit any officer, employee, or agent of a Lender or Agent to visit and inspect during ordinary business hours any of the their Property, to examine their books of record and accounts and corporate records, to take copies and extracts from such books of record and accounts, and to discuss the affairs, finances, and accounts of the Consolidated Entities with their respective officers, accountants, and auditors, all at such reasonable times and as often as a Lender may reasonably desire and upon reasonable advance notice absent an Event of Default. Without limiting Agent's right to obtain equitable relief as to any other appropriate right in this Agreement or in other Loan Documents, Borrower agrees that the rights in this Section may be enforced by affirmative injunction and, to the extent the right to review records may be 39 45 denied, the right may be enforced by a restraining order prohibiting the interference by Borrower with the exercise of rights to review of the records pursuant to this Section. Absent an Event of Default or Unmatured Default, all expenses of such inspections, etc. shall be paid by Lenders, and in the presence thereof, all expenses shall be paid by Borrower. 5.18 ERISA Information and Compliance. The Consolidated Entities shall comply with ERISA and all other applicable laws governing any pension or profit sharing plan or arrangement to which they are a party. The Consolidated Entities shall (i) upon request, provide Agent with copies of any annual report required to be filed pursuant to ERISA with respect to any Plan or any other employee benefit plan; (ii) notify Agent upon the occurrence of any ERISA Event or of any additional act or condition arising in connection with any Plan which they believe might constitute grounds for termination thereof by the PBGC or for the appointment of a trustee to administer the Plan; and (iii) furnish to Agent, promptly upon request, such additional information concerning any Plan or any other employee benefit plan as Agent may request. 5.19 Indemnity; Expenses. Borrower agrees to indemnify, defend (with counsel reasonably satisfactory to the indemnified party or parties) and hold harmless Lenders and Agent against any loss, liability, claim or expense, including reasonable attorneys' fees, that they may incur in connection with the Loan Documents or the Obligations, except those losses, etc. that may result from a Lender's or Agent's gross negligence or willful misconduct. Without limiting the foregoing, upon demand by Agent, Borrower will reimburse Lenders and/or Agent for the following reasonable expenses if not paid by Borrower promptly after written demand by Agent: 5.19.1 Taxes. All taxes that Lenders or Agent may be required to pay because of the Obligations or because of Lenders' or Agent's interest in any property securing the payment of the Obligations, excepting taxes based upon the net income of Lender or Agent. 5.19.2 Administration. All costs of the preparation of this Agreement and any other related documents and the administration of the Obligations (except for Lenders' and Agent's usual overhead incurred in the acceptance and processing of payments, the routine review of financial statements, certifications and reports, routine communications with Borrower, and other ordinary activities that are not occasioned by an Unmatured Default, Event of Default or by a request of Borrower to waive or vary the terms of this Agreement). 5.19.3 Protection of Collateral. All costs of preserving, insuring, preparing for sale (whether by improvement, repair or otherwise) or selling any Collateral. 5.19.4 Costs of Collection. All court costs and other costs of collecting any debt, overdraft or other obligation included in the Obligations. 40 46 5.19.5 Litigation. All reasonable costs arising from any litigation, investigation, or administrative proceeding (whether or not Agent or a Lender is a party thereto) that Agent or a Lender may incur as a result of the Obligations or as a result of their association with any of the Consolidated Entities, including, but not limited to, expenses incurred by Agent or a Lender in connection with a case or proceeding involving any Consolidated Entity under any chapter of the Bankruptcy Code or any successor statute thereto. 5.19.6 Attorneys' Fees. Reasonable attorneys' fees incurred in connection with any of the foregoing. If a Lender or Agent pays any of the foregoing expenses, they shall become a part of the Obligations and shall bear interest at the Maximum Lawful Amount. This Section shall remain in full effect regardless of the full payment of the Obligations, the purported termination of this Agreement, the delivery of the executed original of this Agreement to Borrower, or the content or accuracy of any representation made by Borrower to Lenders or Agent; provided, however, Agent may terminate this Section by executing and delivering to Borrower a written instrument of termination specifically referring to this Section. 5.20 Assistance in Litigation. Borrower covenants to, upon request, cooperatively participate in any proceeding in which Borrower is not an adverse party to Lenders or Agent and which concerns Lenders' or Agent's rights regarding the Obligations or any Collateral. 5.21 Name Changes. Borrower shall give Agent at least thirty (30) days prior written notice before any Consolidated Entity changes its name or begins doing business under any trade name. 5.22 Estoppel Letters. Borrower covenants to provide Agent, within ten (10) days after request, an estoppel letter stating (i) the balance of the Obligations, (ii) whether Borrower has any defenses to payment of the Obligations, and (iii) the nature of any defenses to payment of the Obligations. Such balance as presented for confirmation and the nonexistence of defenses shall be presumed if Borrower fails to respond to such a request within the required period. 5.23 Environmental Matters. 5.23.1 Compliance With Environmental Laws. All Consolidated Entities will (i) employ in connection with their operations, appropriate technology and compliance procedures to maintain compliance with any applicable Environmental Laws, the violation of which would reasonably be expected to have a Material Adverse Effect, (ii) obtain and maintain any and all materials permits or other permits required by applicable Environmental Laws in connection with its operations, excepting only such permits, etc. which could 41 47 not by their absence cause a Material Adverse Effect, and (iii) dispose of any and all Hazardous Substances only at facilities and with carriers reasonably believed to possess valid permits under any applicable state and local Environmental Laws. All Consolidated Entities shall use their best efforts to obtain all certificates required by law to be obtained by them from all contractors employed by them in connection with the transport or disposal of any Hazardous Substances. 5.23.2 Remedial Work. If any investigation, site monitoring, containment, clean-up, removal, restoration or other remedial work of any kind or nature with respect to any Consolidated Entity's Properties is required to be performed by them under any applicable local, state or federal law or regulation, any judicial order, or by any governmental or non-governmental entity or Person because of, or in connection with, the current or future presence, suspected presence, release or suspected release of a Hazardous Substance in or into the air, soil, groundwater, surface water or soil vapor at, on, about, under, or within any of a Consolidated Entity's Property (or any portion thereof), Borrower shall within 30 days after written demand for performance thereof (or such shorter period of time as may be required under applicable law, regulation, order or agreement), commence and thereafter diligently prosecute to completion, all such remedial work. 5.23.3 Indemnification of Lenders and Agent. Borrower agrees to indemnify, defend (with counsel reasonably satisfactory to the indemnified party or parties) and hold harmless Lenders and Agent against any loss, liability claim or expense, including attorneys' fees, that Lender or Agent may incur as a result of the violation or alleged violation of any Environmental Law by a Consolidated Entity or with respect to any other violation of Environmental Laws with respect to any Consolidated Entity's Properties. This covenant shall survive the repayment of the Credit Facilities. 5.24 Opinions of Counsel. Borrower agrees that Agent may from time to time, but not more frequently than once per calendar year absent an Unmatured Default or an Event of Default, request in writing the opinion of in-house counsel and/or outside healthcare counsel to the Consolidated Entities as to the absence, except as disclosed in the opinion, of such counsel's knowledge of any actual, threatened or asserted violation of any Fraud and Abuse Law on the part of any Consolidated Entity and/or the Providers, and the sufficiency of documentation then in use for the acquisition of Practices as complying with Fraud and Abuse Laws. Absent the existence of an Unmatured Default or and Event of Default, such opinions shall require no special diligence on the part of the opining attorney(s), but only requiring a report of matters then known to such attorneys, unless Agent specifically inquires about facts that Agent reasonably believes may raise a Fraud and Abuse Law issue. Such opinions shall be in form and substance acceptable to Agent, shall be delivered to Agent at Borrower's 42 48 expense within fifteen (15) days of the date of request and shall address specifically any facts inquired of in Agent's request. 5.25 Additional Collateral Upon Certain Event. If Borrower's Total Funded Debt to Consolidated EBITDA Ratio (as calculated in Section 7.3 hereof) exceeds 2.75 for any two (2) consecutive fiscal quarters, the Consolidated Entities and all Subsidiaries of Borrower shall, upon demand by Agent, execute and deliver to Agent such additional documents as Agent may require on behalf of Lenders to grant to Lenders, or to Agent for the benefit of Lenders, as Agent may require, a perfected security interest, subject only to Permitted Encumbrances, in all of the Consolidated Entities' then owned and thereafter acquired real property, personal property and fixtures, including, but not limited to, all such equipment, inventory, accounts, general intangibles, instruments, documents, chattel paper and fixtures, and all products and proceeds thereof (all as defined in the UCC), including insurance proceeds. Additionally, Borrower shall use its best efforts to cause to be executed and delivered to Borrower opinions of Borrower's outside counsel in form and substance acceptable to Agent, Lenders and their counsel addressing the sufficiency of the security documentation as to attachment, perfection and priority of the security interest granted therein and such other documents as Agent, Lenders or their counsel may require to evidence the continued compliance of Borrower with all requirements of this Agreement. All of Agent's usual diligence items relating to the applicable types of property shall be conducted at Borrower's expenses, including, but not limited to, environmental surveys, boundary surveys and other real estate diligence procedures. All expenses of recordation of lien instruments, title insurance, document preparation and other transaction costs, including, but not limited to, the reasonable fees and expenses of Lenders' and Agent's attorneys, shall be paid by Borrower. VI. NEGATIVE COVENANTS Borrower covenants and agrees that without the advance written consent of Agent, until the Obligations are repaid in full: 6.1 Debts, Guaranties, and Other Obligations. No Consolidated Entity shall incur, create, assume, or in any manner become or be liable with respect to any Liability, except the following: 6.1.1 Obligations to Lenders. Any Obligations to Lenders under this Agreement. 6.1.2 Existing Liabilities. Liabilities, direct or contingent, of Consolidated Entities existing on the date of this Agreement that are reflected in Schedule 6.1.2 hereof. 6.1.3 Endorsements. Endorsements of negotiable or similar instruments for collection or deposit in the ordinary course of business. 43 49 6.1.4 Trade Liabilities. Trade payables and accruals from time to time incurred in the ordinary course of business. 6.1.5 Taxes. Taxes, assessments, or other governmental charges that are not delinquent or are being contested in good faith by appropriate action promptly initiated and diligently conducted, if Borrower has made the reserve therefor required by GAAP. 6.1.6 Seller Debt. Seller Debt, which must be unsecured. 6.1.7 Purchase Money Debt. Purchase Money Debt, including Assumed Debt, not to exceed (i) Six Million and No/100 Dollars ($6,000,000.00) in the aggregate, including all Purchase Money Debt of all Consolidated Entities, (ii) Three Million and No/100 Dollars ($3,000,000.00) in the aggregate, excluding for this Section (ii) all Purchase Money Debt owed by individual Practices that have total Purchase Money Debt of less than One Hundred Thousand and No/100 Dollars ($100,000.00) per Practice, or (iii) One Million and No/100 Dollars ($1,000,000.00) as to any single Practice, absent the prior written approval of Agent as to this Section (iii). 6.1.8 Accounting Accruals. Liabilities arising from reserves and accruals required by GAAP that do not reflect liquidated and mature obligations to third parties, including, but not limited to, current deferred income taxes. 6.1.9 Liabilities Among Consolidated Entities. Liabilities incurred to other Consolidated Entities incurred in the ordinary course of business. 6.2 Change of Management. Borrower shall not allow or suffer any change of management effecting a material change in the duties or change in the personnel presently staffing the positions of Chief Executive Officer, President or Chief Financial Officer, as set forth in Schedule 6.2 hereto. Notwithstanding the foregoing, should any of the named managers cease such active participation in Borrower's management due to their death or disability, Agent shall allow Borrower a period of sixty (60) days thereafter in which a management succession plan may be presented to Agent so that Agent may, in its discretion, elect to accept new management in lieu of prior management, subject to such revisions of this Agreement as Agent may require. Additionally, Lenders have been advised that a change is pending regarding the office of Chief Financial Officer. Borrower shall give Agent written notice of this change when a proposal is available, and Agent shall allow Borrower a period of sixty (60) days thereafter so that Agent may, in its discretion, elect to approve the proposed change in management. 6.3 Change of Ownership. Borrower shall not cause or suffer to exist a change of ownership or suffer the issuance of new stock or other event that would result in the 44 50 ownership of more than 25% of the stock of Borrower by any Person not presently a shareholder thereof, except as may result from the sale or disposition of the Seafield Position. 6.4 Distributions. No Consolidated Entity shall declare or pay any dividend or other distribution or redeem any of its capital stock except for dividend payments and other distributions from Subsidiaries to Borrower. 6.5 Encumbrances. No Consolidated Entity shall create, incur, assume, or permit to exist any Encumbrance on any of its Property (now owned or hereafter acquired) except for Permitted Encumbrances, and shall not undertake a commitment of any kind in favor of any Person (other than Lenders) (i) requiring that any or all of such Consolidated Entity's Property be or remain unencumbered, or (ii) requiring that a Consolidated Entity grant an Encumbrance (other than a Permitted Encumbrance) in favor of any Person (other than Lenders) on a Consolidated Entity's Property under any circumstances whatsoever. No Consolidated Entity shall sign or file under the Uniform Commercial Code a financing statement that names such Consolidated Entity as debtor or the equivalent or sign any security agreement authorizing any secured party thereunder to file any such financing statement, except to secure Permitted Encumbrances. 6.6 Investments. No Consolidated Entity shall make investments (including but not limited to acquisitions or purchases of the obligations or stock of, or any other or additional interest) in any person, firm, partnership, joint venture or corporation except: (a) those investments in existence as of the Closing Date, (b) general obligations of, or obligations unconditionally guaranteed as to principal and interest by, the United States of America maturing within fifteen (15) months of the date of purchase, (c) commercial paper having a rating of not less than "A2" or "P2" from Moody's or S & P,respectively, (d) Permitted Acquisitions, (f) certificates of deposit and bankers acceptances issued by a Lender or another banking institution with a minimum net worth of Five Hundred Million and No/100 Dollars ($500,000,000.00) and having a letter of credit rating of not less than "A" from Moody's or S & P, respectively, and (g) such other investments as Agent may approve, in its discretion. 6.7 Sales and Leasebacks. No Consolidated Entity shall enter into any arrangement, directly or indirectly, with any Person other than another Consolidated Entity by which such Consolidated Entity shall sell or transfer any of its Property, whether now owned or hereafter acquired, and by which a Consolidated Entity shall then or thereafter rent or lease as lessee such Property or any part thereof or other Property that it intends to use for substantially the same purpose or purposes as the Property sold or transferred. 6.8 Change of Control. Borrower shall not suffer or permit the occurrence of a Change of Control. 6.9 Nature of Business. No Consolidated Entity shall suffer or permit any material changes to be made in the character of its business as carried on at the Closing Date, except for the accomplishment of Permitted Acquisitions. 45 51 6.10 Further Acquisitions, Mergers, Etc. Except for Permitted Acquisitions and transactions involving only Consolidated Entities, no Consolidated Entity shall enter into any agreement to merge, consolidate, or otherwise reorganize or recapitalize, or sell, assign, lease, or otherwise dispose of (whether in one transaction or in a series of transactions) all or substantially all of their Property (whether now owned or hereafter acquired). 6.11 Advances. No Consolidated Entity shall extend any loans to any other Persons, except for (i) loans to other Consolidated Entities in the ordinary course of business and (ii) advances to Providers not to exceed Five Hundred Thousand and No/100 Dollars ($500,000.00) per Practice and Three Million and No/100 Dollars ($3,000,000.00) in the aggregate at any one time. 6.12 Disposition of Assets. No Consolidated Entity shall dispose of any of its assets other than in the ordinary course of their present business upon terms standard in its industry. 6.13 Inconsistent Agreements. No Consolidated Entity shall enter into any agreement containing any provision which would be violated or breached by the performance by Borrower of the Obligations. 6.14 Fictitious Names. Borrower shall not use any name other than the name used in executing this Agreement or any assumed or fictitious name. 6.15 Subsidiaries and Affiliates. No Consolidated Entity shall create or acquire any direct or indirect Subsidiary or Affiliate or divest itself of any material assets by transferring them to any existing Subsidiary or Affiliate other than Permitted Subsidiaries; nor shall Borrower enter into any partnership, joint venture, or similar arrangement, or otherwise make any material change in its corporate structure, except that Borrower may acquire and create Permitted Subsidiaries from time to time in the ordinary course of business. 6.16 Place of Business. Borrower shall not transfer its executive offices, or maintain records with respect to accounts at any locations other than at the address for notices specified herein and at the locations of Practices affiliated with Borrower, except as Agent may approve, in its reasonable discretion. 6.17 Adverse Action With Respect to Plans. No Consolidated Entity shall take any action to terminate any Plan which could reasonably result in a material liability of a Consolidated Entity to any Person. 6.18 Transactions With Affiliates. No Consolidated Entity shall enter into any transaction with any Affiliate except in the ordinary course of business and on fair and reasonable terms no less favorable to the Consolidated Entity than it would obtain in a comparable arms length transaction with a Person not an Affiliate. 46 52 6.19 Constituent Document Amendments. No Consolidated Entity shall amend its corporate charter or bylaws, except as necessary to accomplish corporate transactions that do not require Lenders' or Agent's specific approval or transactions for which such approval is necessary and has been granted. 6.20 Adverse Transactions. No Consolidated Entity shall enter into any transaction that materially and adversely affects or, to the best of its knowledge, is likely to materially and adversely affect the Collateral or Borrower's ability to repay the Obligations. 6.21 Margin Securities. No Consolidated Entity shall own, purchase or acquire (or enter into any contract to purchase or acquire) any "margin security" as defined by any regulation of the Federal Reserve Board as now in effect or as the same may hereafter be in effect. 6.22 Accounting Changes. Borrower shall not change its fiscal year or make any other significant change in consolidated or consolidating accounting treatment and reporting practices, except as required or permitted by GAAP or the Securities and Exchange Commission. Any change in fiscal year shall be subject to Agent's prior written approval. 6.23 Action Outside Ordinary Course. No Consolidated Entity shall take any other action outside the ordinary course of their business. VII. FINANCIAL COVENANTS 7.1 Current Ratio. Borrower shall maintain a Consolidated Current Ratio of not less than 2.00:1.00, tested as of the end of each fiscal quarter. 7.2 Total Funded Debt to Capital. Borrower shall maintain a ratio of Total Funded Debt divided by Consolidated Capital of no greater than .50:1.00, tested as of the end of each fiscal quarter. 7.3 Total Funded Debt to Consolidated EBITDA. Borrower shall maintain a ratio of Total Funded Debt divided by Consolidated EBITDA, measured as of the end of each fiscal quarter for the previous four consecutive fiscal quarters, of no greater than 3.00:1.00. 7.4 Fixed Charge Coverage. Borrower shall maintain a Fixed Charge Coverage Ratio of at least 1.25:1.00 for the previous four consecutive fiscal quarters through the fiscal quarter ending December 31, 1996, and of at least 1.50:1.00 thereafter. 7.5 Net Worth. Borrower shall maintain a Consolidated Net Worth as of the end of each fiscal quarter in an amount at least equal to the sum of Nineteen Million Eight Hundred Forty-Three Thousand and No/100 ($19,843,000.00), plus any Net Equity Proceeds, plus eighty-five percent (85%) of the amount of net income for the fiscal quarter ending June 30, 1996 and for each fiscal quarter thereafter, without adjustment for net losses. 47 53 7.6 Capital Expenditures. Lender approval shall be required for Borrower to expend Capital Expenditures in excess of 115% of an annual budget to be approved by Lender. The proposed budget for each year shall be delivered to Lender no later than sixty (60) days after the end of the previous fiscal year. VIII. EVENTS OF DEFAULT 8.1 Events of Default. Any of the following events shall be considered an Event of Default under this Agreement: 8.1.1 Payments. Borrower's failure to make payment of any amount of the Obligations within five (5) days after the date due. 8.1.2 Representations and Warranties. Any representation or warranty made by Borrower or any other party in any Loan Document having been incorrect in any material respect as of the date thereof. 8.1.3 Negative Covenants. The failure of Borrower to comply with any of the requirements of Article VI hereof; provided, however, as to any such event that is both (i) the result of an act by a third party absent the cooperation of any Consolidated Entity, and (ii) reasonably susceptible to being cured, the event shall not constitute an Event of Default unless the event remains uncured for a period of twenty (20) days following the earlier of (i) Borrower's knowledge of the facts giving rise thereto or (ii) Agent's written notice to Borrower given in accordance with the provisions hereof. 8.1.4 Financial Covenants. The failure of Borrower to comply with any of the requirements of Article VII hereof, unless, on or before the date that is the earlier of (i) twenty (20) days after the date on which the breach is timely reported to Agent, or (ii) if the financial statements disclosing the breach were submitted to Agent later than required by this Agreement, twenty (20) days after the date on which such financial statements were due, Borrower provides Agent with additional financial statements demonstrating that the breach has been cured, which statements may be as of any other date after the reporting date for which the breach occurred (provided that such interim statements prepared for this purpose must be accompanied by the same certifications as quarterly financial statements and shall not disclose any additional breach of a financial covenant). 8.1.5 Reporting Requirements. The failure of Borrower or any other party to timely perform any covenant in the Loan Documents requiring the furnishing of notices, financial reports or other information to Lender within twenty (20) days of when due; and provided, however, that during any period 48 54 of time that a report is delinquent, Agent may at its option increase the Pricing Values to their highest levels permitted under this Agreement. 8.1.6 Other Covenants. The failure of Borrower to observe or perform any covenant contained in any Loan Document, which covenant is not subject to any specific provision in this Article VIII; provided, however, as to any such breach that is reasonably susceptible to being cured, the occurrence of such breach shall not constitute an Event of Default hereunder if such breach is fully cured within twenty (20) days after the earlier of Borrower's knowledge of the facts giving rise thereto or Agent's written notice thereof to Borrower given in accordance with the provisions hereof. 8.1.7 Involuntary Bankruptcy or Receivership Proceedings. The appointment of a receiver, custodian, liquidator, or trustee for any Significant Consolidated Entity, or for any of its Property, by the order or decree of any court or agency or supervisory authority having jurisdiction; or a Significant Consolidated Entity's adjudication as being bankrupt or insolvent; or the sequestering of any of the Property of any Significant Consolidated Entity by court order or the filing of a petition against a Significant Consolidated Entity under any state or federal bankruptcy, reorganization, debt arrangement, insolvency, readjustment of debt, dissolution, liquidation, or receivership law of any jurisdiction, whether now or hereafter in effect, and in each case without the acquiescence of a Significant Consolidated Entity, unless dismissed within sixty (60) days. 8.1.8 Voluntary Petitions. Any Significant Consolidated Entity's filing of a petition in voluntary bankruptcy or to seek relief under any provision of any bankruptcy, reorganization, debt arrangement, insolvency, receivership, readjustment of debt, dissolution, or liquidation law of any jurisdiction, whether now or hereafter in effect, or its acquiescence in the filing of any petition against it under any such law. 8.1.9 Discontinuance of Business. Any Significant Consolidated Entity's discontinuance of its usual business or its dissolution, except pursuant to transactions permitted under this Agreement. 8.1.10 Default on Other Liabilities. Any Significant Consolidated Entity's failure to make any payment when due on any Liabilities in excess of One Hundred Thousand and No/100 Dollars ($100,000.00). 8.1.11 Undischarged Judgments. The existence of a final judgment or judgments for the payment of money in excess of One Hundred Thousand and No/100 Dollars ($100,000.00) by any court or other Governmental Authority against a Significant Consolidated Entity, which is not paid, discharged, stayed, 49 55 dismissed through appropriate appellate proceedings or bonded within thirty (30) days after entry. 8.1.12 Insolvency. Any Significant Consolidated Entity's no longer being Solvent. 8.1.13 Attachment. The issuance of an attachment or other process against any Property of any Significant Consolidated Entity, unless removed (by bond or otherwise) within twenty (20) days. 8.1.14 Insurance. Any Consolidated Entity's failure to maintain any insurance required herein or in any other Loan Document. 8.1.15 Contest. Any Consolidated Entity's challenge or contest of the validity or enforceability of this Agreement or any other Loan Document or the validity, priority or perfection of any security interest created hereunder or under any other Loan Document in any action, suit or proceeding. 8.1.16 Fraud and Abuse Laws. Receipt by one or more Consolidated Entities of a notice from a Governmental Authority that it (i) intends to disallow requested reimbursements, demand adjustment or repayment of past reimbursements in excess of one-half of one percent (1/2%) of the gross revenues of Borrower for the previous four (4) fiscal quarters in the aggregate respecting amounts submitted for reimbursement or collected by Borrower or a Provider, or (ii) intends to impose civil money penalties or to seek to exclude Borrower or a Provider from participation in the Medicare or Medicaid programs due to a failure to comply with Fraud and Abuse Laws, if the gross revenues to Borrower arising from Borrower or Provider exceed one-half of one percent (1/2%) of the gross revenues of Borrower for the previous four (4) fiscal quarters in the aggregate. 8.2 Remedies. Upon the happening of any Event of Default: 8.2.1 Default Rate. Agent may declare the Obligations to thereafter bear interest at the Default Rate. 8.2.2 Acceleration. Agent may declare the entire principal amount of all Obligations then outstanding, including interest accrued thereon, to be immediately due and payable without presentment, demand, protest, notice of protest, or dishonor or other notice of default of any kind, all of which are hereby expressly waived. 8.2.3 Setoff. Any Lender may exercise its lien upon and right of setoff against any monies, items, credits, deposits or instruments that such 50 56 Lender may have in its possession and which belong to Borrower or to any other person or entity liable for the payment of any or all of the Obligations. 8.2.4 Other Remedies. Lenders and Agent may exercise any right that they may have under any other document evidencing or securing the Obligations or otherwise available to Lenders or Agent at law or equity. 8.2.5 Attorney-in-Fact. Borrower hereby irrevocably appoints Agent as Borrower's attorney-in-fact to take any action to facilitate Agent's exercise of remedies hereunder. IX. AGENT 9.1 Appointment of Agent. Lenders hereby appoint Agent to act as specified in this Article IX. Agent's duties hereunder are administrative and ministerial in nature, and Agent's capacity is that of an independent contractor for Lenders. Agent is not a trustee or other fiduciary for Lenders, and Agent has no duties whatsoever to Lenders except as expressly set forth in this Agreement. 9.2 Powers of Agent. 9.2.1 Administration of Credit Facilities. Except as otherwise provided in this Section 9.2, Agent shall have the exclusive power and authority to (i) give all consents and approvals, issue waivers and amendments, enforce the Loan Documents (including, but not limited to, the power to enforce the Loan Documents in any relevant case under the Bankruptcy Code) and otherwise take all actions permitted of Agent under this Agreement or any other Loan Document, (ii) give all consents and approvals, issue waivers and amendments, enforce the Loan Documents (including, but not limited to, the power to enforce the Loan Documents in any relevant case under the Bankruptcy Code) and otherwise take all actions permitted of Lenders under this Agreement or any other Loan Document, excepting only those matters that the Loan Documents specifically reserve[d] for the respective Lenders severally (such as the computation of LIBOR charges unique to the circumstances of a given Lender), (iii) receive all payments, notices and other deliveries and communications to be given Lenders or Agent under this Agreement or any other Loan Document, and (iv) to perform such actions as are incidental to any of the foregoing. 9.2.2 Matters Reserved to Required Lenders. Absent the prior approval of the Required Lenders, Agent shall not waive or amend any financial covenant set forth in Article VII hereof or approve any acquisition for which approval is necessary under the definition of Permitted Acquisitions set forth in Article I hereof. 51 57 9.2.3 Matters Reserved to all Lenders. Absent the prior approval of all Lenders, Agent shall not forgive any principal included in the Obligations; waive or amend any interest rate applicable to the Obligations; waive or amend the Maturity Date; waive or amend the amount of any Lender's Commitment; release or subordinate any security interest securing the Obligations (other than releases thereof in connection with transactions for which the approval of Lenders and/or Agent is not required, such as the release of pledged stock of a Subsidiary in connection with the merger of that Subsidiary into another Subsidiary); waive an Event of Default arising from non-payment of any principal or interest due on the Obligations; accelerate the maturity of the Obligations; or amend the definitions of Pro Rata Share or Required Lenders. 9.3 Duties of Agent. 9.3.1 Specific Duties of Agent; Standard of Care. Agent shall (i) remit to each Lender, with reasonable promptness, the appropriate Pro Rata Share of payments received or other amounts collected on account of the Obligations, (ii) forward to Lenders, with reasonable promptness, counterparts or copies of Borrowing Notices, financial reports and other information that may be delivered to Agent by Borrower pursuant to the requirements of the Loan Documents, (iii) notify Lenders of any Unmatured Default or Event of Default known to Agent, in accordance with Section 9.7 below, and (iv) otherwise administer the Credit Facilities through the exercise of such of the powers granted herein as Agent deems appropriate from time to time. Agent shall have no liability to Lenders for any action or inaction relating to this Agreement or the other Loan Documents, except for actual losses caused by its gross negligence or reckless or willful misconduct. 9.3.2 Limitations on Agent's Duties. Agent shall not be obligated to take any action hereunder or under any other Loan Document (i) if such action would, in the opinion of Agent, be contrary to applicable law, this Agreement or the other Loan Documents, (ii) if it shall not first be specifically indemnified to its satisfaction against any and all liability and expense that may be incurred by it by reason of taking or continuing to take any such action, (iii) if it would likely subject Agent to a tax in any jurisdiction where it is not then subject to a tax, (iv) if it would likely require Agent to qualify to do business in any jurisdiction where it is not then so qualified, unless Agent receives security or indemnity satisfactory to it against any tax or other liability in connection with such qualification or resulting from the taking of such action in connection therewith, or (v) if it would likely subject Agent to in personam jurisdiction in any location where it is not then so subject. 9.3.3 Agent's Right to Require Instructions in Performance of Duties. If Agent, in its sole and absolute discretion, requests instructions from the 52 58 Required Lenders with respect to any act or action (including the failure to act) in connection with this Agreement or any other Loan Document for which the approval of the Required Lenders or all Lenders is not otherwise required, Agent shall be entitled, at its option, to refrain from such action, or to continue such inaction, unless and until Agent shall have received such instructions, and Agent shall incur no liability by reason of so acting or refraining from action. No Lender shall have any right of action whatsoever against Agent as a result of Agent's acting or refraining from acting hereunder or under any other Loan Document in accordance with the instructions of the Required Lenders in such a case. 9.3.4 Agent's Reliance on Others in Performance of Duties. Agent shall be entitled to rely, and shall be fully protected in relying, upon any note, writing, resolution, notice, statement, consent, certificate, telex, teletype or facsimile message, order or other documentary, teletransmission or telephone message believed by it in good faith to be genuine and correct and to have been signed, sent or made by the proper Person. Agent may consult with legal counsel (including counsel for Borrower), accountants and other experts selected by it with respect to all matters pertaining to this Agreement and the other Loan Documents and its duties hereunder and thereunder and shall not be liable for any action taken or omitted to be taken by it in good faith in accordance with the advice of such counsel (including counsel for Borrower), accountants or experts. 9.3.5 Sharing of Information. Except as otherwise expressly provided in this Article IX, Agent shall have no duty or responsibility, either initially or on a continuing basis, to provide any Lender with any credit or other information concerning the business, prospects, operations, properties, financial or other condition or creditworthiness of the Consolidated Entities or any other Person that may come into its possession, whether before the making of the initial Loans or at any time or times thereafter. All notices to be given to Borrower by a Lender hereunder shall be concurrently given to Agent and all other Lenders. 9.4 Indemnification of Agent. To the extent Agent is not reimbursed by or on behalf of Borrower, and without limiting the obligation of Borrower to do so, Lenders will reimburse and indemnify Agent, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses (including attorneys' fees and expenses) or disbursements of any kind or nature whatsoever that may at any time (including at any time following the indefeasible repayment in full of the Loans) be imposed on, incurred by or asserted against Agent in any way relating to or arising out of this Agreement or any other Loan Document or the transactions contemplated thereby or any action taken or omitted by Agent under or in connection with any of the foregoing, and in particular will reimburse Agent for out-of-pocket expenses promptly upon demand by Agent therefor; provided, 53 59 however, that no Lender shall be liable for any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements finally determined by a court of competent jurisdiction and not subject to any appeal or pursuant to arbitration to have resulted from Agent's gross negligence or reckless or willful misconduct. Agent may offset any amounts due Agent by any Lender against obligations of Agent to that Lender. 9.5 No Representations by Agent. Each Lender acknowledges that neither Agent nor any of its officers, directors, employees, attorneys, accountants or agents has made any representation or warranty to it regarding the Consolidated Entities, the Credit Facilities, the Collateral or otherwise relating to this Agreement. Agent shall not be responsible to any Lender for any recitals, statements, information, representations or warranties herein or in any other Loan Document or in any document, instrument, certificate or other writing delivered in connection herewith or therewith or for the execution, effectiveness, genuineness, validity, enforceability, perfection, priority or sufficiency of this Agreement or any other Loan Document or the financial condition of the Consolidated Entities or any other Person, or be required to make any inquiry concerning either the performance or observance of any of the terms, provisions or conditions of this Agreement or any other Loan Document, or the financial condition of the Consolidated Entities or any other Person or the existence or possible existence of any Unmatured Default or Event of Default. 9.6 Independent Investigations by Lenders. Each Lender acknowledges that, independently and without reliance upon Agent or any other Lender and based on such documents and information as it has deemed and may deem appropriate, (i) it has made its own appraisal of and investigation into the business, prospects, operations, properties, financial and other condition and creditworthiness of the Consolidated Entities in connection with its decision to enter into this Agreement and extend credit to Borrower hereunder, and (ii) it will continue to make its own credit analysis, appraisals and decisions in taking or not taking action hereunder. 9.7 Notice of Default. Agent shall not be deemed to have knowledge or notice of the occurrence of any Unmatured Default or Event of Default, other than any Unmatured Default or Event of Default arising out of the failure to pay any principal, interest, fees or other amounts payable to Agent for the account of the Lenders, unless Agent has received written notice from Borrower or a Lender describing such Unmatured Default or Event of Default and stating that such notice is a "notice of default." In the event that Agent receives such a notice, Agent shall give notice thereof to the Lenders as soon as reasonably practicable; provided, however, that if any such notice has also been furnished to the Lenders, Agent shall have no obligation to notify the Lenders with respect thereto. Each Lender shall promptly give Agent such a notice upon its actual knowledge of an Unmatured Default or an Event of Default; provided, however, that the failure of any Lender to deliver such notice in the absence of gross negligence or reckless or willful misconduct shall not affect its rights hereunder or under the other Loan Documents. 54 60 9.8 Funding of Loans Pursuant to Borrowing Notices. Promptly following receipt of notice from Agent that a Borrowing Notice has been submitted, and provided that all conditions to funding are believed to have been satisfied, each Lender shall transfer to a designated account with Agent that Lender's Pro Rata Share of the requested funding. The transfer of funds shall occur within the time required for funding under this Agreement. Should any Lender fail to timely fund its Pro Rata Share of a requested Loan, Agent may, but shall be under no obligation whatsoever to, advance to Borrower the defaulted Lender's Pro Rata Share of the requested Loan. If such an advance is made, it shall be deemed an advance by Agent for the account of the defaulting Lender and shall bear interest at the rate applicable to the Loan funded by the advance, payable on demand. 9.9 Agent in its Individual Capacity. With respect to its Commitments, and the Loans made by it, Agent shall have the same rights and powers under the Loan Documents as any other Lender or holder of a Note and may exercise the same as though it were not performing the duties specified herein; and the terms "Lenders," "Required Lenders," and any similar terms shall, unless the context clearly otherwise indicates, include Agent in its individual capacity as a Lender. Agent may accept deposits from, lend money to and generally engage in any kind of banking, trust, financial advisory or other business with the Consolidated Entities or any of their respective Affiliates as if it were not performing the servicing duties specified herein, and may accept fees and other consideration from Borrower for services in connection with this Agreement and otherwise without having to disclose or account for the same to Lenders. 9.10 Holders. Agent may deem and treat the payee of any Note as the holder thereof and Lender hereunder for all purposes hereof unless and until a written notice of the assignment, transfer or endorsement thereof purportedly executed by the payee, as the case may be, shall have been filed with Agent. Any request, authority or consent of any Person that, at the time of making such request or giving such authority or consent, is the holder of any Note according to Agent's information, shall be conclusive and binding on any subsequent holder, transferee, assignee or endorsee, as the case may be, of such Note or of any Note or Notes issued in exchange therefor. 9.11 Successor Agent. Agent may resign at any time upon sixty (60) days' prior written notice to Borrower and the Lenders. Agent may be removed upon Agent's insolvency, liquidation or the appointment of a receiver for Agent, by action of the Required Lenders, at any time upon sixty (60) days' prior written notice to Borrower and Agent. Such resignation or removal, as the case may be, shall take effect upon the appointment of a successor Agent as provided herein. The Required Lenders will appoint from among the Lenders a successor Agent. If no successor Agent shall have been appointed within such sixty (60) day period, Agent may appoint, after consulting with the Lenders and Borrower, a successor agent from among the Lenders, who shall serve as Agent until such time, if any, as the Required Lenders shall have appointed a successor Agent as provided hereinabove. Upon the written acceptance of any appointment as Agent hereunder by a successor Agent, such successor Agent shall thereupon succeed to and become vested with all the rights, powers, 55 61 privileges and duties of the retiring Agent, and the retiring Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents. After any retiring Agent's resignation as Agent, the provisions of this Article shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Agent. 9.12 Sharing of Payments, etc. Each Lender agrees that if it shall, through the exercise of a right of banker's lien, set-off, counterclaim or otherwise, obtain payment with respect to the Obligations which results in its receiving more than its Pro Rata Share of the aggregate payments with respect to all of the Obligations, then (a) such Lender shall be deemed to have simultaneously purchased from the other Lenders a share in the Obligations so that the amount of the Obligations held by each of the Lenders shall continue to equal their respective Pro Rata Shares, and (b) such other adjustments shall be made from time to time as shall be equitable to insure that the Lenders share such payments ratably. No Lender shall exercise its banker's lien, set-off or other right to accomplish such payment absent Agent's prior consent. 9.13 Separate Liens on Collateral. Each Lender agrees with the other Lenders that, with the exception of security interests in deposit accounts and like property in the possession of a Lender as expressly provided for in this Agreement, it will not take or permit to exist any Encumbrance in its favor on any of the Collateral or other property of any of the Consolidated Entities other than Encumbrances securing the Obligations due to all Lenders pursuant to the Loan Documents. 9.14 Payments Between Agent and Lenders. All payments by Agent to any Lender, and all payments by any Lender to Agent, under the terms of this Agreement shall be made by wire transfer in immediately available funds to the receiving party's address specified for notices in this Agreement. If any of the Lenders fail to pay when due any sum payable to Agent, then, except as otherwise provided in Section 9.8 hereof, such sum shall bear interest until paid at the interest rate per annum for overnight borrowing by the payee from the Federal Reserve Bank for the period commencing on the date such payment was due and ending on, but excluding, the date such payment is made. 9.15 Assignments and Participations. Absent the approval of the other Lenders, no Lender shall assign its interest in the Credit Facilities without first offering to sell such Lender's interest to the other Lenders to be closed Pro Rata to the Lender(s) who may elect to purchase such interest. Such offers to sell shall be made in writing, shall provide the other Lenders ten (10) days to accept or reject, and shall allow an additional ten (10) days to close. Lenders may sell participation interests in their interests in the Credit Facilities as long as the terms of such participations establish that no participant will be regarded as a Lender under this Agreement. 9.16 Bankruptcy Provisions. Should any of the Consolidated Entities become a party to a case under the Bankruptcy Code, each Lender shall be entitled to file its own claim, to the extent such a filing may be necessary. Agent shall review each claim before 56 62 being filed by a Lender to assure that the claim is filed on a basis consistent with Agent's records and Agent's legal positions taken pursuant to this Agreement. Should any of the Consolidated Entities become a party to a reorganization proceeding under the Bankruptcy Code, each Lender shall be recognized as the holder of a separate claim for the purpose of the approval or rejection of a Plan under 11 U.S.C. ss. 1126, may freely vote such claim, and the provisions of that Section shall control the other provisions of this Agreement that otherwise require the consent of the Required Lenders or all Lenders in certain circumstances. Agent shall continue to administer the Credit Facilities on behalf of Lenders, as they may be amended by any adopted Plan of Reorganization. 9.17 Foreclosure of Collateral. In the event of a foreclosure of any Collateral, Agent may issue a credit bid for the account of all Lenders, up to the amount of the then outstanding Obligations. Any Property acquired at such a foreclosure (or acquired by Agent through a conveyance in lieu of foreclosure) shall be held and administered by Agent for the benefit of all Lenders pursuant to the terms of this Article IX. 9.18 Procedures for Notices and Approvals. All notices given among Lenders and Agent with respect to this Agreement or the other Loan Documents shall be given in the manner provided in this Agreement. Additionally, should Agent request Lenders' approval of any matter, each Lender shall respond in writing within five (5) Business Days after the Business Day on which the request was received. If a Lender fails to so respond, it shall be deemed to have approved the action proposed by the Agent. 9.19 Amendments to Article IX. No provision of this Article IX may be amended or waived absent the prior written consent of all Lenders and Agent. Borrower's approval shall not be required for the amendment or waiver of any provision of this Article IX; provided, however, Borrower's written consent shall be required for any amendment of this Article IX that would eliminate the position of Agent. X. GENERAL PROVISIONS 10.1 Notices. All communications relating to this Agreement or any of the other Loan Documents shall be in writing and shall effective when be delivered by mail, overnight courier, special courier, telecopier or otherwise to the following addresses: if to Borrower: Response Oncology, Inc. Attn: John A. Good 1775 Moriah Woods Blvd. Memphis, Tennessee 38117 Telecopier: (901) 683-7277 With a Copy To: 57 63 Baker, Donelson, Bearman & Caldwell Attn: Mary L. Aronov, Esq. 165 Madison Ave. 20th Floor Memphis, Tennessee 38103 Telecopier: (901) 577-2303 If to NationsBank or Agent: NationsBank of Tennessee, N.A. Attn: Cathy M. Wind 1 NationsBank Plaza Nashville, Tennessee 37239 Telecopier: (615) 749-4951 With a Copy To: Boult, Cummings, Conners & Berry Attn: John E. Murdock III, Esq. 414 Union Street, Suite 1600 Nashville, Tennessee 37219 Telecopier: (615) 252-2380 If to Union Planters: Union Planters National Bank Attn: Leonard McKinnon 6200 Poplar Avenue Memphis, Tennessee 38119 Telecopier: (901) 383-6681 With a Copy To: ------------------------ ------------------------ ------------------------ Any party may change its address for receipt of notice by written direction to the other parties hereto. 10.2 Renewal, Extension, or Rearrangement. All provisions of this Agreement relating to Obligations shall apply with equal force and effect to each and all 58 64 promissory notes executed hereafter which in whole or in part represent a renewal, extension for any period, increase, or rearrangement of any part of the Obligations originally represented by any part of such other Obligations. 10.3 Application of Payments. Amounts received with respect to the Obligations shall be applied (i) first, to any expenses due Lenders or Agent, (ii) second, to accrued and unpaid interest under any of the Obligations, and (iii) third, to reduce the unpaid principal portion of the Obligations, in such manner as determined by Agent. 10.4 Counterparts. This Agreement may be executed in counterparts with all signatures or by counterpart signature pages, and it shall not be necessary that the signatures of all parties be contained on any one counterpart. Each counterpart shall be deemed an original, but all of them together shall constitute one and the same instrument. 10.5 Negotiated Document. This Agreement and the other Loan Documents have been negotiated by the parties with full benefit of counsel and should not be construed against any party as author. 10.6 Consent to Jurisdiction; Exclusive Venue. Borrower hereby irrevocably consents to the jurisdiction of the United States District Court for the Middle District of Tennessee and of all Tennessee state courts sitting in Davidson County, Tennessee, for the purpose of any litigation to which Lenders or Agent may be a party and which concerns this Agreement or the Obligations. It is further agreed that venue for any such action shall lie exclusively with courts sitting in Davidson County, Tennessee, unless Lenders and Agent agree to the contrary in writing. This election applies only for the limited judicial proceedings that may apply as set forth in the provision of this Agreement electing binding arbitration for the resolution of disputes and does not impair the effect of that provision in any way. 10.7 Not Partners; No Third Party Beneficiaries. The relationship of Lenders and Borrower is that of lenders and borrower only, and neither is a fiduciary, partner or joint venturer of the other for any purpose. This Agreement has been executed for the sole benefit of Lenders, and no third party is authorized to rely upon Lenders' rights or duties hereunder. 10.8 No Reliance on Lenders' Analysis. Borrower acknowledges and represents that, in connection with the Obligations, Borrower has not relied upon any financial projection, budget, assessment or other analysis by Lenders or Agent upon any representation by Lenders as to the risks, benefits or prospects of Borrower's business activities or present or future capital needs incidental thereto, all such considerations having been examined fully and independently by Borrower. 10.9 No Marshaling of Assets. Lenders and Agent may proceed against collateral securing the Obligations and against parties liable therefor in such order as they may elect, and neither Borrower nor any surety or guarantor for Borrower nor any creditor of 59 65 Borrower shall be entitled to require Lenders or Agent to marshal assets. The benefit of any rule of law or equity to the contrary is hereby expressly waived. 10.10 Impairment of Collateral. Lenders or Agent may, in their sole discretion, release any Collateral securing the Obligations or release any party liable therefor. The defenses of impairment of collateral and impairment of recourse and any requirement of diligence in collecting the Obligations are hereby waived. 10.11 Business Days. If any payment date under the Obligations falls on a day that is not a Business Day, or if the last day of any notice period falls on such a day, the payment shall be due and the notice period shall end on the next following Business Day. 10.12 Participations. Lenders may, from time to time, in their sole discretion, and with concurrent notice to Borrower, sell participations in any credit subject hereto to such other investors or financial institutions as it may elect. Lenders and Agent may from time to time disclose to any participant or prospective participant such information as they may have regarding the financial condition, operations, and prospects of Borrower. 10.13 Standard of Care; Limitation of Damages. Lenders and Agent shall be liable to Borrower only for matters arising from this Agreement or otherwise related to the Obligations resulting from such Lender's or Agent's gross negligence or reckless or willful misconduct, and liability for all other matters is hereby waived. Lenders and Agent shall not in any event be liable to Borrower for special or consequential damages arising from this Agreement or otherwise related to the Obligations. 10.14 Incorporation of Schedules. All Schedules and Exhibits referred to in this Agreement are incorporated herein by this reference. 10.15 Indulgence Not Waiver. Lenders' or Agent's indulgence in the existence of a default hereunder or any other departure from the terms of this Agreement shall not prejudice Lenders' or Agent's rights to declare a default or otherwise demand strict compliance with this Agreement. 10.16 Cumulative Remedies. The remedies provided Lenders and Agent in this Agreement are not exclusive of any other remedies that may be available to Lenders and Agent under any other document or at law or equity. 10.17 Amendment and Waiver in Writing. No provision of this Agreement can be amended or waived, except by a statement in writing signed by the party or parties against whom enforcement of the amendment or waiver is sought. Waivers and amendments may be executed by Agent on behalf of Lenders, subject to the requirements of Article IX hereof requiring the consent of some or all of Lenders under certain circumstances. 60 66 10.18 Assignment. This Agreement shall be binding upon and inure to the benefit of the respective successors and assigns of Borrower and Lenders, except that Borrower shall not assign any rights or delegate any obligations arising hereunder without the prior written consent of Lenders. Any attempted assignment or delegation by Borrower without the required prior consent shall be void. 10.19 Entire Agreement. This Agreement and the other written agreements among Borrower, Lenders and Agent represent the entire agreement between the parties concerning the subject matter hereof, and all oral discussions and prior agreements are merged herein. Provided, if there is a conflict between this Agreement and any other document executed contemporaneously herewith with respect to the Obligations, the provision in this Agreement shall control. 10.20 Severability. Should any provision of this Agreement be declared invalid or unenforceable for any reason, the remaining provisions hereof shall remain in full effect. 10.21 Time of Essence. Time is of the essence of this Agreement, and all dates and time periods specified herein shall be strictly observed. 10.22 Applicable Law. The validity, construction and enforcement of this Agreement and all other documents executed with respect to the Obligations shall be determined according to the laws of Tennessee applicable to contracts executed and performed entirely within that state. 10.23 Captions Not Controlling. Captions and headings have been included in this Agreement for the convenience of the parties, and shall not be construed as affecting the content of the respective Sections. 10.24 Arbitration. Any controversy or claim between or among the parties hereto including but not limited to those arising out of or relating to this instrument, agreement or document or any related instruments, agreements or documents, including any claim based on or arising from an alleged tort, shall be determined by binding arbitration in accordance with the Federal Arbitration Act (or if not applicable, the applicable state law), the Rules of Practice and Procedure for the Arbitration of Commercial Disputes of J.A.M.S./Endispute or any successor thereof ("J.A.M.S."), and the "Special Rules" set forth below. In the event of any inconsistency, the Special Rules shall control. Judgment upon any arbitration award may be entered in any court having jurisdiction. Any party to this Agreement may bring an action, including a summary or expedited proceeding, to compel arbitration of any controversy or claim to which this Agreement applies in any court having jurisdiction over such action. 10.24.1 Special Rules. The arbitration shall be conducted in Nashville, Tennessee and administered by J.A.M.S who will appoint an arbitrator; if J.A.M.S. is unable or legally precluded from administering the arbitration, then 61 67 the American Arbitration Association will serve. All arbitration hearings will be commenced within 90 days of the demand for arbitration; further, the arbitrator shall only, upon a showing of cause, be permitted to extend the commencement of such hearing for up to an additional 60 days. 10.24.2 Reservation of Rights. Nothing in this arbitration provision shall be deemed to (i) limit the applicability of any otherwise applicable statutes of limitation or repose and any waivers contained in this arbitration provision; or (ii) be a waiver by any Lender of the protection afforded to it by 12 U.S.C. Sec. 91 or any substantially equivalent state law; or (iii) limit the right of any Lender (a) to exercise self help remedies such as (but not limited to) setoff, or (b) to foreclose against any real or personal property collateral, or (c) to obtain from a court provisional or ancillary remedies such as (but not limited to) injunctive relief, writ of possession or the appointment of a receiver. Lenders and Agent may exercise such self help rights, foreclose upon such property, or obtain such provisional or ancillary remedies before, during or after the pendency of any arbitration proceeding brought pursuant to this instrument, agreement or document. Neither this exercise of self help remedies nor the institution or maintenance of an action for foreclosure or provisional or ancillary remedies shall constitute a waiver of the right of any party, including the claimant in such action, to arbitrate the merits of the controversy or claim occasioning resort to such remedies. 10.25 Facsimile Signatures. This Agreement may be executed by facsimile signatures, and shall be effective when Agent has received telecopy transmissions of the signature pages executed by all parties hereto; provided, however, that all parties shall deliver original executed documents to Agent promptly following the execution hereof. Executed as of the date first written above. RESPONSE ONCOLOGY, INC. By:__________________________________ Title:_______________________________ NATIONSBANK OF TENNESSEE, N.A. By:__________________________________ Title:_______________________________ 68 UNION PLANTERS NATIONAL BANK By:__________________________________ Title:_______________________________ 69 EXHIBIT 1.2 Notice of Extension [On letterhead of Borrower] NationsBank of Tennessee, N.A., Agent Attn: Cathy M. Wind 1 NationsBank Plaza Nashville, Tennessee 37239 Re: Notice of Extension of Working Capital Loan Under Loan Agreement Among NationsBank of Tennessee, N.A., Union Planters National Bank, Response Oncology, Inc. and NationsBank of Tennessee, N.A., as Agent Dated as of May 31, 1996 (the "Loan Agreement") Ladies and Gentlemen: Please accept this letter as our notice that Response Oncology, Inc. hereby elects to extend the Maturity Date of the Working Capital Loan, as defined in the Loan Agreement, until May 31, 1998. The required extension fee is enclosed herewith. This election shall have the effect of making applicable the optional May 31, 1998 Maturity Date in the Loan Agreement and in the corresponding Working Capital Notes, as provided for therein. Your acceptance of the enclosed fee does not waive any Unmatured Default, Event of Default or other matter that may exist with respect to the Loan Agreement. Very truly yours, RESPONSE ONCOLOGY, INC. By:__________________________ Title:________________________ cc: Boult, Cummings, Conners & Berry Attn: John E. Murdock III, Esq. 414 Union Street, Suite 1600 Nashville, Tennessee 37219 70 EXHIBIT 2.8.1(B) BORROWING/CONVERSION NOTICE TO: NationsBank of Tennessee, N.A., Agent LENDERS: NationsBank of Tennessee, N.A. Date: __________, 199_ Union Planters National Bank BORROWER: Response Oncology, Inc. This notice is delivered under the Loan Agreement (as renewed, extended and amended, the "Loan Agreement") dated as of May __, 1996, between Borrower and Lender. Terms defined in the Loan Agreement have the same meanings when used -- unless otherwise defined -- in this request. Borrower requests a Loan under the Loan Agreement as follows: The requested draw is from (select one): _____ Acquisition Loan _____ Working Capital Loan Borrowing Date1 ___________, 199_ Amount of Borrowing $________________ Type of Borrowing2 _________________ For LIBOR Loans, the Interest Period3 __________ months Select one: ____ The proceeds of the requested Loan shall be disbursed to Borrower as provided in the Loan Agreement. The purpose of the requested Loan is (select one for this Loan): _____ New advance for a Permitted Acquisition _____ New advance for capital expenditures other than Permitted Acquisitions _____ New advance for IMPACT Center development _____ New advance for working capital ____ The proceeds of the requested LIBOR Loan shall be applied to the payment of Borrower's existing Prime Rate Loan, this new Loan being a conversion of a Prime Rate Loan to a LIBOR Loan - -------- 1 Same Banking Day for Prime Rate Loans, second following Banking Day for LIBOR Loans 2 LIBOR or Prime Rate Loan. 3 1, 2, 3, 6 or 12 months. 71 ____ The proceeds of the requested LIBOR Loan shall be applied to the payment of the following LIBOR Loan, subject to all requirements of the Loan Agreement, this new Loan being a conversion of a LIBOR Loan to a different LIBOR Loan: Date:_______________________ Amount:_____________________ Interest Period:____________ ____ The proceeds of the requested Prime Rate Loan shall be applied to the payment of the following LIBOR Loan, subject to all requirements of the Loan Agreement, this new Loan being a conversion of a LIBOR Loan to a Prime Rate Loan: Date:______________________ Amount:____________________ Interest Period:___________ Date:______________________ Amount:____________________ Interest Period:___________ Borrower certifies that on the date hereof and on the date of the above Borrowing Date -- after giving effect to the requested Loan -- (a) all of the representations and warranties in the Loan Documents will be true and correct in all material respects -- unless they speak to a specific date or the facts on which they are based have been changed by transactions contemplated or permitted by the Loan Agreement, (b) no Event of Default or Unmatured Default will exist, and (c) all conditions to Borrower's right to receive the requested Loan under the Loan Agreement have been satisfied. RESPONSE ONCOLOGY, INC., Borrower By:______________________________ (Name)___________________________ (Title)__________________________ 72 FIRST AMENDMENT TO LOAN AGREEMENT This First Amendment to Loan Agreement ("Amendment") is entered into as of the 18th day of June, 1996 by Response Oncology, Inc. ("Borrower"), a Tennessee corporation; Union Planters National Bank, a national banking association; and NationsBank of Tennessee, N.A. , a national banking association, in its individual capacity and as Agent for itself and Union Planters. R E C I T A L S: WHEREAS, the parties hereto have previously executed that Loan Agreement dated as of May 31, 1996 (the "Loan Agreement"); and WHEREAS, the parties wish to amend the Loan Agreement in certain respects; NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows: 1. The Loan Agreement is hereby amended by revising Section 7.3 thereof to reflect a required value of 3.25:1 until August 19, 1996 and 3.00:1 thereafter. A certification of compliance with this ratio shall be submitted as of July 31, 1996 for the prior twelve months, such report to be submitted no later than August 31, 1996. 2. Borrower acknowledges that its $10,000,000.00 loan from Seafield Capital Corporation has not been approved as Subordinated Debt under the Loan Agreement. Executed as of the date written above. RESPONSE ONCOLOGY, INC. By:_________________________________ Title:______________________________ NATIONSBANK OF TENNESSEE, N.A. By:_________________________________ Title:______________________________ UNION PLANTERS NATIONAL BANK By:_________________________________ Title:______________________________ 73 SECOND AMENDMENT TO LOAN AGREEMENT This Second Amendment to Loan Agreement ("Amendment") is entered into as of the first day of July, 1996 by Response Oncology, Inc. ("Borrower"), a Tennessee corporation; Union Planters National Bank ("Union Planters"), a national banking association; and NationsBank of Tennessee, N.A. , a national banking association, in its individual capacity and as Agent for itself and Union Planters. R E C I T A L S: WHEREAS, the parties hereto have previously executed that Loan Agreement dated as of May 31, 1996, as amended by that First Amendment to Loan Agreement (the "First Amendment") dated as of June 18, 1996 (the Loan Agreement, as amended by the First Amendment, is referred to herein as the "Loan Agreement"); and WHEREAS, the parties wish to further amend the Loan Agreement in certain respects; NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows: 1. The Loan Agreement is hereby amended by revising Section 7.3 thereof to read in full as it existed prior to the execution of the First Amendment. 2. The Loan Agreement is hereby amended by revising the definition of "Subordinated Debt" set forth in Article I thereof by adding the following sentence at the end of the present definition: The indebtedness evidenced by that Adjustable Rate Convertible Note made by Borrower dated April 12, 1996, payable to the order of Seafield Capital Corporation in the original principal amount of Ten Million and No/100 Dollars ($10,000,000.00), as amended by letter agreement dated June 3, 1996 and by First Amendment to Note dated July 1, 1996, shall also be regarded as Subordinated Debt hereunder, even though its maturity date is August 1, 1998. 3. As amended hereby, the Loan Agreement remains in full effect, and all agreements among the parties with respect to the subject hereof are represented fully in this Amendment and the other written documents among the parties. The validity, construction and enforcement hereof shall be determined according to the substantive laws of the State of Tennessee. 74 Executed as of the date written above. RESPONSE ONCOLOGY, INC. By:___________________________________ Title:________________________________ NATIONSBANK OF TENNESSEE, N.A. By:___________________________________ Title:________________________________ NATIONSBANK OF TENNESSEE, N.A., as Agent By:___________________________________ Title:________________________________ UNION PLANTERS NATIONAL BANK By:___________________________________ Title:________________________________ - 2 - 75 THIRD AMENDMENT TO LOAN AGREEMENT This Third Amendment to Loan Agreement ("Amendment") is entered into as of the 29th day of August, 1996 by Response Oncology, Inc. ("Borrower"), a Tennessee corporation; Union Planters National Bank ("Union Planters"), a national banking association; and NationsBank of Tennessee, N.A. , a national banking association, in its individual capacity and as Agent for itself and Union Planters. R E C I T A L S: WHEREAS, the parties hereto have previously executed that Loan Agreement dated as of May 31, 1996, as amended by that First Amendment to Loan Agreement (the "First Amendment") dated as of June 18, 1996 and by that Second Amendment to Loan Agreement (the "Second Amendment") dated as of July 1, 1996 (the Loan Agreement, as amended by the First Amendment and the Second Amendment, is referred to herein as the "Loan Agreement"); and WHEREAS, the parties wish to further amend the Loan Agreement in certain respects; NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows: 1. The parties agree that the first numbered paragraph of the Second Amendment was included in the Second Amendment in error and agree that the first numbered paragraph of the Second Amendment has been and hereby is retroactively nullified as to be of no effect at any time. 2. The Loan Agreement is hereby amended by revising Section 7.3 thereof to reflect a required value of Total Funded Debt to Consolidated EBITDA of no greater than 3.50:1.00 until the occurrence of the Secondary Offering and no greater than 3.00:1.00 thereafter. 3. The Loan Agreement is hereby amended by revising subsection (ii) of the definition of "Borrowing Base" in Article I thereof to read "(ii) multiplied by 3.25 until the occurrence of the Secondary Offering, and multiplied by 3.00 thereafter." 4. The Loan Agreement is hereby amended by inserting the following definition between the definitions of "Seafield Position" and "Seller" in Article I: "Secondary Offering" means an issuance of equity by Borrower after August 20, 1996 yielding Net Proceeds in an amount of at least $30,000,000.00. 5. The Loan Agreement is hereby amended by revising the first paragraph of Section 2.8 thereof to read in full as follows: 76 2.8 Advances of Loans. Subject to the terms and conditions of this Agreement, Borrower may borrow, repay and reborrow Loans under the Credit Facilities, provided that the outstanding principal balance of the Acquisition Loan and the Working Capital Loan, respectively, shall not at any time exceed the amounts permitted under Sections 2.1 and 2.4 above, and further provided that no new borrowings may be obtained after January 1, 1997, if amortization of the Credit Facilities is then required under Section 2.13 hereof. Loans shall be disbursed as follows: 6. The Loan Agreement is hereby amended by revising Section 2.13 thereof to read in full as follows: 2.13 Principal Repayment. Principal payments under the Credit Facilities shall become due immediately and without notice at such time that the outstanding principal balance of the Credit Facilities may exceed the Credit Ceiling, in an amount sufficient to reduce the outstanding principal balance to an amount no greater than the Credit Ceiling. All remaining principal outstanding under the Credit Facilities shall become due on the Maturity Date or the earlier acceleration of the Credit Facilities in accordance with the terms of this Agreement. Notwithstanding the foregoing, if the Secondary Offering has not occurred on or before January 1, 1997, principal payments shall become due on the first day of each month beginning January 1, 1997, in the amount of one eighty-fourth (1/84th) of the outstanding principal balance under each of the respective Credit Facilities as of January 1, 1997. 7. It is a condition to the effect of this Amendment that the indebtedness owed to Seafield Capital Corporation referenced in the definition of "Subordinated Debt" be converted to equity. 8. It is a condition to the effect of this Amendment that Borrower pay to Agent for distribution to Lenders a restructuring fee in the amount of Seventy-six Thousand and No/100 Dollars ($76,000.00). 9. As amended hereby, the Loan Agreement remains in full effect, and all agreements among the parties with respect to the subject hereof are represented fully in this Amendment and the other written documents among the parties. The validity, construction and enforcement hereof shall be determined according to the substantive laws of the State of Tennessee. - 2 - 77 Executed as of the date written above. RESPONSE ONCOLOGY, INC. By:_________________________________ Title:______________________________ NATIONSBANK OF TENNESSEE, N.A. By:_________________________________ Title:______________________________ NATIONSBANK OF TENNESSEE, N.A., as Agent By:_________________________________ Title:______________________________ UNION PLANTERS NATIONAL BANK By:_________________________________ Title:______________________________ - 3 - 78 FOURTH AMENDMENT TO LOAN AGREEMENT This Fourth Amendment to Loan Agreement ("Amendment") is entered into as of the 4th day of October, 1996 by Response Oncology, Inc. ("Borrower"), a Tennessee corporation; Union Planters National Bank ("Union Planters"), a national banking association; and NationsBank of Tennessee, N.A., a national banking association, in its individual capacity and as Agent for itself and Union Planters. R E C I T A L S: WHEREAS, the parties hereto have previously executed that Loan Agreement dated as of May 31, 1996, as amended by that First Amendment to Loan Agreement (the "First Amendment") dated as of June 18, 1996; by that Second Amendment to Loan Agreement (the "Second Amendment") dated as of July 1, 1996; and by that Third Amendment to Loan Agreement (the "Third Amendment") dated as of August 29, 1996 (the Loan Agreement, as amended by the First Amendment, Second Amendment and Third Amendment, is referred to herein as the "Loan Agreement"); and WHEREAS, the parties wish to further amend the Loan Agreement in certain respects; NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows: 1. Capitalized terms not defined herein have the meanings set forth in the Loan Agreement. 2. The Loan Agreement is hereby amended by revising the definition of "Subordinated Debt" set forth in Article I thereof by adding the following sentence at the end of the present definition: The indebtedness evidenced by that Adjustable Rate Convertible Note made by Borrower dated October ___, 1996, payable to the order of Seafield Capital Corporation in the original principal amount of Twenty-Three Million Five Hundred Thousand and No/100 Dollars ($23,500,000.00) (the "October 1996 Seafield Debt") shall also be regarded as Subordinated Debt hereunder, even though its final maturity date is August 1, 1998. 3. The Loan Agreement is hereby amended by adding a Section 6.1.10 thereto, stating in full as follows: 6.1.10 Certain Subordinated Debt. The October 1996 Seafield Debt. 79 4. The Loan Agreement is hereby amended by deleting the period at the end of Section 6.23 thereof, substituting a comma therefor, and adding the following language: [...,] except that the incurrence of the October 1996 Seafield Debt shall be permitted. 5. The Loan Agreement is hereby amended by revising Section 7.3 thereof to reflect a required value of Total Funded Debt to Consolidated EBITDA of no greater than 3.00:1.00. 6. The Loan Agreement is hereby amended by revising subsection (ii) of the definition of "Borrowing Base" in Article I thereof to read "(ii) multiplied by 3.00." 7. The Loan Agreement is hereby amended by revising the following definition in Article I to read in full as follows: "Seafield Position" means the equity interest of Seafield Capital Corporation borrower and the October 1996 Seafield Debt. 8. The Loan Agreement is hereby amended by adding the following definition in Article I between "Seafield Position" and "Secondary Offering": "Seafield Recapitalization" means a recapitalization of the Borrower's Capital Stock which (i) provides (a) that the Capital Stock of the Borrower owned by Seafield Capital Corporation immediately after consummation of the recapitalization (which was derived from common stock of the Borrower which immediately before consummation of the recapitalization had been owned by Seafield Capital Corporation for at least five years) constitutes common stock possession at least 80% of the total combined voting power of all classes of common stock of the Borrower entitled to vote and (b) that the Borrower will not have authorized or outstanding any shares of the class of common stock which are not voting stock, (ii) shall contain such other terms and conditions necessary or appropriate in the opinion of Seafield Capital Corporation's counsel or Borrower's counsel either to satisfy the substantive requirements of the Internal Revenue Code of 1986, as amended ('Code") and the regulations thereunder or other law or to obtain advance administrative approval of the transactions by the Internal Revenue Service, the National Association of Securities Dealers, Inc. or other administrative authority, and (iii) makes no changes in the capital structure of the Borrower except as necessary to accomplish the foregoing. For purposes of this definition, "Capital Stock" shall have the same meaning as the term "Stock" in Section 368(c) of the Code and the percentages of voting power shall be determined in a manner consistent with requirements of Section 355 of the Code. The Seafield Recapitalization shall not require the making of any dividend of cash or debt or any other distribution of any cash or debt by any Consolidated Entity. - 2 - 80 9. The Loan Agreement is hereby amended by deleting Section 6.4 in its entirety and by substituting in lieu thereof: 6.4 Distributions. No Consolidated Entity shall declare or pay any dividend or other distribution or redeem any of its capital stock except (i) for dividend payments and other distributions from Subsidiaries to Borrower or (ii) non-cash dividends or distributions in connection with or pursuant to the Seafield Recapitalization, or (iii) in the absence of an Unmatured Default or Event of Default, Borrower may repurchase stock representing part of the Seafield Position for a total price of up to Ten Million and No/100 Dollars ($10,000,000.00) prior to January 1, 1997, provided that such payment is made from Net Equity Proceeds received by Borrower after October 4, 1996. 10. The Loan Agreement is hereby amended by deleting the period at the end of Section 6.10 and adding the following language: [...,] except that the Seafield Recapitalization shall be permitted. 11. As amended hereby, the Loan Agreement remains in full effect, and all agreements among the parties with respect to the subject hereof are represented fully in this Amendment and the other written documents among the parties. The validity, construction and enforcement hereof shall be determined according to the substantive laws of the State of Tennessee. 12. This Amendment shall be effective upon the parties' exchange by telecopier of copies hereof showing the signatures of the other parties; provided, however, each party shall immediately forward an executed original hereof to Agent. The failure of any party to so provide Agent with an original hereof shall not impair the validity of this Amendment, but shall entitle Agent to obtain specific performance of the obligation to provide an executed original of this Amendment. - 3 - 81 Executed as of the date written above. RESPONSE ONCOLOGY, INC. By:________________________________ Title:_____________________________ NATIONSBANK OF TENNESSEE, N.A. By:________________________________ Title:_____________________________ NATIONSBANK OF TENNESSEE, N.A., as Agent By:________________________________ Title:_____________________________ UNION PLANTERS NATIONAL BANK By:________________________________ Title:_____________________________ - 4 - 82 FIFTH AMENDMENT TO LOAN AGREEMENT This Fifth Amendment to Loan Agreement ("Amendment") is entered into as of the 8th day of October, 1996 by Response Oncology, Inc. ("Borrower"), a Tennessee corporation; Union Planters National Bank ("Union Planters"), a national banking association; and NationsBank of Tennessee, N.A., a national banking association, in its individual capacity and as Agent for itself and Union Planters. R E C I T A L S: WHEREAS, the parties hereto have previously executed that Loan Agreement dated as of May 31, 1996, as amended by that First Amendment to Loan Agreement (the "First Amendment") dated as of June 18, 1996; by that Second Amendment to Loan Agreement (the "Second Amendment") dated as of July 1, 1996; by that Third Amendment to Loan Agreement (the "Third Amendment") dated as of August 29, 1996, and by the Fourth Amendment to Loan Agreement (the "Fourth Amendment") dated as of October 4, 1996 (the Loan Agreement, as amended by the First Amendment, Second Amendment, Third Amendment and Fourth Amendment, is referred to herein as the "Loan Agreement"); and WHEREAS, the parties wish to further amend the Loan Agreement in certain respects; NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows: 1. Capitalized terms not defined herein have the meanings set forth in the Loan Agreement. 2. The Loan Agreement is hereby amended by inserting the following language as a new Section 2.19 thereof: 2.19. Letters of Credit. Subject to the terms and conditions of this Agreement, the Lenders' respective Commitments for the Acquisition Loan may be utilized, upon the request of the Borrower, for the issuance by NationsBank of letters of credit (the "Letters of Credit") for the account of the Borrower for uses that would be permitted for the Acquisition Loan; provided that in no event shall (i) the aggregate amount of all stated and undrawn amounts under Letters of Credit (the "Letter of Credit Liabilities"), together with the aggregate principal amount of the Loans advanced under the Acquisition Loan, exceed the amount stated in Section 2.1 hereof, (ii) the outstanding aggregate amount of all Letter of Credit Liabilities exceed Seven Million Five 83 Hundred Thousand and No/100 Dollars ($7,500,000.00), and (iii) the expiration date of any Letter of Credit extend beyond the Maturity Date applicable to the Acquisition Loan. The following additional provisions shall apply to Letters of Credit: 2.19.1. Procedure for Issuance. The Borrower shall give the Agent at least three Business Days' irrevocable prior notice (effective upon receipt) specifying the Business Day (which shall be no later than 30 days preceding the Maturity Date applicable to the Acquisition Loan) each Letter of Credit is to be issued and describing in reasonable detail the proposed terms of such Letter of Credit (including its beneficiary) and the nature of the transactions or obligations proposed to be supported. The Borrower shall be the account party for each Letter of Credit, including Letters of Credit issuable to a beneficiary having a claim or potential claim against a Subsidiary of the Borrower. 2.19.2. Participation Among Lenders. On each day during the period commencing with the issuance by NationsBank of any Letter of Credit and until such Letter of Credit shall have expired or been terminated or, if drawn upon, until the resulting obligations of reimbursement (the "Reimbursement Obligations") have been satisfied in full by the Borrower (whether by a borrowing under this Agreement or otherwise), the Commitment of each Lender shall be deemed to be utilized for all purposes of this Agreement (including, but not limited to, the calculation of availability and the nonuse fee) in an amount equal to such Lender's Pro Rata Share of the Letter of Credit Liabilities associated with such Letter of Credit. Each Lender (other than NationsBank) agrees that, upon the issuance of any Letter of Credit, it shall automatically be deemed to have acquired a participation in NationsBank's liability under such Letter of Credit in an amount equal to such Lender's Pro Rata Share of such liability, and each Lender (other than NationsBank) thereby shall absolutely, unconditionally and irrevocably assume, as primary obligor and not as surety, and shall be unconditionally obligated to NationsBank to pay and discharge when due, its Pro Rata Share of NationsBank's liability under such Letter of Credit. 2.19.3. Reimbursement Obligation. Upon receipt from the beneficiary of any Letter of Credit of any demand for payment under such Letter of Credit, NationsBank shall promptly notify the Borrower of the amount to be paid by NationsBank as a result of such demand and the date on which payment is to be made by - 2 - 84 NationsBank to such beneficiary in respect of such demand. The Borrower hereby unconditionally agrees to pay and reimburse the Agent for the account of NationsBank and the other Lenders Pro Rata with respect to the amount of each demand for payment under such Letter of Credit at or prior to the date on which payment is to be made by NationsBank to the beneficiary under such Letter of Credit, without presentment, demand, protest or other formalities of any kind. Any amounts not so paid or borrowed as set forth in Section 2.19.4 below shall bear interest at the rate(s) specified in the documents relating to the issuance of the Letter of Credit (the "Letter of Credit Documents") or, if higher, at the rate(s) specified on the Notes (including the Default Rate, if applicable). 2.19.4. Means of Reimbursement. Forthwith upon its receipt of a notice referred to in Section 2.19.3 hereof, the Borrower shall advise the Agent whether or not the Borrower intends to obtain a Loan to finance its obligation to reimburse NationsBank for the amount of the related demand for payment and, if it does, submit a notice of such borrowing as provided in this Agreement. In the event that the Borrower fails to so advise the Agent, and if the Borrower fails to reimburse NationsBank for a demand for payment under a Letter of Credit by the date of such payment, the Agent shall give each Lender prompt notice of the amount of the demand for payment, specifying such Lender's Pro Rata Share of the amount of the related demand for payment, and the Borrower shall be deemed in default hereunder for breaching Section 2.19.3 above. 2.19.5 Payments by Lenders. Each Lender (other than NationsBank) shall pay to the Agent for the account of NationsBank in Dollars and in immediately available funds, such Lender's Pro Rata Share of any payment under a Letter of Credit upon notice by the Agent to such Lender requesting such payment and specifying such amount as provided in Section 2.19.4. Each such Lender's obligation to make such payments to the Agent for the account of NationsBank under this Section 2.19.5, and NationsBank's right to receive the same, shall be absolute and unconditional and shall not be affected by any circumstance whatsoever, including the failure of any other Lender to make its payment under this Section 2.19.5, the financial condition of the Borrower, the existence of any Unmatured Default or Event of Default or the termination of the Commitments. Each such payment to NationsBank shall be made - 3 - 85 without any offset, abatement, withholding or reduction whatsoever; provided, nothing contained in the foregoing shall limit NationsBank's liability for its gross negligence or willful misconduct in improperly honoring a draft drawn under a Letter of Credit. 2.19.6 Settlement Among Lenders. Upon the making of each payment by a Lender to NationsBank pursuant to Section 2.19.5 above in respect of any Letter of Credit, such Lender shall, automatically and without any further action on the part of the Agent, NationsBank or such Lender, acquire (i) a participation in any amount equal to such payment in the Reimbursement Obligation owing to NationsBank by the Borrower under this Agreement and under the Letter of Credit Documents relating to such Letter of Credit and (ii) a participation in a percentage equal to such Lender's Pro Rata Share in any interest or other amounts payable by the Borrower under such Letter of Credit Documents and the other Loan Documents in respect of such Reimbursement Obligation. Upon receipt by NationsBank from or for the account of the Borrower of any payment in respect of any Reimbursement Obligation or any such interest or other amount (including by way of set-off or application of proceeds of any collateral security) NationsBank shall promptly pay to the Agent for the account of each Lender who shall have previously assumed a participation in such payment under clause (ii) above, such Lender's Pro Rata Share of such payment, each such payment by NationsBank to be made in the same money and funds in which received by NationsBank. In the event any payment received by NationsBank and so paid to the Lenders is rescinded or must otherwise be returned by NationsBank, each Lender shall, upon the request of NationsBank (through the Agent), repay to NationsBank (through the Agent) the amount of such payment paid to such Lender, with interest at the rate specified in Section 2.19.10. 2.19.7. Letter of Credit Fee. Borrower shall pay to the Agent for the account of each Lender a letter of credit fee in respect of each Letter of Credit on the daily average undrawn face amount of such Letter of Credit for the period from and including the date of issuance of such Letter of Credit to and including the date such Letter of Credit is drawn in full, expires or is terminated (such fee to be non-refundable, to be paid in arrears on the first day of each calendar quarter and on the Maturity Date applicable to the Acquisition Loan and to be - 4 - 86 calculated, for any day, after giving effect to any payments made under such Letter of Credit on such day) in an amount equal to the Applicable LIBO Rate Margin(s) in effect during the relevant period. All calculations of Letter of Credit fees shall be based on a 360 day year counting the actual number of elapsed days. 2.19.8. Letter of Credit Information. Upon the request of any Lender from time to time, NationsBank shall deliver any information reasonably requested by such Lender with respect to each Letter of Credit then outstanding. - 5 - 87 2.19.9. Conditions Relating to Letters of Credit. The issuance by NationsBank of each Letter of Credit shall be subject, in addition to the conditions precedent set forth in Article III hereof (as though the issuance of the Letter of Credit were the making of a Loan), to the conditions precedent that (i) such Letter of Credit shall be in such form, contain such terms and support such transactions as shall be satisfactory to NationsBank consistent with its then current practices and procedures with respect to letters of credit of the same type and (ii) the Borrower shall have executed and delivered such applications, agreements and other instruments relating to such Letter of Credit as NationsBank shall have reasonably requested consistent with its then current practices and procedures with respect to letters of credit of the same type; provided that in the event of any conflict between any such application, agreement or other instrument and the provisions of this Agreement, the provisions of this Agreement shall control. 2.19.10. Payments Among Lenders. In the event that any Lender fails to pay any amount required to be paid pursuant to this Section 2.19 when due, such Lender shall pay interest to NationsBank (through the Agent) on such amount from and including such due date to but excluding the date such payment is made (i) during the period form and including such due date to but excluding the date three Business Days thereafter, at a rate per annum equal to the federal funds rate (as in effect from time to time as determined by Agent) and (ii) thereafter, at a rate per annum equal to the Prime Rate plus 2.0%. 2.19.11. Modifications. The issuance by NationsBank of any modification or supplement to any Letter of Credit shall be subject to the same conditions applicable under this Section 2.19 to the issuance of new Letters of Credit, and no such modification or supplement shall be issued unless either (x) the respective Letter of Credit as affected by such action would have complied with such conditions had it originally been issued in such modified or supplemented form or (y) each Lender shall have consented to such modification or supplement. 2.19.12 Absolute Obligations of Borrower. The obligations of the Borrower under this Section 2.19 shall be unconditional and absolute and shall not be affected, modified or impaired, upon the happening at any time or from time to time of - 6 - 88 any event, including any of the following, whether or not with notice to or the consent of the Borrower: (1) the compromise, settlement, release, modification, amendment (whether material or otherwise) or termination of any or all of the obligations, conditions covenants or agreements of any Person in respect of any of the Loan Documents; (2) the occurrence, or the failure by the Agent, any Lender or any other Person to give notice to the Borrower of the occurrence, of any Event of Default or any default under any of the other Loan Documents; (3) the waiver of the payment, performance or observance of any of the obligations, conditions, covenants or agreements of any Person contained in any of the Loan Documents; (4) the extension of the time for performance of any other obligations, covenants or agreements of any Person under or arising out of any of the Loan Documents; (5) the taking or the omission of any of the actions referred to in any of the Loan Documents; (6) any failure, omission or delay on the part of the Agent, any Lender, the Borrower or the beneficiary of any Letter of Credit to enforce, assert or exercise any right, remedy, power or privilege conferred by this Agreement or any of the Loan Documents, or any other act or acts on the part of the Agent, any Lender, the Borrower or the beneficiary of any Letter of Credit; (7) the voluntary or involuntary liquidation, dissolution, sale or other disposition of all or substantially all the assets of, the marshaling of assets and liabilities, receivership, insolvency, bankruptcy, assignment for the benefit of creditors, reorganization, arrangement, composition with creditors or readjustment of, or other similar proceedings which affect, the Borrower or any other party to any of the Loan Documents; (8) any lack of validity or enforceability of this - 7 - 89 Agreement, any Letter of Credit or any other Loan Document, or any allegation of invalidity or unenforceability or any contest of such validity or enforceability; (9) the existence of any claim, set-off, defense or other right which the Borrower may have at any time against the Agent, any Lender or any beneficiary or any transferee of any Letter of Credit (or any persons or entities for whom the Lender or any such beneficiary or transferee may be acting), or any other Person, whether in connection with this Agreement or any of the other Loan Documents or any of the transactions contemplated by any Loan Document or any unrelated transaction; (10) any statement in any certificate or any other document presented under any Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any such statement being untrue or inaccurate in any respect whatsoever; (11) payment by NationsBank under any Letter of Credit against presentation of a demand or certificate which does not comply with the terms of such Letter of Credit; (12) the release or discharge by operation of law of the Borrower form the performance or observance of any obligation, covenant or agreement contained in any of the Loan Documents; or (13) any other circumstance or happening whatsoever, whether or not similar to any of the foregoing. 2.19.13 Without affecting the Borrower's liability under any other provision of this Agreement, the Borrower agrees to indemnify each of NationsBank, the Agent and the Lenders and their respective affiliates, directors, officers, employees, attorneys and agents from, and hold each of them harmless against, any and all losses, liabilities, damages or expenses incurred by any of them in connection with or by reason of any actual or threatened investigation, litigation or other proceeding (including, in respect of NationsBank and the Agent, any such investigations, litigation or other proceeding between - 8 - 90 NationsBank or the Agent and any Lender) relating to (a) the execution and delivery of any Letter of Credit; (b) the use of the proceeds of any drawing under any Letter of Credit; or (c) the transfer or substitution of, or payment or failure to pay under, any Letter of Credit, including the reasonable fees and disbursements of counsel incurred in connection with any such investigation, litigation or other proceeding, but excluding damages, losses, liabilities or expenses to the extent, but only to the extent, incurred by reason of the willful misconduct or gross negligence of NationsBank in determining whether a document presented under any Letter of Credit complies with the terms of such Letter of Credit. It shall not be a condition to any such indemnification that NationsBank, the Agent or any Lender shall be a party to any such investigations, litigation or other proceeding. Nothing in this Paragraph 2.19 is intended to limit the Borrower's payment obligations under this Agreement. 2.19.14 The Borrower assumes all risks of the acts or omissions of any beneficiary of any Letter of Credit with respect to the use of the Letter of Credit. None of the Agent, any Lender nor any of their respective affiliates, officers, directors, employees, attorneys or agents shall be liable or responsible for: (a) the use which may be made of the Letter of Credit or for any acts or omissions of any beneficiary of any Letter of Credit in connection with such Letter of Credit; (b) the validity, sufficiency or genuineness of documents presented to NationsBank, or of any endorsement on such documents, even if such documents should in fact prove to be in any or all respects invalid, insufficient, fraudulent or forged; (c) payment by NationsBank against presentation of documents which do not comply with the terms of any Letter of Credit, including failure of any documents to bear any reference or adequate reference to such Letter of Credit; or (d) any other circumstances whatsoever in making or failure to make payment under any Letter of Credit; provided that the Borrower shall have a claim against NationsBank to the extent, but only to the extent, of any direct, as opposed to consequential, damages suffered by the Borrower which the Borrower proves were caused by NationsBank's willful misconduct or gross negligence in determining whether a document presented under any Letter of Credit complies with the terms of such Letter of Credit. In furtherance and not in limitation of the foregoing, NationsBank may accept documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to - 9 - 91 the contrary. 3. As amended hereby, the Loan Agreement remains in full effect, and all agreements among the parties with respect to the subject hereof are represented fully in this Amendment and the other written documents among the parties. The validity, construction and enforcement hereof shall be determined according to the substantive laws of the State of Tennessee. 4. This Amendment shall be effective upon the parties' exchange by telecopier of copies hereof showing the signatures of the other parties; provided, however, each party shall immediately forward an executed original hereof to Agent. The failure of any party to so provide Agent with an original hereof shall not impair the validity of this Amendment, but shall entitle Agent to obtain specific performance of the obligation to provide an executed original of this Amendment. Executed as of the date written above. RESPONSE ONCOLOGY, INC. By:___________________________________ Title:________________________________ NATIONSBANK OF TENNESSEE, N.A. By:___________________________________ Title:________________________________ NATIONSBANK OF TENNESSEE, N.A., as Agent By:___________________________________ Title:________________________________ UNION PLANTERS NATIONAL BANK By:___________________________________ Title:________________________________ - 10 - EX-11 4 LIST OF SUBSIDIARIES 1 EXHIBIT 21 RESPONSE ONCOLOGY, INC. LIST OF SUBSIDIARIES Company State of Incorporation - ------- ---------------------- IMPACT(R) Center of Albany, LLC Tennessee IMPACT(R) Center of Bayonne, LLC New Jersey IMPACT(R) Center of Fort Smith, LLC Tennessee IMPACT(R) Center of Glendale, LLC Tennessee IMPACT(R) Center of Mobile, LLC Tennessee IMPACT(R) Center of Mt. Diablo, LLC Tennessee IMPACT(R) Center of Northridge, LLC Tennessee IMPACT(R) Center of St. John's, LLC Tennessee IMPACT(R) Center of Tri-City Medical Center, LLC Tennessee IMPACT(R) Center of Washington, D.C., LLC Tennessee Response Oncology of Fort Lauderdale, Inc. Florida Response Oncology of Miami Beach, Inc. Florida Response Oncology of St. Petersburg, Inc. Florida Response Oncology of Tamarac, Inc. Florida Response Oncology of Treasure Coast, Inc. Florida Response Oncology of West Ft. Lauderdale, Inc. Florida South Florida Response Oncology, Inc. Florida EX-23 5 ACCOUNTANTS' CONSENT 1 EXHIBIT 23 ACCOUNTANTS' CONSENT The Board of Directors Response Oncology, Inc. We consent to incorporation by reference in the Registration Statement (No. 33-45616) on Form S-8, the Registration Statement (No. 33-21333) on Form S-8 and the Registration Statement (No. 333-14371) on Form S-8 of Response Oncology, Inc. of our report dated February 12, 1997, relating to the consolidated balance sheets of Response Oncology, Inc. and subsidiaries as of December 31, 1996 and 1995, and the related consolidated statements of operations, stockholders' equity, and cash flows for each of the years in the three year period ended December 31, 1996 and the related financial statement schedule, which report appears in the December 31, 1996 annual report on Form 10-K of Response Oncology, Inc. KPMG Peat Marwick LLP Memphis, Tennessee March 26, 1997 EX-27 6 FINANCIAL DATA SCHEDULE
5 THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FORM 10-K FOR THE PERIOD ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. 1,000 U.S. DOLLARS YEAR DEC-31-1996 JAN-01-1996 DEC-31-1996 1,000 415 0 16,071 1,774 2,415 31,718 13,566 8,160 142,950 17,052 62,106 0 27 89 38,051 142,950 67,353 67,353 0 61,479 608 1,594 2,589 907 0 907 0 0 0 907 .11 .11
-----END PRIVACY-ENHANCED MESSAGE-----